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Abstract 
 
Autoimmune diseases and mood-related disorders are among the major plagues of 
our modern society, as they impair the normal daily life of patients at both social and 
physical levels. 
 
Autoimmunity is caused by the loss of immunological tolerance i.e. the inability of 
immune cells to make a distinction between self and non-self antigens. Intriguingly, 
patients suffering from autoimmune diseases also show higher rate of “unjustified” 
mood disorders, such as depression and anxiety. Recent evidence indicates mood 
disorders as biomarkers for autoimmunity rather than co-morbidities since their 
occurrence is unrelated to the time of diagnosis of the autoimmune disease or to the 
degree of disability.  
 
In this thesis I investigated the phenotype of T cell-specific transgenic mice 
overexpressing Annexin-A1 (AnxA1
tg
): homeostatic immunomodulatory protein 
with dual opposite functions in the innate and adaptive immune system. Consistent 
with the previously observed pro-inflammatory role in T cells, AnxA1
tg
 mice showed 
higher susceptibility to develop autoimmune diseases like multiple sclerosis and 
systemic lupus erythematosus. Most interestingly, using a battery of behavioural 
tests, we showed an increased anxious-like behaviour in AnxA1tg mice compared to 
wild type. This phenotype was associated with a specific gene pattern in the brain 
and in T cells as shown by microarray analyses. Adoptive transfer of AnxA1
tg
-CD4+ 
T cells into wild-type mice caused an increased anxiety-like behaviour in the 
recipient animals thus providing first experimental evidence for emotional 
dysfunction in autoimmunity-prone animals.  
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In conclusion, the results of this study provide novel evidences for the strong link 
between immune system and CNS. More specifically, our findings highlight a novel 
function of CD4+ T cells as the drivers of mental and physical wellbeing. Future 
studies will assess the potential of strategies targeting AnxA1 in T cells as new 
therapeutic tools for the combined treatment for autoimmunity and associated mental 
disorders.  
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Abbreviations 
-/-
 Knockout  
ACTH Adrenocorticotropin hormone 
AICD Activation induced cell death 
AIRE Autoimmune regulator  
AnxA1  Annexin A1 
AnxA1
tg
  Transgenic annexin A1 
AP-1 Activator protein 1 
APC Antigen presenting cell 
APC Allophycocyanin 
BAD Bcl-2-associated death promoter 
BBB Blood brain barrier 
BSA Bovine serum albumin 
CD Cluster of differentiation 
CFA  Complete freund’s adjuvant 
CIA Collagen induced arthritis  
CNS  Central Nervous System 
CRH Corticotropin releasing hormone 
CSF Cerebrospinal fluid 
CTLA-4 Cytotoxic T lymphocyte antigen-4 
CXCR5 C-X-C chemokine receptor type 5 
DAG Diacylglycerol 
DC Dendritic cell 
DMD Disease modifying drug 
EAE  Experimental autoimmune encephalomyelitis 
EDTA Ethylenediaminetetraacetic acid 
ERK Extracellular signal-regulated kinase 
FACS  Fluorescence activated cell sorting 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
fMLP N-formyl-methionine-leucine-phenylalanine 
Foxp3 Forkhead box P3 
FPR Formyl peptide receptor  
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FSC Forward side channel 
HPA Hypothalamic-pituitary-adrenal 
GA Glatiramer acetate 
GCs Glucocorticoids 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
hrAnxA1 Human recombinant AnxA1 
JAK Janus kinase 
LCK Lymphocyte specific protein tyrosine kinase 
LPS Lipopolysaccharide 
IFN! Interferon beta 
IFN" Interferon gamma 
IFN"R Interferon gamma receptor 
IgG Immunoglobulin G  
IL Interleukin 
MAPK Mitogen-activated protein kinase 
MHC Major Histocompatibility Complex 
MFI Mean Fluorescence Intensity 
MOG  Myelin Oligodendrocyte Glycoprotein 
MS  Multiple Sclerosis 
NFAT Nuclear factor of activated T cells 
NF-!B 
Nuclear factor kappa-light-chain-enhancer of   
activated B cells  
PBS Phosphate buffered Saline 
PE Phycoerythin 
PKC Protein kinase C 
PI3K Phosphoinositide 3-kinase 
PLC"1 Phospholipase C gamma 1 
PML Progressive multifocal leukoencephalopathy 
PTX Pertussis toxin 
RA Rheumatoid arthritis  
ROR"t RAR related orphan receptor gamma t 
rRIK Recombinant protein 2610019F03Rik 
RSS Recombination signal sequence 
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SLE Systemic lupus erythematous 
SSC Side scatter channel 
STAT Signal transducer and activator of transcription 
TCR  T cell receptor 
Tfh Follicular T helper 
Th T helper  
TNF# Tumor necrosis factor alpha 
TGF# Transforming growth factor beta 
Treg Regulatory T cell 
ZY Zymosan 
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1.1 Immune tolerance and autoimmunity 
We are healthy if our immune system is healthy. In the course of our lives, when we 
encounter something that poses a threat to our body, an efficient immune system is 
able to identify it and eliminate it. The immune cells are the guardians responsible 
for our defence against foreign insults and they successfully accomplish it by their 
ability to distinguish body components (self-antigen) and the threats coming from the 
outside (non-self antigen). Thus, the immune system reacts against non-self 
components, such as bacteria or viruses, while it ignores our own tissues and organs 
(1). However, recent studies have also suggested that the immune system is able to 
react against danger/alarm signals that originate from stressed self-cells (2). The self-
non-self discrimination dogma and this more recent danger model are considered the 
pillars of the sophisticate mechanism by which self-tolerance is established. Through 
self-tolerance, the immune system prevents the occurrence of inappropriate immune 
reactions that could potentially cause permanent or deleterious body injuries (3, 4). 
Break of self-tolerance is thus the leading cause of autoimmunity i.e of an 
uncontrolled and self-harming reaction against our own tissues and organs.  
1.1.1 Self-tolerance of the adaptive immune system 
Self-tolerance is pursued in two main forms: central and peripheral tolerance. Central 
tolerance is established during the development and maturation of immune cells in 
the primary lymphoid organs. B cells in the bone marrow and T cells in the thymus, 
respectively, are screened for their ability to discriminate between self and non-self 
through a receptor-antigen recognition system. In the same way a keyhole matches a 
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unique key, immune cells expose specific receptors, each of which recognises only 
one unique antigen (3, 5).  
 
T cell or B cell receptors (TCRs and BCRs, respectively) are generated through 
similar processes such as somatic gene rearrangement and junctional diversity. TCR 
and BCR genes exist as separate multiple gene segments called V (for Variable), D 
(for directional) and J (for junctional). These “segments” are randomly recombined 
in a single V(D)J sequence in order to have a functional gene. The recombination 
process is under the control of RAG1/RAG2 proteins whose function is to bind to 
and cleave a recombination signal sequence (RSS). This introduces double-strand 
DNA breaks (hairpin structures) in the gene sequences that need to be rearranged. 
The hairpins are then cleaved and the gene sequences are ligated with the eventual 
addition of random nucleotides. In this way, several different and new combinations 
of receptors are created. This is crucial to increase variability in the repertoires of 
TCRs and BCRs that will be able to recognise a different number of antigens. 
Considering the continuous and rapid evolutionary changes of pathogens, the high 
variability of these receptors is beneficial and advantageous for adequate immune 
protection. However, this can also leads to the formation of potentially self-reactive 
receptors, which can cause autoimmunity. 
 
The binding of TCR and BCR to their cognate antigen presented in the context of the 
mayor histocompatibility complex (MHC) molecules is the driving force behind the 
identification of potential auto-reacting cells. In the case of B cells, the exposure of 
immature B cells to bone marrow-specific antigens and additional antigens imported 
by blood circulation in the marrow can lead to B cells apoptosis or to no response 
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(tolerance). In a similar way, T cells are exposed to a wide variety of self antigens, 
known to be tissue- and organ-specific (about 3000 genes) – such as insulin – 
because they are expressed by specialised epithelial cells in the thymus (4). 
 
Upon exposure to self-antigens, T cells undergo two main selection steps named 
positive and negative selection. The first occurs in the cortex of the thymus and 
allows T cells that are able to recognise self-antigen-MHC complexes to proceed to 
maturation, while T cells unable to recognise self-antigen-MHC complexes are 
deleted by neglect-induced death (3, 6-8). Negative selection occurs in the inner part 
of the thymus – the medulla. Notoriously, T cells require two signals to be activated 
and to react; signal one is triggered by the binding of TCRs and antigen-MHC 
complexes, while signal two is mediated by the binding of CD28 co-receptors to 
costimulatory molecules. Thus, positively selected T cells are newly exposed to self-
antigens and to costimulatory molecules. Those that bind to self-antigens and 
costimulatory molecules with high affinity are eliminated by apoptosis, while the rest 
continue maturation and differentiation into either CD4+ or CD8+ T cells. Negative 
selection is also known as clonal deletion and it is fundamental to ensure the 
formation of self-tolerant T cells (3, 6, 7, 9). Along clonal deletion, immune 
tolerance is pursued by clonal diversion. In this case, self-reactive clones are 
reprogrammed and differentiate in regulatory T cells (Tregs), which are able to 
suppress auto-reactive T cells (7, 10). 
 
Central tolerance is not able to eliminate all the possible auto-reactive cells. Among 
the mature immune cells, there are a variable number of auto-reactive cells which are 
not exposed to their self-antigens in the central lymphoid organ. These cells only 
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encounter their self-antigens in secondary lymphoid organs. Thus, humans have 
developed peripheral tolerance mechanisms to peripherally repress potential 
dangerous immune cells. For instance, peripheral tolerance is maintained by anergy 
or peripheral deletion of auto-reactive T cells (7, 11). The former is a long-term 
unresponsiveness state of T cells caused by the activation of TCR in the absence of 
signal two (12). The latter is a programmed cell death (apoptosis) that can be induced 
by Fas-death receptor signalling (13). Other possible mechanisms of tolerance 
induction include the TCR/co-receptor down-regulation (14), immune deviation (15) 
or secretion of immuno-regulatory cytokines such as IL-10 or TGF! (16). 
 
In certain conditions, however, immune tolerance towards self-components 
dramatically fails causing aberrant immune responses, collectively referred to as 
autoimmunity. The action of autoantibodies and self-reactive T cells against self-
components causes a state of chronic inflammation and permanent damage that are 
features of several autoimmune diseases. 
 
The failure of immune tolerance has no clear origins. Multiple factors seem to 
contribute to the development of autoimmune diseases. These include genetic, 
hormones, diet, chemical and/ or exposure to infections (17). Systemic inflammatory 
conditions show strong associations between autoimmune diseases and specific 
MHC genes (18). Another example in human is the severe autoimmune 
polyendocrine syndrome which is caused by aberrations of a single gene, 
AutoImmune REgulator (AIRE) gene (19). Genetic susceptibility is not always 
sufficient to explain the occurrence of autoimmune disorders. The higher prevalence 
of autoimmune diseases in developed countries suggests a strong influence of 
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environmental risk factors. Exposure to metal, ultraviolet and infectious agents has 
been linked to various autoimmune conditions. For example, the Epstein-Barr viral 
infection might contribute to multiple sclerosis (20, 21) and group A streptococcus 
can trigger rheumatic heart disease (22). The exact mechanism by which an infection 
induces a specific autoimmune disease is unknown. It has been proposed that 
microbial antigens might resemble self-antigen structures and because of this, induce 
a cross-reactive immune response – a hypothesis referred to as molecular mimicry 
(23). Increased salt (sodium chloride) concentration has been shown to boost the 
induction of pathogenic T cells (24); ultraviolet exposure, in contrast, has been 
identified as a positive factor that prevents from the development of autoimmune 
diseases (25). 
1.1.2 Autoimmune diseases 
Autoimmune diseases affect about 3-8% of the world’s population. The female/male 
ratio shows that women are most affected (26). To define a disease as an 
autoimmune disease, we use direct, indirect and circumstantial evidences. The direct 
evidence is the transmissibility of the disease by transferring of antibodies or T cells. 
The indirect evidence is based on the possibility to reproduce the disease in animal 
models. If direct or indirect evidence is not available, the presence of typical 
markers, such as high serum level of IgG autoantibodies or infiltration of immune 
cells in the affected organ or tissue, provides circumstantial evidence. Moreover, 
family history of the same autoimmune disease or multiple autoimmune diseases in 
the same patient are also helpful criteria used for the diagnosis of autoimmune 
disease (27). 
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Among the autoimmune diseases, we can pedagogically distinguish localized and 
systemic diseases (3). Multiple sclerosis (MS) and type 1 diabetes are, for example, 
classified as localized autoimmune diseases since they are restricted to a specific 
tissue or organ. Diseases like systemic lupus erythematous (SLE) and rheumatoid 
arthritis (RA), on other hand, are systemic diseases because the autoantibodies can 
cause multiple organ impairment (3). 
 
A list of the most common autoimmune diseases and their associated self-antigen is 
reported in the Table 1.1 below. 
 
Table 1.1: Autoimmune diseases 
 
 
Sometimes these diseases can be silent for a long period of time before presenting 
general and/or specific symptoms. Most of them cause fatigue, fever and general ill 
feeling, such as body pain, muscle weakness, insomnia, loss of appetite, variation of 
weight and/or loss of coordination. Patients suffering from autoimmune diseases are 
likely to present psychiatric disorders including depression, anxiety, obsession, 
DISEASE AUTO-ANTIGEN CONSEQUENCES 
Type 1 diabetes 
mellitus 
Insulin Destruction of pancreatic # cells. 
Rheumatoid arthritis 
Unknown synovial joint 
proteins 
Joint inflammation and destruction. 
Multiple Sclerosis Myelin associated proteins Brain inflammation and demyelination. 
Graves’ disease 
Thyroid-stimulating 
hormone receptor 
Hyperthyroidism. 
Hashimoto’s 
thyroiditis 
Thyroid peroxidase Hypothyroidism. 
Myasthenia gravis 
Nicotine acetylcholine 
receptor 
Neuromuscular impairments. 
Systemic lupus 
erythematosus 
DNA, histones, ribosomes, 
protein of the spliceosome 
complex 
Glomerulonephritis, vasculitis, rush. 
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irritability and hallucinations (28). Indeed, autoimmune patients have the highest 
chances of developing schizophrenia with autoimmune hepatitis being at the highest 
risk and rheumatoid arthritis at the lowest. 
 
Many studies have shown that patients affected by autoimmune diseases have higher 
probability to develop other forms of autoimmunity in their lifespan. An example is 
the case of a 30-year-old woman suffering from myasthenia gravis and 
hypothyroidism (29). After her thymus was surgically removed, first she developed 
RA and later SLE (29). The manifestation of two or more autoimmune diseases in 
the same patient occurs with a rate greater than expected by chance (30). Thus, 
among patients affected by type 1 diabetes, RA and autoimmune thyroiditis have 
higher prevalence (31). The coexistence of several autoimmune diseases in the same 
patient (polyautoimmunity) is referred to as a kaleidoscope of autoimmunity (32). 
Polyautoimmunity suggests the existence of shared pathological mechanisms among 
autoimmune diseases and the possibility to have a single therapeutic approach for at 
least those conditions that are strongly associated with each other. It should be noted 
that not all autoimmune diseases are positively correlated. For instance, RA and MS 
seem to have an inverse correlation (30). 
 
1.1.2.1 Therapeutic approaches to autoimmune diseases 
The therapeutic treatments of autoimmune diseases are often directed at relieving the 
symptoms, considering surgical interventions in extreme cases (33). Other 
approaches aim to help patients by administering either lacking vital products or 
nutrients that have been affected by the impairment of target organs such as insulin 
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in the case of type 1 diabetes (34) or vitamin B12 for SLE (28, 35). Anti-
inflammatory drugs such as aspirin or glucocorticoids are used to reduce 
inflammation and pain associated with autoimmunity (36). However, these 
therapeutic approaches address only the symptoms instead of removing the causes of 
the disease. For this purpose, immunosuppressive and disease-modifying drugs are 
employed.  
 
Immunosuppressive drugs reduce the activation and efficacy of the immune system 
(37). However, their use needs to be limited because they cause several side effects 
and make the patient more vulnerable to opportunistic infectious (38). A list of the 
most commonly used immunosuppressive drugs, their mechanisms of action and 
toxicity are reported in Table 1.2. 
 
Table 1.2: Immunosuppressive drugs  
  
 
Disease-modifying drugs (DMD) alter the course of disease as well as improve 
symptoms (37). These drugs are immune modulators that interfere with the 
pathogenic mechanisms underlying autoimmune diseases. They are also called 
biologics. Among them there are monoclonal antibodies which have achieved 
DRUG ACTION MAJOR TOXICITY 
Cyclophosphamide 
Intercalates DNA interfering with 
cell proliferation 
Leukopenia, myeloproliferative 
disorders, infertility. 
Azathioprine 
Interferes with purine nucleotide 
synthesis 
Leukopenia, pancreatite, 
hepatotoxicity. 
Mycophenolato 
Interferes with de novo guanosine 
nucleotide synthesis 
Gastrointesinal bleeding, 
lymphopenia, infectious. 
Cladribine Interferes with purine synthesis Lymphopenia. 
Cyclosporine and 
Tacrolimus 
Inhibits calcineurin-mediated 
production of IL-2 and clonal 
expansion of T helper cells 
Nephrotoxicity, hypertension. 
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resounding success in the treatment of RA and MS (39, 40). Their mechanisms of 
action differ depending on the molecular target. For instance, Rituximab binds to the 
CD20 antigen on the surface of mature B cells causing their depletion (41). Instead, 
Natalizumab targets the alpha-4 subunit of integrins on the surface of lymphocytes. 
This prevents the adhesion of lymphocytes to the vascular walls and their migration 
from the blood stream into target tissues (42, 43). 
 
Other biologics exert their immune modulating effects by redistributing lymphocytes 
from the circulation to the secondary lymphoid organs (Fingolimod) (44), preventing 
T cell costimulation (Abatacept) (45) or interfering with TNF activity (Etanercept) 
(46). Finally, there are biologics which are used for their known therapeutic effect in 
autoimmune diseases, although their mechanisms of action are only partially known 
(47). 
 
Glatiramer acetate (GA), for instance, is a random synthetic polymer of 4 specific 
amino acids (Glutamic acid, Lysine, Alanine and Tyrosine) that are naturally present 
in the myelin basic protein. Despite its wide use and its beneficial effects in MS 
patients, its mechanism of action has not been fully understood yet (48). Indeed, it 
has been proposed that GA might interfere with T cell differentiation promoting the 
formation of anti-inflammatory T helper 2 (Th2) and reducing the pro-inflamamtory 
Th1 (46). GA might also exert direct neuroprotective effects through the induction in 
situ of neurotrophic factors such as BDNF (48).!
 
Treatments based on biologics have several advantages including high tolerability by 
the patients and greater selectivity for the target (47). However, they are rarely 
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curative and are burdened by serious side effects (38). The most adverse side effect 
is progressive multifocal leukoencephalopathy (PML) (49), which is a viral infection 
of the brain. Other common side effects include serious infections, headaches, fever, 
fatigue, bradycardia and paradoxically autoimmunity (38).  
 
A list of the most used DMDs, their action and toxicity is provided below in Table 
1.3.  
 
Table 1.3: Biologic drugs 
 
TNFRs: TNF receptors; BAFF: B-cell activator factor; DHODH: Dihydroorotate dehydrogenase. 
 
DRUG DISEASES 
ACTION AND  
PROPOSED MECHANISM 
SIDE EFFECTS 
Natalizumab 
MS, Crohn’s 
disease 
Prevents transmigration of 
lymphocytes: 
Binds to and blocks #4 integrins 
exposed on leucocytes 
PML, opportunistic 
infectious, fatigue, 
hypersensitivity 
Rituximab 
RA, MS, 
SLE 
Deletion of B cells: binds to CD20 
on mature B cells 
PML, opportunistic 
infectious. 
Etanercept  
RA, 
psoriasis, 
ankylosing 
spondylitis 
Neutralize TNF activity: binds 
soluble and transmembrane TNF 
and inhibits binding to TNFRs  
Serious bacterial and 
fungal infectious, 
tuberculosis, 
malignancies.  
Fingolimod 
MS, SLE, 
psoriasis 
Lymphatic sequestration of 
lymphocytes: modulator of 
sphingosine 1-phosphate receptor 
Bradycardia, 
infectious, macular 
edema, shingles, skin 
cancer 
Belimumab SLE, RA Inhibits BAFF 
Severe infectious, 
hypersensitivity.  
Leflunomide 
(Teriflunomide) 
RA, MS 
Inhibits de novo pyrimidine 
synthesis (inhibitor of the 
DHODH); inhibitor of Jak1 and 
Jak3 
PML, nausea, oral 
ulcers, alopecia, 
increased of liver 
enzymes, infections 
Glatiramer 
Acetate 
MS Induce Th2 and regulatory T cells 
Anxiety, rapid 
heartbeats, tightness in 
the throat, chest pain, 
hypersensitivity 
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1.1.2.2 Psychiatric health and autoimmune diseases 
Patients affected by autoimmune diseases frequently develop psychotic disturbances 
(28). To some extents, the same correlation has been found in the reverse scenario: 
people affected by psychotic disorders often show immune imbalance and 
abnormalities (50, 51). The most common neuropsychiatric symptoms found in 
autoimmune patients are depression, anxiety and mood disorders. Depression and 
anxiety have high lifetime prevalence in MS, around 79% and 40% respectively, 
followed by scleroderma (another chronic multisystem disorder) and SLE (28). 
Suicide risk reaches 28.6% prevalence in MS (28). This raises questions such as 
whether the coexistence of psychotic symptoms and autoimmune diseases results 
from a cause-effect relationship. Epidemiological study of the nature of their 
comorbidity shows that suicidal intents as well as depression and anxiety do not 
correlate to the degree of physical disabilities (52). It has also been documented that 
depression and other psychotic symptoms, such as bipolar disorder, affect patients 
even before the diagnosis is made and before the development of physical signs of 
autoimmunity (53), i.e. in one sixth of the cases of MS associated depression is 
diagnosed prior to the MS diagnosis (54). MS patients have higher prevalence of 
anxiety or depression compared to patients suffering from other unrelated diseases or 
healthy controls (55).  
 
Hence, the higher prevalence of depression or anxiety in patients affected by 
autoimmune diseases might be not only a psychological consequence of general 
malaise or physical impairments caused by autoimmune reactions. New hypotheses 
are investigated with the intent to explain such association. Among those, some 
suggest that mental disorders are a reflection of direct effects of cytokines on the 
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central nervous system. Others suggest that mental disorders and autoimmune 
diseases share common pathological pathways or, simply, that mental disorders 
predispose to the development of chronic physical illness (56).  
1.1.2.3 Multiple sclerosis and its experimental models 
Multiple Sclerosis (MS) is a neurodegenerative disorder that affects the central 
nervous system (CNS) and it is a major cause of non-traumatic disability in young 
adult. Around 2,500,000 people in the world are estimated to suffer from MS, with a 
prevalence of 1 in 600 in the UK, about 100,000 cases.  
 
MS is characterized by lesions of the white matter in the CNS, often referred to as 
plaques. These are the result of an inflammatory reaction that causes the degradation 
of myelin, the fatty sheath of the neuronal axons. The process is known as 
demyelination and is responsible for the impaired transmission of the electrical 
signals across the axons. This causes several unpredictable disabilities, including 
optic neuritis, ataxia, muscle weakness, speech problem, and bowel and sexual 
dysfunctions.  
 
MS is diagnosed when the first neurological attack lasts for 24 hours and it is 
followed by subsequent attacks which occur at least 30 days after the previous attack 
in order to be considered separate events. However, patients manifest different 
disease courses. About 85% of the patients initially present a relapsing-remitting 
disease form, in which clearly defined, repeated attack are followed by remissions. 
Approximately 50% of this might transit into a secondary progressive form in which 
neurological deficits cumulate without relapse. About 15% of the patients develop a 
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primary progressive course in which the disease worsens progressively without 
remission (57). 
 
The current understanding of the pathogenesis of MS comes from direct studies of 
MS patient lesions, as well as from investigation performed on animal models of 
encephalomyelitis. EAE (experimental autoimmune encephalomyelitis) is generally 
accepted as the model that better shares the clinical and pathological features of MS 
(58). It models the MS disease pattern, i.e. relapses/remissions, as well as its 
manifestations such as paralysis, ataxia and visual impairment. Both MS and EAE 
share MHC-linked susceptibility, T cells and antibodies reactive to myelin, 
demyelination and axonal dystrophy. In addition, studies performed with this model 
have allowed for the discovery of several effective therapeutics including GA and 
interferon-! (IFN!) (59, 60). 
 
T cells play a key role in the development of EAE (61) as it has been shown by the 
induction of the disease following transfer of purified, activated myelin-specific 
CD4
+
 T cells into healthy syngenic animals (62) as well as by the isolation of auto-
aggressive T lymphocytes in naïve rats (63). Less clear is the contribution of CD8+ T 
cells. However, a recent study has shown that CD4+, but not CD8+ T cells are the 
inducer of the diseases (64).  
 
The EAE can be induced in a wide range of species by immunization with CNS 
white matter protein (either self or non-self) called encephalitogen. These include 
myelin basic protein (MBP), proteolipid protein (PLP), myelin oligodendrocyte 
glycoprotein (MOG), or their peptides (PLP139-151 and MOG35-55). Each 
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encephalitogen and animal species offers different advantages. Rodent models in 
particular allow for the study of genetically homogeneous population, which reduces 
disease variability and increases reproducibility. However, the severity of the disease 
is greatly dependent on the MHC haplotype, the encephalitogen’s amino acid 
sequence and the immunization protocol (58). 
 
Among the murine models, the most commonly used strains are: 
• SJL/J (MHC haplotype: H-2(s)). Immunization of these mice with PLP139-151 
causes the development of an acute EAE, similar to a single relapsing event in 
MS patients (65); 
• Biozzi (H-2dq1) AB/H. Immunization of these mice with spinal cord 
homogenate or MOG induces a chronic relapsing/remitting EAE that resembles 
the relapsing/remitting MS in humans (66); 
• NOD (H-2(g7)). Immunized mice with MOG35-55 display a relapsing/remitting 
EAE that is followed by a chronic non-remitting phase, resembling a secondary 
progressive course of MS; 
• C57BL/6 (H-2(b)). Immunization of these mice with MOG35-55 leads to the 
development of chronic progressive EAE, which can be a model for the primary 
progressive MS in human (67). 
• 2D2 Mice. TcR transgenic model of MOG-driven EAE on C57BL/6 background. 
These mice have clonally homogenous MOG-specific CD4 T cells, which make 
them prone to develop EAE with a suboptimal dose of MOG35-55 and around 4% 
of 2D2 mice develop spontaneous EAE. 
• 1C6 Mice. TcR transgenic model of MOG-driven EAE on NOD background. 
These mice have clonally homogenous MOG-specific CD4 and CD8 T cells.  
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In all these models, a correlation between behavioural changes and the development 
of EAE has been described. For instance, Pollak and colleagues showed that the EAE 
induced in mice is accompanied by sickness behaviour that resembles the symptoms 
of depression. Indeed, in these mice autoimmunity was associated with anhedonia, 
social disinterest and cognitive impairment typical of depressive episodes (68, 69). 
EAE mice also display anxiety-like behaviour measured, for instance, by the 
reduction of exploratory activity (70). This is clearly observed even before the onset 
of motor dysfunction (71), therefore both sickness behaviour and anxiety-like 
behaviour do not correlate temporally to the muscle weakness and are the 
consequences of independent causes. The hypoactivity of the serotonergic system, 
the hyper-activation of the hypothalamic-pituitary-adrenal (HPA) axis (72) or the 
increase of cytokines such as IL1! or TNF# in the CNS, in particular in the striatum 
and hippocampus, have been described as possible biological alterations responsible 
for these observations. However, we have recently shown that the migration of T 
cells into the blood after immunisation is associated with the rise of mood changes in 
the early stage of the EAE. This would suggest the circulation of effector T cells also 
has an effect on the induction of anxiety-like behaviour (73).  
 
Although the EAE shows clinical and genetic features of MS, there are serious 
limitations to its use in translational studies. For instance, several successful 
therapies for EAE, such as treatment with anti-TNF#, have been proven to worsen 
the clinical conditions of MS patients (74). However, EAE remains a valid 
instrument to dissect the pathogenesis of MS and to give insights into the role of T 
cells in autoimmunity.  
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1.2 T cells and their role in autoimmunity 
T cells are fundamental players in the adaptive immune system. They are responsible 
for the host defence against a number of pathogens including bacteria, viruses and 
parasites. As discussed in Section 1.1 Immune tolerance and autoimmunity, immune 
homeostasis is the result of the balance between the various mechanisms that control 
immune tolerance and potentially autoreactive T cells (7, 75). In fact, autoreactive T 
cells can be considered one of the main therapeutic targets for the treatment of 
several autoimmune diseases. 
 
Next paragraphs provide a brief overview of the life cycle of a T cell, naïve T cell 
activation, T helper cell differentiation and their plasticity, as well as a description of 
the main T cell phenotypes associated with autoimmune diseases.  
1.2.1 Life cycle of a T cell  
The T cell repertoire develops in the thymus, from where functional T cells born #/! 
or "/$ TCR are selected and survive. The T cell precursor starts the maturation as a 
double negative (DN) T cell, which expresses neither CD4 nor CD8. During the 
maturation, first the functional rearrangement of the ! chain and later pre-#/! TCR 
promote the development of DN to double positive (DP; CD4+ CD8+) T cells (76). 
Both DN and DP are heterogeneous populations, in which several cell subsets are 
distinguished according to the expression of cell surface markers. Each cell subset is 
considered to be a distinct developmental step that a T cell undertakes to mature.  
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DN T cells are subdivided into at least 4 different subtypes called DN1, DN2, DN3 
and DN4. The maturation of DN T cells occurs in 4 stages, from DN1 to DN4, 
during which CD44+ CD25- DN T cells progressively decrease CD44 and increase 
CD25 expression. The ! selection, i.e. the rearrangement of a functional VDJ TCR!, 
occurs during DN1 and DN2 and it is critical for the passage from DN3 to DN4 (77). 
At this stage, RAG1/2 proteins play a key role in T cell development (see section 
1.1.1 Self tolerance of the adaptive immune system) and defective Rag gene 
expression arrest T cells at DN3 (78). The formation of a functional pre-#/! TCR is 
critical for the further proliferation and differentiation step that brings CD44- CD25+ 
DN4 T cells to CD44- CD25- CD3+ DP T cells (77). In 6-8 cell divisions, DP T cells 
generate the mature #/! TCR which drives the clone selection and lineage 
commitment (77, 78).  
 
Positive and negative selection allows for the survival and maturation of #/! TCR 
clones that bind to MHC molecules with low avidity and do not recognise, with some 
exceptions, self-antigens. Positive selected DP T cells progressively increase the 
expression of CD69 and CD5, which continue to be highly expressed until the DP T 
cells become single positive (SP; CD4+ or CD8+) T cells (79, 80). The passage from 
DP T cells to CD4 or CD8 lineage has been explained using different models of 
lineage commitment. The stochastic/selection model suggests that DP T cells 
randomly commit to a lineage at the start of the positive selection (78, 81). In 
contrast, the instructive model proposes that the co-engagement of TCR and CD4 or 
CD8 co-receptor determine specific intracellular signals that influence the 
progression towards one or the other lineage (78, 81). Engagement of one co-
receptor induces transcriptional silencing and thus the progressive loss of the other 
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co-receptor. A third model, called the instructive/default model, suggests that DP T 
cells are by default committed to the CD4 lineage and can be diverted from their fate 
by the MHC-class I instructive signal, which commits cells to the CD8 lineage (78, 
81). The most recent lineage commitment model is the strength of signal model. This 
suggests that the intensity or duration of signalling direct the development into CD4 
or CD8 lineage. In particular, short or weak signal generate CD8 SP T cells, whereas 
long or intense signal produce CD4 SP T cells (78, 81, 82).  
 
CD4 or CD8 SP T cells populate the lymphoid organs. Upon recognition of the 
specific antigen, they activate, proliferate and differentiate in different effector T 
cells. Upon antigen clearance, the expanded T cell population is reduced and rescued 
as memory T cells (83). In humans and mice, two major memory-T cell subsets have 
been described: central memory and effector memory T cells, TCM and TEM 
respectively. TCM constitutively express CCR7 and CD62L, fundamental receptors 
for the homing into secondary lymphoid organs, which are also typical markers of 
naïve T cells. They show little effector function, but rapidly proliferate and 
differentiate to effector cells after antigenic stimulation. TEM express typical 
receptors for the homing in inflamed tissues where they show rapid effector function 
(84). Memory T cells ideally can survive for a lifetime. However, their number is 
limited by a virtual immunologic space in the body where T cells have access to and 
yet must share limited survival resources such as homeostatic cytokines (83).   
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1.2.2 Naïve T cells and their activation 
Naïve T cells are normally quiescent and low-proliferating cells. To become fully 
activated they need three different signals (3). 
 
Signal 1 is triggered by the recognition of the antigen-MHC complexes by the TCRs 
and its co-receptors. Antigen presentation occurs via two main classes of MHC, 
which are called class I and class II. MHC class I molecules are widely expressed in 
our body and present mainly cytosolic antigens, while MHC class II molecules are 
mainly expressed on antigen-presenting cells (APC) and present antigens processed 
through endocytic pathway (85). The recognition of MHC class I or II is mediated by 
the CD8 and CD4 co-receptors, respectively (78).  
 
Signal 2 is provided by the binding of costimulatory receptors to costimulatory 
proteins expressed on APCs. There are several kinds of costimulatory receptors; 
some induce the T cell activation, such as CD28, whereas others elicit inhibitory 
signals, such as CTLA-4 (86). CD28-mediated signal 2 integrates signal 1 and it is 
non-redundantly required for the activation and clonal expansion of T cells; in the 
absence of CD28 co-stimulation, T cell anergy is observed (87). 
 
Signal 3 is mediated by a variety of cytokines and soluble mediators secreted by 
APC(s) and the surrounding tissues. These skew T cell differentiation towards a 
specific phenotype and are important modulators of T cell plasticity. This will be 
discussed in more details in section 1.2.3. 
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Once naïve T cells have received all the information for their activation, a complex 
cascade of intracellular signalling events occurs (88). In summary, engagement of 
TCR and its co-receptors allows for their clustering followed by activation of the 
lymphocyte-specific protein tyrosine kinase (Lck), phospholipase C gamma 1 
(PLC"1) and phosphoinositide 3-kinase (PI3K). These signalling pathways generate 
secondary cell messengers such as diacylglycerol (DAG) and calcium. The former 
activates mitogen-activated protein kinase (MAPK) pathways and protein kinase C 
(PKC), upstream the activation of transcription factors such as NF-!B and AP-1. The 
release of intracellular calcium from the endoplasmic storages induces the activation 
of calcineurin which in turn activates the transcription factor NFAT. All together 
NF-!B, AP-1 and NFAT control T cell proliferation, death and differentiation. 
 
The binding of CD28 to costimulatory B7 molecules activates phosphatidylinositol 3 
kinase (PI3K)-AKT pathway activating NF-!B and PKC signalling (89). The PI3K-
AKT pathway promotes the production of IL-2, expression of IL-2R and cell-cycle 
progression leading to the survival of T cells (87). Signal 2 has synergic effect to 
signal 1, thus favouring the setting of the biological threshold for T cell activation. 
Indeed, TCR signal is strictly dependent on the quality and quantity of T cell-APC 
interactions (90). Signal 2 is able to potentiate the strength of the TCR signal and 
influence the potency of the signalling, which is then responsible for quality and 
magnitude of the T cell response (91). 
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1.2.3 T helper cells and their differentiation 
T helper (Th) cells are CD4+ T cells that recognise bacterial and parasitic antigens 
presented by MHC class II molecules on the surface of APCs, including 
macrophages and dendritic cells. Once naïve Th cells recognise the antigen-MHC 
complexes and receive all the activating signals, they go through clonal expansion 
and differentiation in effector T cells. Clonally expanded T cells then undergo 
through clonal contraction and remain as memory Th cells (83). Activated Th cells 
communicate with a variety of immune cells, such as macrophages and B cells 
(hence the name “helper cells”), providing instructions for the elimination of the 
pathogen. 
 
Various effector Th cells exist in our immune system. They contribute to different 
immune responses through the secretion of specific cytokines, which are used to 
distinguish and describe each Th subtype. The profile of cytokines associated with 
each Th subset reflects the activation of different intracellular pathways and relative 
transcription factors. Table 1.4 summarizes these different features. 
 
Th1 cells express the transcription factor T-bet and release IFN"; they fight mainly 
intracellular pathogens. Th2 cells, instead, express GATA-3 and produce IL-4, IL-5, 
IL-13, which give protection mainly against extracellular parasites (92). Th17 cells 
express the transcription factor ROR"t and high level of IL-17, IL-22, IL-21 and IL-
23R. These cytokines are important for the defence against extracellular pathogens 
and fungi in specialised tissues like skin and gut (93). More recently, Th9, Th22 and 
Tfh cells have been described. The first two are named after the main cytokine they 
produce- IL-9 and IL-22- while the latter mostly release IL-6. Similarly to Th2, Th9 
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cells protect from parasites (94), while Th22 cells are implicated in the defence 
against microbes in the skin (95). Tfh cells steadily reside in the germinal centres of 
secondary lymphoid organs due to the continuous expression of the B cell follicle 
homing receptor CXCR5 and, in turn, regulate antigen-specific B cell activation (96). 
ThGM-CSF cells have been recently added to the list; they have been identified as T 
cells expressing ROR"t and GM-CSF with crucial pathogenic action in autoimmune 
neuroinflammation (97).  
 
All effector responses incited by Th cell subtypes can be “tamed” by Treg cells. 
These subtypes of T cells are generated during T cell development (these are known 
as naturally occurring Treg) or can be induced in the periphery by exposure of naïve 
T cell to TGF# (called induced Treg). In both cases, Treg cells are characterized by 
the expression of Foxp3 and by the production of anti-inflammatory cytokines such 
as TGF# and IL-10 (98). 
 
Table 1.4: Proprieties of T cell helper lineages 
 
 
 
 
 
 
 
 
 
 
 Cytokine(s) signature Master Regulator STAT Regulator 
Th1 IFN" T-bet STAT1; STAT4 
Th2 IL-4; IL-5; IL-13 Gata-3 STAT6 
Th9 Il-9 - - 
Th17 IL-17; IL-21; IL-22 ROR"t STAT3 
Th22 IL-22 AHR - 
Tfh IL-6 BCL6 STAT3 
Treg TGF# Foxp3 STAT5 
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As mentioned earlier, the differentiation of naïve CD4+ T cells in one or another 
subset is determined by quantity and type of antigen (avidity for TCR binding) as 
well as by specific cytokines that are present in the cell surrounding (Figure 1.1). For 
example, low-affinity binding between antigen and TCR skews towards Th2 
phenotype (91). IFN" and IL-12 strongly guide the differentiation towards Th1 
phenotype, while IL-4 leads to the Th2. TGF# induces the differentiation of Treg, but 
the combination of TGF# and IL-6 skews the differentiation towards Th17 cell type 
(99).  
  
Figure 1.1. Phenotype of CD4+ Th cells. Naïve CD4 T cells can differentiate in 
several phenotypes depending on the cytokines released in the milieu.  
 
 
Cytokines transduce their signalling through JAK/STAT pathway (100). STAT 
proteins are transcription factors that translocate into the nucleus upon 
homodimerisation and phosphorylation by JAK. There are 7 different STAT proteins 
which have non-redundant functions in the Th differentiation. STAT1 and STAT4 
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are required for Th1 cell differentiation, whereas STAT6, STAT3 and STAT5a/b are 
required for Th2, Th17 and Treg cell differentiation, respectively (see Table 4) (101).  
 
STAT activation regulates gene transcription directly by binding gene promoters and 
indirectly through epigenetic modifications of the chromatin (102, 103). The latter 
leads to a variation in chromatin condensation which determines the accessibility of 
transcription factors to gene regulatory sequences. In this way, epigenetic 
modifications strongly influence expression and/or repression of specific cytokine 
loci and thus, the stability of Th phenotypes. For instance, the IFN" promoter is 
accessible for the transcription in Th1 cells, while the IL-17 promoter is not. 
Conversely, the IFN" promoter show repressive genetic marks in Th17 cells, while 
the IL-17 promoter becomes accessible to the transcription (102). Thus, cytokines 
that promote a particular T cell phenotype also influence negatively the 
differentiation by silencing key factors regulating the others. Another example is the 
ability of IL-12 to induce the expression of T-bet and the silencing of GATA-3 
favouring the skewing towards Th1 phenotype or the capacity of IL-4 to exert the 
opposite effect thus favouring the development of Th2 cells (92). Hence, the 
differentiation towards a particular Th subset antagonizes the development of the 
others.  
 
For many years Th differentiation was considered a terminal commitment to a 
specific Th lineage. However, recent studies on T cell polarization and on cell-fate 
mapping have revealed that Th cells show several degrees of flexibility in expressing 
Th-specific transcription factors in response to extracellular stimuli (99, 104, 105). 
For instance, signalling through IL-12R induces destabilization of both Th17 and 
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Th2 subsets, both of which then assume Th1 features, i.e. expression of T-bet and 
production of IFN" (106, 107). The conversion of Th17 cells in Th1 has been 
observed in several animal models of experimental autoimmunity (105, 108). The 
switching from one T cell phenotype to another has often been detected at the site of 
chronic inflammation and correlated with the manifestation of signs of disease (105, 
109). This is consistent with the previously mentioned concept that it is mainly the 
local tissue milieu (i.e. signal 3 factors) that dictates the specific effector function of 
Th cells.  
 
 
 
Figure 1.2. Transitions of CD4+ T phenotypes. A hierarchy of stability has been 
suggested to explain experimental observations of Th phenotype transitions. Naïve 
CD4+ T cells are placed in higher unstable state followed by iTreg and Th17 cells. 
Th1 and Th2 cells are considered stable, although a switch from Th2 to Th1/Th2 
hybrid phenotype has been shown. 
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As electrons decay from high energy levels to low energy levels, CD4
+
 T cell 
plasticity has been defined as a cell transition from an unstable T cell subtype to a 
more stable phenotype (96) (Figure 1.2). The stability of a specific Th-phenotype has 
been explored through genome-wide studies of epigenetic modifications i.e. DNA 
methylation sites which are known to be permissive or recessive marks for gene 
transcription. These studies showed that some genomic regions present both 
activating and repressive epigenetic marks (bivalent modifications), which 
predispose to either the expression or the silencing of that particular region (110). 
For instance, Th17 cells present bivalent modifications in both T-bet and GATA3 
loci. Hence they are preconditioned cells that can be reprogrammed into Th1 or Th2 
subtype (111). Thus, Th17 cells are considered an unstable Th subtype. Conversely, 
Th1 and Th2 cells are classified as stable subtypes since transitions from these 
phenotypes to Th17 are not observed (96). This finding correlates with the only 
presence of repressive epigenetic configuration found in IL-17 and ROR" genes in 
both Th1 and Th2 cells (111). 
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1.2.4 T helper cells and autoimmune diseases 
Dys-regulation of T cell self-tolerance leads to a number of problems including 
autoimmune diseases. Although we can only speculate on the cause(s) of the breach 
of immune tolerance, we do know that Th cells have a key role in the pathogenesis of 
these disorders. One of the main matters of debate currently discussed is whether a 
single subtype of effector Th has predominant role in the diseases or combination of 
factors and Th phenotypes contribute to these.  
 
For a long time, Th1 cells and its signature cytokine IFN" were considered the main 
pathogenic driving factors of organ-specific autoimmune diseases. IFN" and other 
Th1 cytokines are detected at the sites of inflammation in both patients and animal 
models; for examples, IFN" is abundant in MS lesions as well as in EAE (112, 113). 
Furthermore, T-bet and STAT4 knockout animals are protected from developing 
signs of diseases such as in model of diabetes, EAE or experimental arthritis (CIA) 
(114-117). However, the incidence and severity of these autoimmune diseases either 
do not vary or may even increase as reported in animals deficient in IFN", IFN"R or 
STAT1 (114, 118, 119).  
 
This led to the identification of Th17 lineage as an alternative key T cell subset in 
autoimmunity. Indeed, Th17 cells and IL-17 have been detected in various 
autoimmune diseases including MS, RA and psoriasis (113, 120). Studies on mice 
deficient in the IL-23p19 or IL-12p40 indicated that IL-23 is critical in Th17 cell-
driven autoimmune response. In this instance, the absence of the IL-23 signal 
correlates with a reduced number of IL-17-producing Th cells leading, functionally, 
to a degree of resistance in the development of EAE and CIA models (121). 
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Conversely, mice knocked out in IL-17 do not show the same resistance proprieties 
and develop these autoimmune responses (122, 123). Thus, the attention has been 
recently focused on the IL-23/IL-23R signalling pathway, its downstream signals – 
both non genomic and genomic – and on how this influences the development of the 
diseases. 
 
Among the IL-23-induced molecules in Th17 cells, GM-CSF has been shown to be 
highly pathogenic. In contrast to IFN" or IL-17 knockout mice, mice knocked out for 
GM-CSF do not develop EAE and CIA, suggesting the existence of a new 
pathogenic Th phenotype: ThGM-CSF (97, 124, 125). Neutralizing antibodies 
against GM-CSF have proven clinical efficacy in RA patients, while this needs to be 
tested in patients suffering from MS (126).  
 
Studies on Th17 skewing have shown that depending on the polarising conditions, 
IL-17-producing Th cells can be pathogenic or non-pathogenic upon adoptive 
transfer. These two Th17 populations differ in the expression of several molecules 
including key cytokines and transcription factors. For instance, Th17 cells induced 
by TGF#3 and IL-6 are pathogenic, whereas differentiation in the presence of TGF#1 
and IL-6 induces non-pathogenic Th17 which can become pathogenic following 
further IL-23 stimulation (127). Pathogenic Th17 cells express higher levels of 
several factors such as GM-CSF, T-bet and STAT4 that, as mentioned above, are 
highly correlated with the development of autoimmune reactions (127). Hence, 
pathogenic Th17 cells have been suggested to have a hybrid Th17/Th1 phenotype i.e. 
they express both ROR"t and T-bet as well as they release both IL-17 and IFN". 
Consistent with these observations, these two Th17 populations are detected in 
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human samples and have been associated with the immune response to different 
pathogens (128). 
 
Other data show that the plasticity of Th17 has an important role in the pathogenesis 
of autoimmune diseases. Indeed, as mentioned earlier, in target tissues Th17 cells 
switch to Th1 and this conversion is necessary for the induction of full-blown disease 
in an experimental model of diabetes (129). Furthermore, hybrid Th17/Th1 cells and 
Th17-derived Th1 cells have been detected in synovial fluid of juveniles RA patients 
(130). These and many other observations thus suggest that the two phenotypes are 
connected with each other and are important in orchestrating the development of 
autoimmune diseases.  
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1.3 Annexin protein family 
The annexins are a family of 13 proteins that present an evolutionary conserved 
carboxyl terminal core of four to six homologous repeats and a unique N-terminal 
segment. The protein core mediates their ability to bind negatively-charged 
membrane phospholipids in a calcium-dependent manner. The N-terminal segment 
varies in length and mediates the biological functions of each annexin (131).  
 
Annexins are important for cell membrane scaffolding since they influence cell 
shape and stabilize membrane lipid rafts. They are also involved in trafficking and 
organization of vesicles, exocytosis and endocytosis and contribute to control cell 
growth and ion flux (131). All the annexins are mainly intracellular proteins that can 
be sequestered at the plasma membrane of the cells; however Anx-A1, -2 and -5 
make an exception since they can be secreted extracellularly to elicit biological 
effects in an autocrine/paracrine manner (132).  
 
1.3.1 Annexin A1 
Annexin A1 (AnxA1), also known as lipocortin or lipomodulin, is identified as a 
glucocorticoid-inducible protein able to inhibit the phospholipaseA2 activity, thus 
altering downstream the arachidonic acid cascade (133, 134). AnxA1 is a 37kDa 
protein constituted by 346 amino acids. In mice, AnxA1 is 355 amino acids long and 
its gene shares 70% homology with the human gene. AnxA1 has an N-terminal 
segment of 47 amino acids which mediates, in the presence of high concentration of 
calcium, its biological activity (135). The N-terminal segment contains a 
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phosphorylation and a proteolytic cleavage sites that are likely regulatory sites for 
the activity of the protein (136). 
 
AnxA1 is widely expressed in different cell types and is detectable in almost all the 
leukocytes. Neutrophils contain the largest amounts of Anx-A1, which is stored 
predominantly into gelatinase granules (137, 138), followed by monocytes, 
macrophages, mast cells and dendritic cells. T and B cells have lower levels of 
AnxA1 comparing to the other leukocytes. However these levels increase in 
activated T cells (138).  
 
After treatment with glucocorticoids, AnxA1 expression augments in myeloid-
derived leukocytes (139). Cell treatment with glucocorticoids has the opposite effect 
in T cells, with decreased expression and synthesis of AnxA1 (140). In all the cell 
types, first AnxA1 is mobilised by translocation to the plasma membrane, and then it 
is released in the extracellular space (141). 
 
AnxA1 and its-derived peptides are ligands of the formyl peptide receptors (FPRs). 
Three FPRs have been described in humans: FPR1, FPR2/ALX and FPR3. Both 
FPR1 and FPR2/ALX share about 80% homology with the murine genes. In mice 
these are known as fpr1 and fpr2, respectively. FPR3 seems to share similarities with 
fpr2. Additional members of FPR have been identified in mice but they do not have 
counterparts in humans (142). All these receptors belong to a family of seven G-
protein-coupled receptors used by the bacterially-derived product fMLP and an array 
of endogenous mediators to deliver a wide range of signalling molecules that are 
important for leukocyte activation and trafficking (143). Full length AnxA1 exerts its 
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biological functions mainly via activation of FPR2/ALX (144). In T cells, both FPR1 
and FPR2/ALX are expressed at very low levels with activated and memory cells 
expressing more than naïve T cells (138). Consistent with this, a study from our 
group has shown that activation of T cells with anti-CD3 plus anti-CD28 leads to the 
upregulation and externalisation of FPR2/ALX as quickly as after 30 minutes after 
stimulation and remained stable for the following 6 hours (145). 
 
1.3.2 Annexin A1 and its dual role in immune responses 
AnxA1 has dual actions in the immune response. In the innate immune system, 
AnxA1 has been shown to reduce the recruitment of leukocytes into inflamed tissues 
by inhibiting the adhesion and transmigration of leucocytes (146-148). For instance, 
AnxA1 knockout mice exhibit an exaggerated inflammatory response in the 
experimental model of zymosan-induced peritonitis – a classical experimental model 
of inflammation used to study leukocyte migration (149). Multiple cellular and 
molecular mechanisms have been proposed to be responsible for these effects. These 
include downregulation of neutrophil transmigration, apoptosis of neutrophils in the 
sites of inflammation, inhibition of eicosanoid production – such as leukotrienes or 
prostaglandins – as well as stimulation of phagocytosis by macrophages (132, 150, 
151). This wide spectrum of functions reflects the pleiotropic nature of this molecule 
as well as its cell-specific functions. In addition to this, different effects can be 
observed if the endogenous molecule or the recombinant protein/peptides are being 
investigated. In all cases, it is important to highlight that AnxA1 has unique place in 
the arsenal of anti-inflammatory molecule because of its ability to act as a pro-
resolving mediator for innate immune responses.  
  Introduction 
 
 52 
In the adaptive immune system AnxA1 has been shown to have pro-inflammatory 
effects on T cells and dendritic cells. Previous studies in our Centre investigated the 
role of AnxA1 in T cells showing that the human recombinant AnxA1 (hrAnxA1) 
increases anti-CD3 plus anti-CD28-induced proliferation, IL-2 production and 
expression of activation markers such as CD69 and CD25 in T cells (145). These T 
cells also show prolonged anti-CD3 plus anti-CD28-induced ERK and AKT 
phosphorylation. Naïve T cells exposed to hrAnxA1 differentiate into a Th1 
phenotype in both neutral and skewed conditions (145). Furthermore, AnxA1 
knockout (AnxA1-/-) T cells display impaired anti-CD3 plus anti-CD28-induced 
proliferation and activation as well as decreased ERK and AKT phosphorylation. 
While, T cells from AnxA1-/- mice show a marked Th2 and an impaired Th17 
phenotype compared to wild type T cells when differentiated in Th2 or Th17 
conditions, respectively (152).  This was also confirmed in Weyd et al., studies, 
which show that T cells pre-treated with AnxA1 secrete higher concentration of TNF 
and IFN" upon stimulation (153). Conversely, a recent study by Yang et al., 
contradicted these findings and proposed that deficiency of AnxA1 in CD4+ T cells 
exacerbates T cell–dependent inflammation (154). 
 
These modulatory effects of AnxA1 on T cell activation have also been explored at 
the level of development. Analysis of AnxA1-/- thymocyte populations at the 
immature DN stage showed a proportional decrease in the DN1 and an increase in 
the DN3 subsets compared to control littermates. There were no significant 
differences in thymocyte numbers or proportions of CD4+ and CD8+ SP populations 
between Anx1-/- and wild type (AnxA1+/+) mice (155). However, crossing AnxA1-
/- mice onto HY-TCR transgenic mice, an increase in DP and CD4 SP cells in male 
  Introduction 
 
 53 
HY-TCR/AnxA1-/- compared to HY-TCR/AnxA1+/+ was observed. Conversely, 
female HY-TCR/AnxA1-/- mice showed an increase in DP and a decrease in CD8 
SP cells compared to female HY-TCR/AnxA1+/+ (155). Consistent with the effects 
observed on mature T cells, AnxA1-/- thymocytes showed a decrease in anti-CD3-
induced Erk phosphorylation and NF!B activation compared to control littermates 
(155). 
 
Together these results indicate that the levels of AnxA1 control the threshold of TCR 
signalling and by doing so, can regulate T cell activation and proliferation. In 
addition, AnxA1 modulates T cell functions acting as master switch in Th1/Th2/Th17 
differentiation and balance. 
 
1.3.3 Annexin A1 and autoimmunity 
A dys-regulated expression of AnxA1 has been associated to several human 
pathologies with controversial outcomes. For instance, loss of AnxA1 expression is 
negatively correlated with breast or gastric cancer, while its upregulation is 
associated with tumour progression in lung and prostate carcinomas (156). In 
autoimmune diseases such as RA or SLE, patients have been found positive to auto- 
antibodies against AnxA1 (157, 158). In some cases, such as SLE, the level of anti-
AnxA1-antibodies was found to correlate with the disease activity (158, 159). The 
biological function of the auto-AnxA1-antibodies is controversial since they could 
impair the anti-inflammatory or inflammatory activities of AnxA1 and thus might 
promote pro- and anti-inflammatory downstream effects, respectively (159). 
Increased levels of AnxA1 protein have been detected in the CNS of MS patients at 
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the peak of disease (160, 161). This was initially associated with the anti-
inflammatory counter-action of AnxA1 on the innate immune response (162). 
However, comparative expression analyses have shown 10-fold increase of AnxA1 
in MS brain lesions at the early stage of inflammation (163). Moreover, AnxA1 was 
upregulated 1.5 to 2 fold changes in peripheral blood mononuclear cells of patients 
affected by autoimmune diseases, including MS patients, compared to healthy 
control volunteers (164-166). RA patients also show higher expression of AnxA1 in 
CD4+ T cells compared to healthy volunteers (145). Together with these evidences, 
studies have shown that administration of hrAnxA1 during the immunisation phase 
of the model exacerbates signs of disease in DBA mice subjected to collagen-
induced arthritis (145). In addition, AnxA1
-/- 
mice have been shown to develop a 
bland EAE compared to wild type mice and this was correlated to a lower number of 
T cells and macrophages infiltrating the CNS (167).  
 
Last but not least, genome-wide association studies (GWAS) database shows that 
single point mutation in the AnxA1 gene has been associated with bipolar disorder, 
as well as with schizophrenia (168). These psychotic disorders have been shown to 
be associated with alterations of immune homeostasis and accompanying 
autoimmune diseases – as extensively discussed in section 1.1.2.2 Psychiatric health 
and autoimmune diseases (169, 170). 
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1.4 Central Nervous System and T cells crosstalk  
The crosstalk between immune system and CNS is fundamental for the homeostasis 
of the whole body and for the synchronization/integration of human functions. There 
are substantial evidences that support this connection, some of which also come from 
daily-life. It is self-evident that systemic inflammation or infections induce 
behavioural responses mediated by the CNS such as fever, reduction in motor 
activity, loss of appetite, sleepiness, hyperalgesia, anxiety and depression. These 
symptoms are often combined under the name of sickness behaviour and are 
mediated by a number of factors including the acute-phase proteins (IL-1, IL-6, IL-8 
and TNF#) (171, 172). This is a form of protective and fitness response of our body 
to cope with adverse health conditions and can be considered a safeguard mechanism 
that our body has evolved in order to favour healing and repair.  
 
The brain and the spinal cord, referred to as CNS, have been considered immuno-
privileged sites of our body thanks to their ability to restrict the access of immune 
cells and also limit immune functions. The CNS microenvironment is able to induce 
immunological ignorance as it has been demonstrated by the prolonged survival of 
tissue grafts in this anatomical site (173, 174).  
 
The blood brain barrier (BBB) plays an important role in separating CNS and the 
immune system, and in regulating tightly their communication (175). It limits the 
penetration of antibodies, immune mediators and immune cells from the systemic 
circulation. However, the BBB is necessary but not sufficient to provide and 
maintain immune privilege. Indeed, even in case of compromised BBB, the CNS 
maintains its separation from the immune system. Consistent with this, studies have 
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shown the injection of an antigen into the CNS is able to induce systemic tolerance 
as showed by the absence of T cell response against the same antigen once this has 
been reintroduced into another part of the body (176). Thus, it seems that it concerns 
active processes able to down-regulate local and systemic inflammation. 
 
As suggested by Britta Engelhardt (University of Bern), the CNS anatomical 
organization resembles the architecture of a medieval castle, where the castle itself 
represents the CNS parenchyma. This is protected by two walls separated by a moat 
(the BBB). Endothelial cells and pericytes resemble the outer castle wall while 
astrocytes resemble the inner castle wall (173). The cerebrospinal fluid (CSF), 
subarachnoid space or meningeal spaces could be represented by the moat. In these 
spaces, the immune surveillance takes place. T cells can cross the outer wall, through 
the recognition of selectins and adhesion molecules and enter into the moat where 
they can encounter meningeal myeloid cells such as macrophages and dendritic cells, 
even if these are less represented (177).  
 
1.4.1 Role of T cells in CNS homeostasis and pathologies 
T cells and leukocytes penetrate into the CNS via the choroid plexus or through post-
capillary venules. In homeostatic and healthy conditions, they accumulate in the 
subarachnoid space while are rare in the CNS parenchyma. On average, the 
leukocytes found in the CSF of normal healthy donors are about 1000–3000 cells/ml. 
T cells in the non-inflamed CSF are predominantly central memory T cells 
(CD4+CD45RO+CD27+CD69+) which have been recently activated and expressing 
high levels of CC chemokine receptor type 7 (CCR7), L-selectin, and P-selectin 
glycoprotein ligand-1 (PSGL-1) (177). The passage into the CSF is partly regulated 
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by the binding of #1!4 integrin (or VLA-4) and PSGL-1 expressed onto T cells to 
their ligands, VCAM-1 and P-selectin, respectively, present onto endothelial cells 
(175).  
 
The immune surveillance exerted by T cells in the CNS is similar to that performed 
in other tissues. The activation of MHC class II
+
 APCs such as microglial cells or 
astrocytes by an immunogenic stimulus, however, increases the expression of MHC 
complexes and co-stimulatory molecules causing an increase of avidity in the 
interaction of T cells and APCs. Therefore, in this context even low avidity TCRs 
such as the ones born by self-reactive T cells can be activated and give rise to 
immune reactions that might result in autoimmunity. This is the case for patients 
suffering from MS who differ from healthy controls not in term of the frequency of 
myelin-specific T cells, which are comparable, but in the frequency of high avidity T 
cells (177). 
 
Besides the regular immune surveillance, T cells have physiological and homeostatic 
effects on the CNS. Studies have shown the existence of self-reactive T cells that are 
able to protect the CNS in presence of neuronal injury by reducing secondary 
degeneration processes and increasing neuronal survival (178-180). Indeed, T cells 
have an active role in modulating neurogenesis as well as in memory and learning 
functions (170, 181-185). This was observed in both SCID mice and nude mice (i.e. 
mice with few or no T cells) which have impaired neurogenesis in response to an 
appropriate stimulus. While, the defect was corrected following the transfer of spleen 
cells from normal animals and was not observed if the splenocyte population was 
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depleted from T cells (182).  
 
Similarly, T cells are able to restore the dysfunctional learning observed in SCID 
mice or following ablation of adaptive immunity (181). In addition, the 
reconstitution of SCID mice with T cells or the boosting of T cells by vaccination 
with myelin specific peptide have been shown to ameliorate and diminish post-
traumatic stress disorder (186, 187). In general, cognitive tasks in mice are 
accompanied by increased number of T cells in the meningeal space (183) and the 
performance are impaired by treatments that reduce T cell migration into CNS (such 
as antibody against VLA-4; (43)) or trap T cells in the lymph nodes (such as 
Fingolimod treatment; (44)) (183). When one considers the different subtypes of T 
cells, it is interesting to note that using CD4 or CD8 specific antibodies, studies have 
shown depletion of CD4 T cells but not of CD8 is associated to learning impairment 
in mice (185). It has been also described that performance of cognitive tasks led 
particularly to accumulation of IL-4 producing T cells in the meninges. This is 
consistent with cognitive defects observed in IL-4
$/$
 mice (183). 
 
The absence of IL-4-/- T cells has been shown to cause a shift in the phenotype of 
meningeal myeloid cells towards a proinflammatory state. This was associated with a 
rise in IL-1!, IL-12 and TNF-% in the meningeal space which in turn negatively 
affected CNS functions (188). Yet, depletion of circulating immune cells worsens 
disease course of neurodegenerative conditions (189). Indeed, T cells with a Th2-like 
phenotype are associated with upregulation of genes involved in tissue repair, 
whereas Th1 phenotype are not (190). It has been shown that IL-4 expression in the 
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CNS is able to upregulate the expression of chemokines (CCL1, CCL17 and CCL22) 
involved in the recruitment of Treg (191) and of brain-derived neurotrophic factor 
(BDNF) (183). 
 
BDNF is an essential neurotrophic factor for adult neurogenesis, spatial learning and 
memory (192). It is classically produced by astrocytes and neurons and it has 
recently discovered being secreted also by immune cells (193). Interestingly, other 
neurotrophins and their receptors are produced and act on the immune system (Table 
1.5), in particular it has been showed that myelin specific T cells in the brain secrete 
high amount of BDNF (193, 194).  
 
 
Table 1.5: Expression of neurotrophic factors by immune cells 
 
 
 
 
NGF: Nerve Growth Factor; NT:Neurotrophin.  
 
All together these observations led to the formulation of a new concept termed 
protective autoimmunity by its own author Prof Michael Schwartz (Weizmann 
Institute of Science, Rehovot, Israel). According to this theory, the adaptive immune 
response is fundamental for the maintenance of CNS integrity and homeostasis. 
More specifically, immune cells (mainly CD4+ T cells) are pivotal for CNS 
neuroprotection and repair. Indeed, CD4+ T cells recognize brain antigens upon 
 T cells B cells Monocytes 
NGF + + + 
BDNF + + + 
NT 3 + + + 
NT 4/5 + No data No data 
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injury to the CNS and this signals the recruitment of the body’s defense mechanisms. 
However, if this response escapes control, its benefit is replaced by a detrimental 
effect that leads to an inflammatory autoimmune disease. This innovative concept 
rebuilds the way to interpret immunobiology and has a wide range of therapeutic 
implications. 
 
1.4.2 Stress, HPA axis and inflammation 
CNS and immune system, together with endocrine system, act in a synchronised 
manner. The co-operations occur through preferential signalling canals that are 
shared by the three systems. 
 
As mention in the section above, neurotrophins are an example of common factors 
that CNS and immune cells used for the crosstalk during stressed conditions for the 
CNS. Interestingly, the presence of both endogenous and exogenous stressors 
activates sympathetic nervous system and HPA axis, which through the secretion of 
their final mediators, catecholamines and glucocorticoids (GCs) respectively, 
regulate many systemic functions such as metabolism, heart rate, thermogenesis and 
also the immune system (195).  
 
Catecholamines act i.e. in secondary lymphoid organs up-regulating IL-1! and IL-6 
expression and release by peripheral macrophages (196). This pro-inflammatory 
profile is for example observed after social disruption stress or exposure to mild 
electric foot shock stress (197). In addition, these mice showed splenomegaly and an 
increase in anxiety- but not depressive-like behaviour (198, 199). Catecholamines 
further potentiate the production of IL-8 by monocytes of the lung thus contributing 
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to the recruitment of leukocytes in local inflammation (200). However, if we 
consider the bigger picture, the systemic effect of catecholamines is to skew T cells 
towards a Th2 phenotype, thus controlling the production of IL-12 and IL-10 (201). 
Studies have shown in both in human and mouse that !2-AR agonists inhibit the 
production of IFN" by Th1 cells while !-ARs antagonists causes a substantial 
increase in LPS-induced TNF# and IL-12 production (195). This is relevant to 
autoimmune conditions where agonists for !-ARs suppress EAE or CIA 
development (202, 203). 
 
Cytokines such as IL-1, IL-6 or TNF# are able to penetrate the BBB and stimulate 
the secretion of corticotropin releasing hormone (CRH) in the hypothalamus (203, 
204). CRH in turn stimulates the secretion of adrenocorticotropin hormone (ACTH) 
in the pituitary and this untimely leads to the increased secretion of GCs in the 
adrenal cortex (204). GCs suppress the production of TNF#, IL-2 and IFN" in vitro 
and in vivo in both mouse and human (205). High concentration of GCs has 
inhibiting effects on the secretion of IL-1 and IL-12 by macrophages (201, 206) or 
on the expression of IL-12 receptor on T cells and NK cells (207). Then, GCs have 
stimulatory effect on the production of IL-10 by CD4+ T cells (208), which has also 
been measured in the blood of MS patients after treatment with GCs (209). 
Circulating GCs act also centrally in the CNS. It has been described two type 
responses to GCs: early and late effects. The former known also as nongenomic 
effects occur rapidly within 15-20 min and lead to a rapid adaptation to stress- i.e. 
they include the increase of locomotion, food intake, aggressive behaviour and the 
decrease of ACTH secretion (210). The late responses, known as genomic effects, 
required de novo protein synthesis and this implies a latency of days. Paradoxically, 
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low concentration of GCs locally activates alveolar macrophages and during chronic 
stress such as autoimmune diseases, characterised by high levels of IL-1, TNF# and 
IL-6, the CRH is suppressed while ACTH and GCs have inappropriately normal 
plasma levels. 
 
1.4.2.1 HPA and Annexin A1 interconnection 
AnxA1 has been proposed to be one of the factors that mediate the negative feedback 
between GCs and ACTH (211). Studying pituitary glands obtained from rats, it has 
been observed that AnxA1 secretion increases in presence of ACTH (212). 
Treatment of pituitary glands with dexamethasone ex vivo inhibits ACTH production 
(213). This inhibitory effect fails in presence of anti-AnxA1 antibody or antisense 
oligonucleotide for AnxA1 (214, 215). However, AnxA1 knockout mice do not 
respond to this mechanism, likely due to compensatory pathways (Prof. Rod Flower 
personal communication).  
  
The expression of AnxA1 in the CNS is not ubiquitous (216). Looking at the 
pituitary gland, AnxA1 is highly and specifically expressed by follicular cell 
localised in the anterior pituitary gland. Then in presence of ACTH, AnxA1 is 
detected at the intercellular contacts between follicular cells and hormone-secreting 
cells. This suggested that upon GCs stimulation AnxA1 is released from the 
cytoplasmic storage of follicular cells using ABC transporters and inhibits the release 
of ACTH by the hormone-secreting cells through the binding to its receptor (211). 
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1.4.3 T cells and Emotional disorders 
It is evident that immune cells are indispensable messengers in our body. Their 
products and cell-cell interactions mediate long and short distance communication in 
the body. It is not yet completely known how this communication is regulated and 
the mechanisms that prevent likely detrimental effects caused by uncontrolled or 
dys-regulated immune system.  
 
For instance, activated macrophages and T cells have been proposed as major cause 
of BBB destabilisation linked to mental disorders. Studies have shown that systemic 
inflammation can trigger dementia and associated depression or anxiety (169, 217, 
218). A very exciting recent study has also shown that treatment of patients suffering 
major depression with anti-TNF-# resulted in a significant improvement only in 
those patients that had high level of C-reactive protein (CRP) further suggesting a 
link between systemic inflammation and mood disorders (219). Consistent with this, 
increased concentration of inflammatory biomarkers, typical Th1 cell signatures – 
such us IL-2 and IFN" – have been detected in the blood of patients with severe 
clinical depression (220, 221). 
 
High prevalence of anxiety- and depression-related disorders has been recorded in 
patients suffering from autoimmune diseases (see section 1.1.2.2 Psychiatric health 
and autoimmune diseases). In a similar way, a high prevalence of autoimmune 
diseases in patients affected by bipolar disorder (a maniac-depressive illness) or 
schizophrenia has been reported (50, 222). 
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Emerging clinic observations on stressed and depressed individuals have shown a 
reproducible decreased number and percentage of leukocytes including T cells, but 
higher CD4/CD8 T cell ratio (223). An impaired T cell response has been also 
described in those patients, in which T cells exhibit accelerated apoptosis (224). In 
another study on stressed law school students, the authors have shown an association 
between optimism and high number of CD4+ T cells (225). It is important to 
highlight that these observations are strictly related to demographic and clinical 
parameters such as age, sex and severity of mental illness, which should be taken in 
account (226). 
 
For instance, schizophrenic patients at the early stage of the disease show increased 
number of CD3+ and CD4+ T cells, among which memory cells are significantly 
fewer (227), while, at later stage, the CD4+/CD8+ T cell ratio decreases (228). In 
contrast to this, an increased number of activated CD4+ T cells have been found in 
patients suffering mood disorders such as patients with treatment-resistant depression 
(229) or anxiety (230).  
 
To add a further level of complexity to this already variegated scenario, evidences 
have shown that chronic and acute stresses seem to have different effect on the 
immune system (231). In the case of acute stress, the immune system and 
lymphocytes are stimulated as shown by the detectable increase of activation marker 
expression, proliferation and production of cytokines including IFN" (232). While 
chronic stress has been shown to lead to a decreased number and percentage as well 
as to lower response of lymphocytes to proliferation stimuli (233). However, this is 
not the case in patients suffering from autoimmune diseases, who exhibit active and 
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proliferative lymphocytes although under chronic stress. In this last scenario the lack 
of immunosuppression has been attributed in EAE to the presence of pro-
inflammatory T-cell lineages that are resistant to GCs (234).  
 
Lymphocytes share more than 75% of the transcriptome with the brain. They express 
several receptors including receptor for cytokines, GCs, catecholamine, dopamine 
and acetylcholine that allow lymphocytes to promptly respond and take part to 
systemic inflammation as well as fight-or-flight body responses. Thus, CNS 
alterations in metabolism or cellular functions observed during neuropsychiatric 
disorders consequently imprint lymphocyte alterations in their metabolism and 
functions. For this tight connection between CNS and lymphocyte actions, studies 
have interestingly suggested to use peripheral blood mononuclear cells (PMBCs), in 
particular lymphocytes, to identify genes associated with CNS diseases including 
psychiatric disorders or, in general, to investigate alterations in the immune-
neuroendocrine system (232, 235). 
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1.5 Hypothesis of the PhD 
The main hypothesis of this PhD project was to demonstrate the proinflammatory 
effects of AnxA1 in T cells in vivo using T cell-specific AnxA1 transgenic mice 
(AnxA1
tg
). We also tested the hypothesis that agents blocking AnxA1 function 
(neutralizing antibody, VJ-4B6) could provide an effective new therapy for the 
treatment of autoimmune diseases.  
 
Serendipitously, while testing these ideas, we observed an abnormal behaviour in 
AnxA1
tg
 mice characterised by a wide range of manifestations ranging from signs of 
anxiety to maternal cannibalism. This behavioural phenotype was particularly 
interesting to us considering the ever-increasing amount of literature describing a 
connection between mood disorder and autoimmunity. 
 
In light of these findings we formulate another new hypothesis i.e. that AnxA1 
overexpression in T cells might represent a predisposing factor for the development 
of mood disorders in autoimmunity and vice-versa.  
 
 
1.6 Aims of the PhD 
The specific aims of this PhD range from wide and macroscopic in vivo evaluations 
to more microscopic cellular and molecular analyses. These are to: 
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• Study the development of MOG33-55-induced EAE and pristane-induced lupus in 
AnxA1
tg
 mice; 
• Characterize at cellular and molecular levels the phenotype of T cells in the 
above-mentioned experimental models; 
• Characterize the emotional behaviour of AnxA1
tg
 mice; 
• Explore molecular mechanisms using microarray gene expression analysis; 
• Test the therapeutic potential of a novel AnxA1 neutralizing antibody called VJ-
4B6 in mouse model of autoimmunity and mood disorders. 
 
 
 
 
 
 
 
        2. Materials & 
Methods 
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2.1 AnxA1tg Mice: genotyping, breeding and husbandry 
In all the experiments we have used T cell specific Annexin-A1 transgenic mice 
(AnxA1
tg
) backcrossed on C57BL/6 background for more than 11 generations. Two 
AnxA1
tg
 colonies have been generated starting by two separate founders: Bella 
(female mouse) and Eric (male mouse). These mice were previously generated in our 
lab using a C terminal FLAG-tagged AnxA1 cDNA construct cloned into the 
VACD2 cassette. The VACD2 plasmid contains promoter and locus control region 
(LCR) sequences of the human CD2 gene, which confer T cell specific expression 
and, integration site independent and copy number dependent expression, 
respectively (Figure 2.1) (236).  
 
 
Figure 2.1. AnxA1
tg
-VACD2 construct used to generate AnxA1
tg
 mice. Scheme of 
the VACD2 backbone plasmid used for the creation of the transgenic strain. AnxA1
tg
 
gene is downstream the CD2 promoter and a schematic representation of AnxA1 
protein domains is depicted. The bleu boxes represent the annexin-repeats which 
follow the unique N-terminus and proceed the FLAG tag. 
 
The AnxA1
tg
 mice were kept inbreeding to maintain the homozygous colony in 
pathogen-free condition in our animal house. If not alternatively specified, 
experiments were done using Eric’s mouse progeny. Control littermates were used 
(CD2 Promoter) (LCR) 
VACD2 (12 Kb) 
AnxA1 Flag  
Flag 
N-terminal Annexin repeats 
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for a comparison throughout the backcrossing. Most of the experiments described in 
this thesis have been performed with commercially available C57BL/6 control mice 
(Charles River Laboratories; Margate, UK) that have been previously shown to have 
no difference compared to AnxA1
tg
 littermate (Dr D’Acquisto personal 
communication). Mice were housed for 7 days for their acclimation according to the 
guidelines given by the local Ethical Committee for the use of Animals. Most of the 
behavioural data have been generated with C57BL/6 control mice bred in house in 
order to avoid any interference of the housing condition onto the behavioural tests 
we have performed. The mice were kept in standard conditions: 12-hour light/dark 
cycles and 22 ±1ºC. Animal work was performed according to Home Office 
regulations in UK (Guidance on the Operation of Animals, Scientific Procedures 
Act, 1986). The animals used in these studies were aged between 5 and 8 weeks. 
 
To genotype the transgenic colony I have used a protocol previously validated in the 
host lab. Briefly, genomic DNA was extracted from ear clips using REDExtract N-
AMP –XNAT kit (Sigma-Aldrich, Dorset, England) as recommended by the 
manufacturer’s instruction. Each tissue clip tissue was incubated in 50&l extraction 
solution prepared by mixing the tissue preparation and the tissue extraction solutions 
in a ratio 1:3. The DNA extraction was achieved at 94ºC for 12minutes. Then, the 
samples were cooled down at 4ºC for 3-5min and 50&l of neutralization solution was 
added in each one. From each sample, 4ul of genomic DNA was then subjected to 
PCR with the following specific primers for AnxA1
tg
: forward primer 5’-
GTATGGAATCTCTCTTTGCCAAGC-3’; reverse primer is 5’-
ACGGATATGCACATCAGGAGGG-3’ (Thermo Scientific, UK). The parameters 
of the PCR reactions are: initial denaturation at 94ºC for 3min followed by 30 cycles 
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of denaturation at 94ºC for 45sec, annealing at 60ºC for 45sec and extension time at 
72ºC for 15sec, and afterwards a final extension step at 72ºC for 7 min.  
 
 
a. PCR samples:  
 
4&l of extracted DNA 
10 &l of PCR Reaction Mix 
0.4&M for each primer* 
x &l of H2O up to 20&l. 
 
 
* Forward and reverse primers were 1:100 diluted in one solution and 3&l of this 
mixed solution was used for the PCR reaction.  
 
 
b. DNA amplification parameters:  
 
 Anx A1tg 
Initial denaturation 94ºC 3min 
  
Denaturation 94ºC 45sec  
Annealing 60ºC 45sec 
Extension time 72ºC 15sec 
 (30 cycles) 
Final extension 
time 
72ºC 7min 
 
 
The amplified DNA was loaded onto 2% agarose gel and detected by GelRed 
Nucleic Acid Gel Stain, 10,000x (Biotium, Hayward, CA) at the transilluminator. 
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2.2 MOG 35-55 induced EAE 
The MOG35-55 induced EAE in C57BL/6 mice is an accepted model to investigate T 
cell- and macrophage-mediated demyelination (58, 67). Other advantages of this 
model include an efficient induction rate and the presence of histopathological signs 
comparable to those found in human lesions (237). This model is induced by the s.c. 
injection of MOG35-55 emulsified to complete Freud’s adjuvant (CFA). The CFA 
contains heat killed Mycobacterium tuberculosis (strain H37Ra), which enhances 
immune responses to the antigen. The immunisation is followed by an i.p. injection 
of Bordetella pertussis toxin (PTX) at day 0 and day 2. The first signs of EAE started 
to manifest around day 10
th
 -12
th
 from when progressive motor deficits were 
observed until day 18
th
 -20
th 
 (Figure 2.2). The animals were weighed daily to 
monitor the progression of the disease. Experiments were carried out using AnxA1
tg
 
and control C57BL/6 male mice of 6-7 week old. 
 
Figure 2.2. Timeline used for the induction of the EAE by MOG35-55 
immunisation. Animals were let acclimating for a week before the immunisation. At 
day 0, MOG35-55 and PTX were injected. A second PTX injection occurs at day 2. The 
scoring of the EAE disease signs starts around day 10. 
 
0 - 7 
Acclimation 
2 10 Days    
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2.2.1 Water-in-oil emulsion preparation and mice immunisation 
The immunisation for MOG35-55 induced EAE was performed following three main 
steps.  
 
First, the emulsion for the immunisation was prepared. Each mouse received an 
emulsion composed of 300&g of MOG35-55 peptide 
(MEVGWYRSPFSRVVHLYRNGK, synthetized by Cambridge Research 
Biochemicals, UK) dissolved in 150&l of PBS and 150&l of CFA (Complete Freud’s 
Adjuvant, Sigma-Aldrich, Dorset, England). Figure 2.3 shows a flowchart of the 
procedure to obtain the emulsion of MOG35-55 in CFA. First, CFA was placed in a 
glass flask and second, MOG35-55 previously dissolved in PBS was add. It is a rather 
important aspect that the blades of the homogenizer are completely submerged into 
the mixture of MOG35-55 and CFA in order to obtain a perfect emulsion. Thus the 
volume of the used glass flask was strictly related to the volume of the emulsion to 
be done, which was dependent on the number of mice to be immunised. For instance, 
to immunise 30 mice, 4.5ml of MOG35-55 solution were dissolved in 4.5ml of CFA 
for a total volume of 9ml for which 50ml glass flask was used to homogenise the 
mixture. To disperse the MOG35-55 solution in the CFA oil, a high-pressure 
homogenizer was used. About 10 minutes were sufficient to obtain the water-in-oil 
emulsion, which was then transferred into 1ml syringes (BD Luer-Lok%). The filling 
up of the syringes has been done slowly and without needle (23G). The emulsion 
was maintained in ice both during the preparation phase and the filling up of the 
syringes (Figure 2.3).  
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Second, the PTX solution was prepared. The PTX (Sigma-Aldrich, Dorset, England) 
arrived as lyophilized powder that was resuspended in 500&l water in order to have 
0.1&g/&l concentrated solution, according the manufacture’ instructions. For each 
mouse 500ng of PTX were diluted in 100&l PBS. The i.p. injections were carried out 
using 500&l tuberculin syringes. 
 
Third, the mice were anesthetized by inhalation of Isoflurane (IsoFlo 100%w/w, 
Abbott, Illinois, USA) mixed to oxygen and nitrous oxide. Finally, the mice were 
immunised with i.d injection of 150&l of emulsion in each flank, i.e. each mouse 
received 300&l total volume of the emulsion, and i.p injection of 100&l of PTX.  
 
 
 
 
Figure 2.3. Preparation of MOG
35-55
 emulsion in CFA. MOG35-55 is diluted in PBS 
and added to CFA in a glass flask (1:1 volume ratio) in order to prepare a water-in-oil 
emulsion (1&2). The homogenization is carried in ice and increasing progressively the 
speed (3). About after 10 min, the emulsion is ready and is transferred in BD Luer-
Lok% 1ml syringes. Keep the emulsion at 0ºC until the time of injection (4). 
 
   
 
 
 
1. CFA 
2. MOG
35-55
 in PBS 
3. Homogenize: 
- Mix for ~10min in ice; 
- 3 progressively higher speeds. 
4. Filling syringe: 
- w/o needle; 
- in ice. 
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2.2.2 Scoring system and time course of MOG 35-55 induced EAE 
The signs of disease for the EAE range from weakness of the tail proceeding to full 
paralysis of hind limbs. A 6-point scale scoring system based on motor deficits was 
used to represent disease severity: 0- no disease; 1- partial flaccid tail; 2- complete 
flaccid tail; 3- impaired righting reflex; 4- partial hind limb paralysis; 5- complete 
hind limbs paralysis; 6- moribund or dead animal (Figure 2.4).  
 
 
Figure 2.4. The EAE scoring system. The scoring system is based on 6-point scale. 
The photos depict the observed motor impairment that is conventionally associated to 
each score. 
 
 
Generally, in a time course of EAE development it is possible to recognise three 
different phases: pre-onset, onset and disease (Figure 2.5a). The pre-onset phase 
starts the day of induction of EAE, when mice are immunized with MOG35-55. 
During this time the immune system is primed towards MOG35-55 and autoreactive T 
cells expand and transmigrate from the draining lymph nodes to CNS (109, 238, 
239). 
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This apparently quiescent phase is followed by the onset phase when the first signs 
of disease start to manifest (around day 10
th
 -12
th
). Here, the inflammatory cascade 
prompted by T cells has been turned on and has started to cause damage in the CNS. 
The following third phase, called for convenience the “disease phase”, is featured by 
the progressive motor deficits upon day 18
th
 -20
th
 (Figure 2.4).  
 
 
 
Figure 2.5. MOG
35-55
-induced EAE. a) MOG35-55 induced EAE in C57BL/6 
manifests as chronic progressive motor disability. Three phases can be distinguished: 
pre-onset, onset and disease. b) Mice are immunized after 7 days of acclimation by 
injection of self-antigen MOG35-55  (day 0) and PTX (day 0 and 2). The mice are scored 
for EAE disease signs after 10 days from immunization.  
 
 
The onset of the disease is a conventionally defined as the time mice manifest a score 
of 1 or 2. This means that when the mouse is held from the base of its tail, the latter 
does not respond to stimuli and falls down lacking in tone. As the disease progresses, 
the mice reach a score of 3 characterised by the loss of righting reflex. This is a 
b) 
a) 
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reflex that occurs naturally when the body of an animal is inverted. In mice affected 
by EAE, such an instinctive reflex is impaired and thus sick mice remain lying on 
their back when turned. When mice show a score of 4 and 5, it is clearly possible to 
notice a partial (one leg) and full (both legs) paralysis of hindlimbs, respectively. The 
development of EAE is not synchronized among the immunised mice, meaning that 
not all mice affected by EAE manifest same score at the same time. This explains the 
existence of a standard deviation of the EAE disease score, which becomes higher 
over time during the disease phase (Figure 2.5a). 
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2.3 Pristane-induced lupus  
Pristane is naturally occurring hydrocarbon oil that induces chronic inflammation 
when introduced into the peritoneal cavity. After a single i.p. injection mice develop 
typical characteristic of SLE including production of autoantibodies, immune 
complex-mediated glomerulonephritis and alveolar haemorrhage. The convenience 
of this experimental system compared to the other well-known model of SLE is that 
is strain-independent and chemically induced (thus more reproducible) (240, 241). 
 
AnxA1
tg
 or wild type female mice of about 6-weeks were injected i.p. with 
500&l/mouse of pristane (Sigma-Aldrich, Dorset, England). All mice were monitored 
for their weight for over one month from the injection. Lethality and tissue histology 
were used to compare the grade of disease in the two groups. T cell phenotype in the 
model was assessed at day 14 from the day of the injection by intracellular staining 
of T cells present in the peritoneal exudates (242). 
 
2.3.1 Proteinuria scoring 
Proteinuria was measured in a drop of murine urine by using a colorimetric assay 
strip for albumin (Siemens/ Bayer Albustix; MidMeds, UK), where 0- absence of 
traces, 1- mild (30mg/dl), 2- moderate (100mg/dl) and 3- severe (>300mg/dl). 
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2.4 Treatments  
VJ-4B6 is a monoclonal antibody with IgG2b isotype that recognizes the AnxA1 in 
its native tertiary and/or quaternary structure. Therefore the binding of VJ-4B6 to 
AnxA1 protein has a neutralizing action. VJ-4B6 antibody was generated using the 
genetic immunization technology developed by Genovac (Aldevron, Freiburg, GE) 
(Figure 2.6).  
 
Figure 2.6. Genetic immunisation through GENOVAC antibody technology. The 
cDNA of an antigen is cloned in a vector, which allows the protein to be expressed in 
the native conformation at the plasma membrane. The cloned vectors are transferred 
into mice carried by gold particles. The murine cells engulf the cDNA and express it 
on their surface leading to the activation of B cells and the production of antibodies 
against the native structure of the antigen. Then, B cells are purified and fused with 
myeloma cells to form hybridomas, which are screening for the different antibody 
clones. *http://www.aldevron.com/antibody/immunization/geneticimmunization/ 
 
 
To study the effect of VJ-4B6 on MOG35-55 induced EAE, C57BL/6 mice received 
three different doses of VJ-4B6 (5, 50 and 100ng per mouse) or 50ng per mouse 
IgG2b (BD-Pharmingen, Oxford, UK) as negative control. The antibodies were 
diluted in PBS and injected i.p. 100&l per mouse at day 4, 10 and 16 from 
* 
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immunisation (Figure 2.7a). To test the therapeutic effects of VJ-4B6 in EAE, we 
administrated i.p. 50ng VJ4B6/mouse soon after the onset of early signs of EAE 
(score 1 or 2).  
 
 
Figure 2.7. Timeline for the different treatments used in EAE model. a) VJ-4B6 
was administered at day 4, 10 and 16 from immunisation day; b) Glatiramer acetate 
(GA) was administered for one week before the immunisation for 7 consecutively 
days. 
 
 
Glatiramer Acetate (GA) (Poly (Ala, Glu, Lys, Tyr) 6:2:5:1 hydrobromide, Sigma-
Aldrich, Dorset, England) exerts a suppressive effect on EAE induced in rodents 
(243, 244). Thus, this drug was used as positive control. GA (10mg) was solubilized 
in PBS in order to have a 1.5&g/&l concentrated solution and administered 
subcutaneously at a dose of 150&g in the mouse back. The administration was 
Days    
0 2 10 4 16 -7 -1 
-2 -3 -4 -5 -6 
 
 
 
  
 
0 2 10 4 16 -7 -1 
-2 -3 -4 -5 -6 
 
 
 
 
 
 
b) 
a) 
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performed daily over 7 days before immunization (Figure 2.7b) and 100&l PBS-
vehicle was used as control.  
 
The 2610019F03Rik gene was chosen as candidate gene out of list of genes obtained 
from the microarray analysis of CD4+ T cells (see section 2.15 and section 3.8.2). 
This gene codifies for 190aa long protein that has 75% homology with the human 
protein and unknown function in vivo. To test the effect of 2610019F03Rik protein in 
anxiety, AnxA1
tg
 mice were injected i.p. with 500ng/mouse anti-C8orf42 polyclonal 
antibody in rabbit (Novus Biologics, Cambridge, UK) or rabbit IgG (Santa Cruz 
Biotechnology, Inc., Dallas, Texas, US) diluted in 100&l/mouse 1x PBS. Otherwise, 
wild type mice were injected i.p. with 500ng/mouse purified human recombinant 
protein C8orf42 (Entrez Gene ID: 157695; OriGene technologies, Inc., Rockville, 
US), called rRik, or with 500ng/mouse rRik previously denatured at 95ºC for 10 min. 
Wild type mice injected with 1xPBS were used as control group. Before and after 
injection, mice were screened for anxiety-like behaviour using the behavioural 
paradigm described in section 2.17.4.  
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2.5 Blood and plasma collection  
Mice were anaesthetized by vapour of Isoflurane in oxygen gas flow (IsoFlo 100%w/w, 
Abbott, Illinois, USA). Blood was collected by intra-cardiac punctures using 1ml 
syringes with 23G needle filled up with at least 200&l of 3.2% p/v sodium citrate 
(C6H5Na3O7 x 2H2O, Sigma-Aldrich, Dorset, England; diluted in distilled water) in order 
to avoid blood coagulation. 
 
A volume ranged from 0.5 to 1ml of blood was collected in 2ml eppendorf and let to 
sediment for couple of hours at 4ºC. To separate the plasma from the cellular 
components, samples were centrifuged at 2.000 rpm for 5 minutes at 4ºC. Plasma was 
transferred into a new tube and store at -80ºC for further analysis. In some experiments 
blood cells were processed for flow cytometer analysis (see section 2.11.3).  
 
2.6 Tissue collection and histology 
Kidney, lungs, spleen and lymph nodes were collected after injection of pristane, 
while brain and spinal cord were collected from MOG35-55 immunised mice. After 
collection, tissues were washed in PBS and fixed with 4% PFA for 24h at 4°C before 
paraffin embedding. The spinal cords were first fixed as described before and then 
decalcified in 10% formic acid for 3-5 days at 4ºC, then resuspended in 4% PFA 
once again overnight at 4ºC before paraffin embedding. The Pathology Service 
(Barts and Cancer Institute, QMUL) performed the embedding in paraffin wax, the 
cutting and hematoxyline & eosin (H&E) staining in the sections. 
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Brain collected for gene expression analysis were harvested in 3ml of RNA later to 
preserve the RNA from degradation and stored at 4ºC for brief time or at -20ºC for 
longer storage. 
  
2.7 Zymosan peritonitis  
Zymosan (ZY) is a component of the yeast wall and it is an inflammatory stimulus 
once injected into a number of tissue sites. Injection of ZY in the peritoneal cavity of 
mice causes inflammatory responses known as peritonitis (148). ZY was dissolved in 
1x PBS and load in 1ml syringes with 26G needle just before the injection and 
administered i.p. at 1 mg/ 500ul PBS/ mouse. 4h after the injection, blood and 
peritoneal lavages were collected. 
 
2.7.1 Peritoneal lavage 
Peritoneal lavages were obtained injecting i.p. 2ml of PBS containing 3mM EDTA. 
Peritoneal fluids were collected through a small cut on the peritoneal membrane 
using a plastic Pasteur pipette. Lavages were centrifuged at 400G for 10 minutes to 
separate the cells from the sup. Cell pellets were resuspended in PBS, counted and 
stained for FACS analysis while sup were stored at -20ºC and used to measure a 
panel of different inflammatory cytokines. 
 
  
  Materials & Methods 
 
 84 
2.8 Isolation of mononuclear cell from lymphoid organs 
The procedure reported here describes how to collect mononuclear cells and 
lymphocytes from thymus, spleen and lymph nodes. Figure 2.8 shows the anatomical 
localisation and macroscopic appearance of these tissues. Each organ was collected 
and smashed through a 70&m mesh cell strainer (Falcon, UK) in RPMI medium 
(PAA laboratories, Buckinghamshire, UK) supplemented with 100U/ml of penicillin 
and streptomycin (PAA laboratories, Buckinghamshire, UK).  
 
 
Figure 2.8. Lymphoid organs collected in these studies. a) Anatomy scheme of 
lymphoid organs in mouse (highlighted in pink shades). (Modified from 
http://eulep.pdn.cam.ac.uk/). b) Lymph nodes, c) spleen and d) thymus after 
collection. Circles in e) to g) highlight the anatomical locations for inguinal and 
axillary lymph nodes and spleen. In h) circle marks the thymus located in the murine 
chest, on top of the heart.  
 
 
 
 
c) a) b) d
e) f) g) h) 
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To isolate mononuclear cells, the cell suspensions were layered onto Histopaque-
1077 (Sigma-Aldrich, Dorset, England) in a ratio 3:1. Histopaque-1077 is a density 
gradient cell separation medium containing Ficoll and sodium diatrizoate. After 10 
min centrifugation at 400G, an opaque ring called buffy coat forms at the cell 
medium/histopaque-1077 interface. The buffy coat is the layer composed by 
mononuclear cells, while rest of cells such as granulocytes and/or red blood cells 
pellet at the bottom of the centrifuge tube (Figure 2.9).  
 
 
Figure 2.9. Lymphocytes and mononuclear cells separation by density gradient 
medium of Histopaque-1077. a) The leukocytes were suspended in RPMI medium 
and then layered onto Histopaque-1077. b) During the centrifugation, cells sediment 
in base on their density giving a typical multilayer sample. The bottom of this is 
constituted by granulocytes and red blood cells, while lymphocytes and other 
mononuclear cells compose the interface layer between Histopaque-1077 and medium. 
 
 
The whole buffy coat was used for cell characterization. Alternatively, the buffy coat 
was used as source of CD3 positive and CD4 positive T cells.   
a) b) 
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2.8.1 Isolation of T cells by negative selection 
Purification of CD3+ or CD4+ T cells was performed using dynal mouse CD3+ T 
cell or CD4+ T cell negative isolation kit (Dynal Invitrogen, life technologies, 
Paisley, UK), respectively (Figure 2.10). The principle of a negative isolation is to 
isolate the cell target by depletion of other unwanted cells through magnetic selection 
(Figure 2.10a). More specifically, the unwanted cells are bound to antigen specific 
antibodies, which are in turn bound to magnetic beads. So when the cell suspension 
contained in a plastic tube or flask is put in contact to a magnet, the unwanted cells 
accumulate at the side of the magnet while the cell target remain in the supernatant.  
 
Lymphocytes were suspended 10x10
6 
cells/100&l in PBS (without Ca
2+
 and Mg
2+
) 
with 0.1% BSA (bovine serum albumin; Sigma-Aldrich, Dorset, England) and 2mM 
EDTA (0.5M EDTA, Gibco) at pH 7.4, called Buffer A. The cells were incubated 
with FCS (20&l; Invitrogen, life technologies, Paisley, UK) and antibody mix (20&l) 
for 20 minutes at 4ºC. After a wash with 2ml of Buffer A at 300G for 8 minutes at 
4ºC, labelled cells were resuspended in Buffer A and incubated with 200&l magnetic 
bead suspension for 15 minutes at 4ºC with gentle tilting and rotation. As final step, 
the cell suspension is put in contact with a magnet and the supernatant transferred in 
a clean tube.  
 
Figure 2.10b and c show an example of the yield of CD3+ T cell  (stained for CD4 
and CD8) and CD4+ T cells obtained after negative isolation, respectively. In Figure 
2.10c, I have also compared the yield and purity of CD4+ T cells obtained after a 
single (middle panel) or a double (right panel) round of purification.  
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Figure 2.10. T cell negative isolation. a) Enrichment of target T cells after the 
removal of other cell types by the binding to magnetic specific antibodies and 
magnetic selection. b) The dot plot shows the staining of lymph nodes cells for CD4 
and CD8 before and after CD3+ T cell isolation. c) Dot plots show the progressively 
enrichment in CD4+ T cells after double negative isolation from lymphocytes pooled 
from spleen and lymph nodes.  
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2.9 Leukocytes isolation from central nervous system 
Mononuclear cells were isolated from spinal cord samples after induction of MOG35-
55 induced EAE, at day 9 and 16 after immunization. Vertebral columns were 
dissected from the lumbar to the cervical region and washed several times in PBS to 
remove blood trace. Spinal cords were extracted by hydro pressure in the spinal canal 
using a 2ml syringe and 19-gauge needle. Subsequently, tissues were torn apart in 
sterile PBS by mechanical pressure through a 70&m mesh cell strainer (BD-Falcon). 
Mononuclear cells were isolated by density gradient centrifugation in Percoll (GE 
Healthcare, Little Chalfont, UK). In detail, cells were pelleted at 400G for 5 min and 
suspended in a 30% Percoll solution. The 30% Percoll solution was carefully layered 
onto a 70% Percoll solution in a ratio 1:2 and centrifuged at 500G for 30 min. In this 
density gradient mononuclear cells sediment at the interface between 30% and 70% 
Percoll layers. About 2-3ml of interface solution was collected only after the fatty 
layer at the top of the centrifuge tube was carefully removed. The purified 
mononuclear cells were washed twice in RPMI supplemented with 100U/ml of 
penicillin and streptomycin and 10% of FCS. 
 
2.10 Cell counting 
Improved Neubauer ruled haemocytometer was used for counting cells. This cell-
counting chamber is composed by 4 primary lateral squares delimitated by triple 
lines and subdivided in 16 smaller secondary squares. Cells located within the 
primary squares have been considered in the count (Figure 2.11). The average 
obtained out of the four squares is multiplied by the dilution factor (if cells were 
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diluted) first and by 10
4
 to obtain the number of cells per ml. The formulae used are 
reported below: 
 
Cells/ml = average of total count x dilution factor x 10
4
 
Total cells = Cells/ml x volume of original cell suspension 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11. Illustration of improved Neubauer ruled haemocytometer. One of the 
primary squares subdivided in 16 secondary squares is enlarged and an example of 
counted and not counted cells is given. 
(http://www.cf.ac.uk/biosi/staffinfo/kille/Methods/Cellculture/HAEMO.html).  
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2.11 Flow Cytometry 
The flow cytometry exploits the light property of interaction with mass to obtain 
qualitative and quantitative information of cells or particles. In flow cytometry, cell 
suspension undergoes hydrodynamic focusing to produce a single stream of cells. 
Single cells pass through a laser beam causing the scattering of the beam in different 
angles. Typically, the light detected up at 20º angle to the excitation line is called 
Forward Scatter Channel (FSC), which is an indication of the size of the cell, and at 
90º angle to the excitation line is named Side Scatter Channel (SSC), which is a 
measure of the cell granularity. FSC and SSC allow the interested cells to be 
identified through their physical characteristics, which are traditionally considered 
unique for a specific type of cell. Lymphocytes are usually a population of cells with 
FSC and SSC lower than 400 and 200, respectively, in a linear scale of brightness 
(Figure 2.12, left panel). After stimulation, they blast and their dimension increases 
in both FSC and SSC, which eventually are lower than 600 and 300, respectively 
(Figure 2.12, right panel). 
 
Figure 2.12. Typical lymphocyte population at flow cytometer. Cell size and 
granularity, FSC and SSC respectively, of freshly isolated (left panel) or anti-
CD3/CD28 stimulated (right panel) lymphocytes.  
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Light interaction also includes light absorbance and light emission of any 
fluorochrome labelling the cells. The most widely used fluorochromes are FITC 
(fluorescein isothiocyanate), PE (Phycoerythin) and APC (Allophycocyanin). Each 
of these absorbs light energy at a certain wavelength and re-emits it at a longer 
wavelength (see Table 2.1). The emission spectra of different fluorochromes can 
overlap as for instance it occurs for FITC and PE. In case of overlapping spectra, 
fluorescence compensation needs to be performed. This consists in subtracting the 
fluorescence of fluorochrome A that interferes with the channel used to detect the 
fluorescence of fluorochrome B and vice versa. Thus, the true fluorescence emitted 
by fluorochrome A is for example the detected value diminished by the percentage of 
fluorescence leaked from fluorochrome B.  
 
Table 2.1: Fluorochrome excitation/emission properties 
 
 
Fluorochrome conjugated antibodies are used to obtain information about cell 
surface proteins or receptors as well as for intracellular molecules such as cytokines. 
We performed multiple fluorochrome staining of cell suspension (usually up to 4 
fluorochromes) to phenotype the cells we obtained.  
 
Dye Excitation (nm) Emission (nm) Fluorescent colour 
FITC 488-490 525 green 
PE 488-565 578 yellow 
APC 633-650 661 purple 
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2.11.1 Cell staining for FACS 
Cells were incubated with specific conjugated antibodies (See Table 2.2 for details) 
diluted in FACS buffer (PBS supplemented with 5% FCS and 0.02% sodium azide) 
for a minimum of 30 minutes up to a 1-hour at 4ºC and then, washed and 
resuspended in FACS buffer. Only when the flow cytometer analysis was performed 
the day after, cells were fixed with 1% PFA (paraformaldehyde; Sigma-Aldrich, 
Dorset, England). Aliquots of cell suspension were kept unstained and single stained 
for each used fluorochrome was made to perform compensation.  
 
2.11.2 Intracellular antigen labelling 
Intracellular staining (ICS) is a widely used technique that allows the measurement 
of a wide range of factors (from signalling molecules to cytokines) that are stored 
inside the cells. In T cell studies, intracellular staining is often used to inform about 
the Th phenotype(s) of the cells under investigation. Lymphocytes were isolated 
from MOG35-55 immunized mice from peripheral lymphoid organs and spinal cord. 
Lymphocytes (10x10
6 
cells/ml) from lymph nodes and spleen were cultured for 72 
hours with either medium alone (CTRL) or with anti-CD3 and anti-CD28 antibodies 
(1&g/ml; plate bound) or with the specific antigen MOG35-55 (100&g/ml). At third 
day, the cells were pelleted and the supernatants stored at -20ºC. Subsequently, the 
cells were triggered again with concanavalin-A (ConA, 5&g/ml; Sigma-Aldrich, 
Dorset, England) in presence of protein transport inhibitor Brefeldin-A (1:1000; 
eBioscience) for 4 hours. Mononuclear cells isolated from the spinal cords instead 
were directly triggered with ConA and Brefeldin-A after collection. While, 2.5x10
6
 
cells/ml cell exudates from peritoneal lavages of mice injected with pristane were 
plated in RPMI medium supplemented with 10% FCS and 1U P/S in presence of 
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50ng/ml PMA (Phorbol 12-myristate 13-acetate; Sigma-Aldrich, Dorset, England), 
1mM Ionomycin (Sigma-Aldrich, Dorset, England) and 1:1000 Brefeldin-A. They 
were incubated for 1h and then processed for ICS of IFNy, IL-17 or IL-4, as 
described below. 
 
In a typical experiment cells were pelleted and then stained for CD4 (1:500) for 
30min and fixed with 1% PFA for 10 minutes. Thereafter, cells were permeabilized 
and stained for 30 min in permeabilization buffer (composed by 0.1% saponin and 
0.09% sodium azide in PBS, eBioscience, Hatfield, UK) containing conjugated 
antibodies for cytokines (dil: 1:250) such as IFN", IL-17, GM-CSF and IL-10 (See 
Table 2.2 for details). Labelled cells were washed and resuspended in FACS buffer 
plus 1% PFA. 
 
2.11.3 Staining of peripheral blood T cells 
We used the following procedure to measure the number of T cell circulating in 
peripheral blood. Typically, we used 100&l of mouse blood freshly isolated by cardiac 
puncture (see paragraph 2.5 for blood collection). First, the plasma was removed as 
described in paragraph 2.5 and the pelleted blood cells were resuspended in 200&l of 
FACS buffer. Next, antiCD16/32-blocking Fc Ab (1:500; 10/15min in ice) is added to 
block unspecific binding. Samples were then stained with either antiCD3-APC or 
antiCD3-APC/antiCD4-PE or antiCD3-APC/antiCD8-PE (1&l of each were added to the 
samples) for 15 to max 45 minutes on ice. After washing, red blood cells were removed 
by lysis. To this aim, 400&l of 1x RBC lysis buffer (diluted in distilled H2O and kept at 
RT; eBioscience, Hatfield, UK) was added to each sample and incubated for a max of 8 
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minutes. During the lysis, samples were pipetted up/down. Finally, samples were 
washed once with PBS/BSA and resuspended in 300&l FACS buffer before the analysis. 
 
2.11.4 CFSE staining 
T cell proliferation was analysed by staining cells with carboxyfluorescein 
succinimidyl ester (CFSE). This is a fluorescent dye that enters into the cells and 
covalently binds intracellular proteins. Therefore it is retained by cells and diluted 
during cell division from mother cell to daughter.  
 
Lymphocytes were resuspended at 10x10
6
 cells in 1 ml of 1x PBS. It is important to 
use 15 ml tubes and to avoid any serum contamination in the cell suspension. CSFE 
(Invitrogen, life technologies, Paisley, UK) was added to the cells at 3&M final 
concentration (from a stock solution of 10&M in DMSO). Samples were incubated 
for 8 min at RT in dark under shacking. Then, the samples were mixed with an equal 
volume of FCS and topped up with 1x PBS. Cells were spun down and washed twice 
with 1x PBS. Finally, cells were resuspended in complete medium and plated at 
2.5x10
5 
cells in 200&l volume per well in a 96-well plate.  
 
To follow the proliferation, cells were incubated at 37ºC in 5% CO2 for 48h and 72h. 
The stimulation conditions tested were: a) 1&g/ml or 0.3 &g/ml of plate-bound anti-
CD3; b) 1&g/ml or 0.3&g/ml anti-CD3 plus 1&g/ml anti-CD28 plate-bound; 3) 
0.3&g/ml plate-bound anti-CD3 and 1&g/ml anti-CD28 diluted in the medium and 4) 
0.3&g/ml anti-CD3 and 1&g/ml anti-CD28 both diluted in the medium. Unstained or 
stained but not stimulated samples were also carried as controls. 
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After the stimulation, cells were collected and analysed at FACS Calibur. Data were 
analysed at FlowJo 9.7.1v for the valuation of the proliferation parameters through 
the proliferation platform (scheme in Figure 3.12). The considered parameters were: 
 
• !"#$%$&'&\!2)!2-02.,)%6!)/%!1%+.%-),J%!*'!1+%.5+6*+!.%&&6!)/,)!02320%0!2-!
)/%!2-2)2,&!1*15&,)2*-`!
• ()*+$,')-.$*/"$/&'0!U>+*&2'#!R-0%AW\!!2)!J23%6!)/%!-54S%+!*'!023262*-6!1%+!
.%&&!)/,)!/,6!02320%0!),Z2-J!2-!,..*5-)!*-&7!)/%!+%61*-02-J!.%&&6`!
• 1'2+$3-.$*/" $/&'0! UH%1&#! R-0%AW\! 2)! 2-02.,)%6! )/%! '*&0! 2-.+%,6%! *'! )/%!
+%61*-02-J!.%&&6#!
!
 
Figure 2.13. Scheme of a flow cytometer analysis of CSFE dilution with cell 
division. Initial cell population (IP) is the brightest population from which CFSE 
intensity reduces at every round of cell division (from 1 to 5 peaks). After cell 
proliferation, IP are the precursor cells that did not divide while the cells in peaks 1 to 
5 come from responding cells.  
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Table 2.2: List of antibodies used in flow cytometry. For each clone, commercial source 
and working dilution are specified.  
  
Name Clone Company Dilution 
Anti mouse CD3e 145-2C11 eBioscience 1:250 
Anti mouse CD4 GK1.5 eBioscience 1:500 
Anti mouse CD5 53-7.3 eBioscience 1:500 
Anti mouse CD8 53-6.7 eBioscience 1:500 
Anti mouse CD25 PC61.5 eBioscience 1:500 
Anti mouse CD28 37.51 Biolegend 1:400 
Anti Human/mouse CD44 IM7 eBioscience 1:500 
Anti mouse CD45 30-F11 Biolegend 1:500 
Anti mouse CD62L MEL-14 eBioscience 1:500 
Anti mouse CD69 H1.2F3 eBioscience 1:500 
Anti mouse CD115 AFS98 eBioscience 1:500 
Anti mouse IL-10 JES5-16E3 eBioscience 1:250 
Anti mouse IL-17A 
eBioTC11-
18H10.1 
eBioscience 1:250 
Anti mouse IFN" XMG1.2 eBioscience 1:250 
Anti mouse GM-CSF MP1-22E9 BD Bioscience 1:250 
Anti mouse CD11b M1/70 eBioscience 1:500 
Anti mouse Ly6G RB6-8C5 eBioscience 1:500 
Anti mouse F4/80 BM8 eBioscience 1:250 
Donkey Anti-Mouse IgG Polyclonal eBioscience 1:500 
F(ab)2 Donkey Anti-
Rabbit IgG 
Polyclonal eBioscience 1:250 
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2.11.5 Cytometric bead array (CBA) 
Cytokine production was measured by bead-based analytic assay in flow cytometry. 
This assay allows the simultaneous quantification of 20 analytes in a single volume 
of sample (as little as 25 µl) using the same principle of an ELISA. Basically, it 
consists of beads that have two different sizes (4 and 5 &m) and are dyed with 
different intensities of a fluorescent dye (far-red emission, 700nm). The group of 
beads having particular size and a certain fluorescent intensity recognise one specific 
analyte thanks to the antibody coating. 
 
We used a Mouse Th1/Th2 10plex and custom-designed Mouse Th1/Th2/ Th17 
/Th22 13plex kits (eBioscience, Hatfield, UK). The former contains antibody-
bounded beads for GM-CSF, IFN", IL-1%, IL-2, IL-4, IL-5 IL-6, IL-10, IL-17 and 
TNF%, while the latter contains antibody-bounded beads for IFN", IL-1%, IL-2, IL-4, 
IL-5 IL-6, IL-10, IL-13, IL-17, IL-21, IL-22, Il-27 and TNF% and was supplemented 
with antibody-bounded beads for GM-SCF and IL-23.  
 
Figure 2.14. Illustration of CBA principles. a) Analytes/cytokines are incubated 
with the antibody-coated beads, which act as capture antibody. b) Captured cytokines 
are bound to biotinylated antibodies and these c) Streptavidin PE, as a sandwich 
ELISA. 
 
analytes Antibody- 
coated beads 
Biotinylated 
antibody 
Streptavidin 
PE 
a) b) c) 
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Each sample (25&l of cell culture supernatant) was incubated with 50&l bead mixture 
and 50&l mix of antibodies conjugated with biotin for 2h. After two washes, 
streptavidin PE conjugated antibodies was added (Figure 2.14) and samples were left 
to rock for 1 hour in dark. Finally, samples were washed and stored overnight at 4ºC. 
Standards diluted 1:3 serially for 7 times were prepared and processed at the same 
time. Table 2.3. shows the parameters which were used for the analysis at BD LSR 
Fortessa (BD Bioscience cell analyser). 
 
Table 2.3: BD LSR Fortessa setting for the CBA analysis. Voltage and mode for FSC, 
SSC, YG-585/15 and R-670/14 filters are specified.  
 
 
 
 
 
 
During detection, two different populations of beads were distinguished according 
their size by SSC/ FSC profile (Figure 2.15, left panel). Within each population, the 
analytes were differentiated by specific internal dye intensity linked to antibody-
coated beads in y-axes (Figure 2.15 right panels). Figure 2.15 (bottom panels) shows 
a typical pattern observed following changes in concentration of each analyte (note 
the shift of intensity in PE emission on x-axes). The concentration of each analyte 
was determined through the calibration curves obtained with the standards by using 
FlowCytomixPro (eBioscience software). 
  
Detector Voltage Mode 
FSC 444 Lin 
SSC 250 Lin 
YG-585/15 430 Log 
R-670/14 400 Log 
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Figure 2.15. CBA flow cytometer analysis. Top-right panel: SSC/FSC dot plot 
showing two populations (highlighted in violet A or green B) of antibody-coated 
beads that are distinguishable based on their size. Top-left panels: Dot plots of A 
(top) and B (bottom). The far-red emission is shown in y-axes while the PE emission 
is shown in x-axes. In the two populations each different cytokine is visualized as a 
unique red cloud at a specific far-red fluorescent intensity. Bottom panels: The 
presence of analytes shifts the PE signal towards higher intensity indirectly correlated 
to the analyte concentrations.  
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2.12 T cell adoptive transfer 
T cells were purified from lymph nodes and spleen of wild type or AnxA1
tg
 mice as 
already described in paragraph 2.8. Wild type mice received i.p. ~6x10
6
 of CD3
+
 or 
CD4
+
 T cells in 200&l of PBS either isolated from wild type or AnxA1
tg
 mice. Mice 
injected i.p. with 200&l PBS-only was carried as further control group. After T cell 
adoptive transfer, recipient mice were tested for anxiety-like behaviour (see section 
2.17.4) and later they were either immunised for MOG35-55 EAE or culled for brain 
collection.  
 
2.13 Purification of total RNA 
Purification of total RNA was carried out using RNeasy Mini kit (Qiagen, 
Manchester, UK) and following the manufacturer’s instructions. The adsorption of 
the RNA to the silica-membrane of RNeasy spin columns is the principle on which 
the kit is based. Total RNA was purified from wild type and AnxA1
tg
 CD4+ T cells 
(2.5-5x10
6
 cells/ml) after stimulation with anti-CD3/anti-CD28 (1&g/ml; plate 
bound) overnight. Cells were collected and lysed in RLT buffer supplemented with 
#–mercaptoethanol and homogenized using syringe fitted with a 19G needle. 70% 
ethanol was added to adjust the binding condition and samples were loaded in the 
RNeasy spin columns. Contaminants were removed by serial washes with buffer 
RW1 and total RNA was eluted with 30&l RNAse free water. Spectrophotometer 
ND-1000 (NanoD rop, ND-1000) was used to quantify the concentration and the 
purity (ratio of 260nm absorbance to 280nm absorbance values were between 1.8 to 
2.0) of the extracted RNA. A microfluidic analysis using Agilent 2100 Bioanalyzer 
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was performed to check the integrity of the purified RNA (performed by the 
microarray facility, see section 2.15), which provides the picture of the RNA 
degradation on the base of the ideal full-length RNA that show a ratio of 28S to 18S 
ribosomal RNA bands equal to 2:1.  
 
2.13.1 Preparing Brain tissue for RNA extraction 
Whole brains were harvested and stored in RNAlater (Ambion, Applied Biosystems, 
life technologies, Paisley, UK) at -20C. The RNA extraction for this tissue was 
performed using a specific RNeasy Lipid Tissue Midi Kit (Qiagen, Manchester, UK) 
and according to the manufacturer’s instructions. Briefly, the whole brain was 
homogenised in 1ml of Qiazol lysis buffer (Qiagen, Manchester, UK) using 2ml tube 
containing 1.4mm ceramic (zirconium oxide) beads (Precellys, Stretton, UK). The 
setting for homogenisation was 4000rpm for 30 sec for 3 cycles. Homogenates were 
transferred in a new 2ml eppendorf tube and diluted with an extra 1ml of Qiazol lysis 
buffer. Proteins and membrane were precipitated adding 200&l of chloroform 
followed by shaking for 15 sec. Samples were then centrifuged at 12000G for 15 
min. Only 300&l of the supernatant was used for the RNA purification while the rest 
was diluted 1:1 with ethanol and stored at -80ºC. 
 
2.14 cDNA synthesis and Real Time PCR 
SYBR green quantitative PCR (Q-PCR or Real Time PCR) was used to measure 
relative or absolute gene expression level. SYBR Green is a dye that fluoresces when 
it intercalates with double-stranded DNA. During the PCR cycles, the intensity of 
fluorescence increases in relationship with the exponential amplification of the DNA 
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amount. The Q-PCR measures the increase of fluorescence during each amplification 
cycle. Conventionally, we use the threshold cycle (Ct) i.e. the number of cycles 
needed for the fluorescence signal to overcome the background noise, as value to 
accurately quantify the amount of a target gene.  
 
A double step protocol was followed, in which first complementary DNA (cDNA) 
was generated from total RNA samples by reverse transcription PCR (RT-PCR). 5-
10&g of total RNA (~10&l) was mixed with 1&l of oligo-dT primer (0.5&g/&l) and 
RNase free water to bring up the volume to 12&l. Samples were incubated at 70ºC 
for 10 min and then on ice for 5 min. A master mix solution composed by 1&l 
RNasin (40U/&l; Promega, Southampton, UK), 1&l dNTPs (10mM), 1&l AMV 
reverse transcriptase (10U/&l Promega, Southampton, UK), 4&l 5x first strand buffer 
and 1&l RNase free water was added to each sample. The retro-transcription was 
carried out at 42ºC for 60 min, followed by incubation at 70ºC for 10 min. cDNA 
samples were stored at -20ºC and used for Q-PCR. 
 
Every sample was tested in triplicate for the gene expression. To do so, 4&l of cDNA 
were mixed with 20&l SYBR Green Master Mix (Qiagen’s QuantiTek, Manchester, 
UK), 4&l primers and 12&l dH2O. From this mix, 10&l were added to 3 wells of a 
384 well plate. GAPDH was used as endogenous housekeeping gene. The PCR 
conditions used were one cycle of 95ºC for 15 min followed by 40 cycles of 94ºC for 
15 sec, 55ºC for 30 sec and 72ºC for 30 sec. These steps were then followed by a 
dissociation step of 95ºC for 15 sec, 60ºC for 15 sec and 95ºC for 15 sec.  The ABI 
prism 7900HT PCR system and SDSv2.4 software (Applied Biosystem Inc., CA, 
USA) were used for the analysis of single transcripts. 
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Relative quantification of the transcripts was performed using the comparative Ct 
method (245). This approach compares the normalised Ct values of the samples of 
interest (transgenic mice in our case) to a control (wild type mice). Briefly, Ct values 
of both samples and control were normalised to the GAPDH gene and then the 
relative normalised values (called &Ct) compared by difference (termed &&Ct). The 
final fold change was calculated using the 2
-&&Ct formulas.  
 
2.15 Microarray analysis 
Purified RNA was processed by using Ambion WT Expression kit and GeneChip 
WT Terminal Labeling Kit (Affimetrix, High Wycombe, UK). Whole-transcript 
expression analysis was performed by using Affimetrix Mouse Gene 1.1 ST array. 
The microarray service and the relative statistical analysis were provided by UCL 
Genomic facility (http://www.genomics.ucl.ac.uk/). The data were analysed by Dr 
Masahiro Ono (Department of Infection and Immunity, Institute of Child Health, 
University College London).  
 
2.15.1 Preparing RNA samples for Affimetrix analysis 
The following procedures and protocol has been provided and performed by Dr 
Simone Sharma at the UCL Genomic, Cancer Institute and Wolfson Institute for 
Biomedical Research, University College London. From the total RNA, transcript 
mRNAs were selected by rRNA reduction procedure. From these samples, double 
strand of complementary DNAs (cDNA) were synthetized by a double-step reaction 
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in presence of reverse transcriptase enzyme and primers containing T7 promoter 
sequence. The cDNA was used as template to synthetize antisense complementary 
RNA (cRNA) by using T7 RNA polymerase in vitro transcription (IVT) technology. 
The cRNA was cleaned up and used for the synthesis of sense single strand DNA 
(ss-DNA). During the synthesis, ss-DNA incorporated dUDP so that it can be 
fragmented in small DNA target. The ss-DNA was fragmented using a combination 
of uracil DNA glycosylase (UDG) and apurinic/apyrimidinic endonuclease 1 (APE 
1), which removes uracil residues and cleaves the phosphodiester backbone where 
the base is missing. The fragmented DNA targets were labelled using terminal 
deoxynucleotidyl transferase (TdT) in presence of a biotinylated compound (Biotin 
Allonamide Triphosphate) and finally, hybridized to the array (Figure 2.16). 
 
Figure 2.16.  Flowchart of microarray sample preparation. Schematic steps for the 
preparation of samples before microarray analysis is performed.  
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2.15.2 Microarray 
The Affimetrix Mouse Gene 1.1 ST array contains more than 770,000 unique, 25-
mer oligonucleotide probes that interrogate more than 28,000 genes. Each gene or 
transcript is represented by 22 different oligonucleotides fragments (11 matches and 
11 mismatches) which are synthetized directly on-chip. 
 
Samples were hybridized to the chip and the excess was removed by washes. The 
arrays were ultimately stained with streptavidin-PE and processed for the analysis. 
The hybridization procedures were performed with a GeneChip Fluidics Station 450 
while the arrays were scanned using the Affymetrix GeneChip Scanner.  
 
Quality control (QC) was performed using Expression Console first and 
Bioconductor. The QC for hybridizations within the microarray experiment allows 
identifying outliers by different quality metrics thus to exclude them from the 
analysis. 
 
The acquired data were normalized using the RMA normalization algorithm in 
Expression Console 1.2. RMA is the standard method used for probe summarization 
(i.e. calculating a transcript signal value from multiple independent probes) and 
normalization of Affymetrix expression array data.   
 
Probe annotation and ANOVA analysis were performed using Partek software. 
Based on these tests, a list of genes with differential expression across groups was 
identified (according to p-values and corrected p-values by multiple hypothesis 
testing with Benjamini-Hochberg). 
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2.16 Immunoprecipitation and Western blot analysis 
Cell lysis was performed using a lysis buffer containing 20mM Tris-HCl and 200mM 
NaCl at pH 8, 10&l/ml T-X100 and the following protease inhibitors (TNT buffer): 
10mg/ml apotinin (10&g/ml), 200&M Na3VO4 (0.2&M; 1&l/ml), 1mg/ml Leupeptin 
(3&g/ml), 100mM PMSF (0.5mM; 5&l/ml), 1M NaF (1mM; 1&l/ml), 0.5mM PeP 
(0.5&M; 1&l/ml) and 0.5M EDTA (0.25mM; 0.5&l/ml). Cell pellets were 
resuspended in a 1:2 volume ratio of lysis buffer in round-bottom microfuge tubes, 
pipetted up/down several times and kept on ice for at least 5 min. Cell lysates were 
centrifuged at 13,226G for 10-15 minutes at 4ºC. 
 
The supernatants were collected and analyzed for protein contents using the Bradford 
protein assay (5x Bio-Rad protein assay dye, Bio-Rad, Hertfordshire,UK) and BSA 
as standard. Briefly, BSA standard curves were prepared by 1:2 serial dilution of 
2&g/&l BSA solution (in dH2O). To determine the proteins content in the lysates, 
each sample was diluted in 1:250, 1:500 and 1:1000 in 1:5 Bio-Rad solution. The 
colorimetric changes were detected at spectrometer by plating 100&l of each sample 
and the standard curve in 96well plate. Absorbance was blanked against the Bio-Rad 
solution alone and read at 595nm using Thermo Scientific Multiskan FC machine. 
 
Protein immunoprecipitates (IPs) were obtained incubating 500&l of conditioned 
medium or 100&l of protein lysate (diluted up to 500µl with TNT) with 1&l of 
primary antibody in presence of 50&l of mixed bead solution of protein A + G. The 
incubation was performed overnight at 4ºC under rocking. Each IP was then spun 
down, washed twice with 500&l TNT buffer and resuspended in 50&l of 6x sample 
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buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromphenol blue 
and 0.125 M Tris-HCl, pH approx. 6.8).  
 
Each sample was denatured at 90ºC for 5 min before loading onto SDS-
polyacrylamide gel (10%) (precast high performance gel; NuPAGE SDS-PAGE Gel 
system, life technologies, Paisley, UK). Proteins were separated at constant voltage 
of 200V and then transferred onto 0.45&m pore size, hydrophobic, polyvinylidene 
difluoride Immobilon-P Transfer Membranes (Millipore, Watford, UK) at 4°C for 
max 2h at 125V. 
 
Membranes were then blocked in 5% non-fat dry milk diluted in Tris-buffer saline 
solution containing 0.1% Tween 20 (TBST). Thereafter, membranes were incubated 
with primary antibody diluted in the same blocking solution – in particular: anti-
AnxA1 polyclonal antibody in rabbit (Zymed Laboratories, Cambridge, UK; 1:1000 
dilution) for 1h at RT under rocking and anti-C8orf42 polyclonal antibody in rabbit 
(Novus Biologics, Cambridge, UK; 1:1000 dilution) overnight at 4ºC under rocking. 
Membranes were then washed for 30 min with TBST with the solution being 
changed at 10-min intervals and incubated with the secondary antibody  (HRP-
conjugated goat anti-rabbit 1:2000, Dako, Cambridge, UK), for 1h at RT under 
rocking. Membranes were again abundantly washed with TBST and proteins were 
then detected using enhanced chemiluminescence (ECL) detection kit or Luminata 
Forte (Millipore, Watford, UK) and visualized on Hyperfilm (GE Healthcare, Little 
Chalfont, UK). 
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2.17 Animal behavioural tests 
There are several experimental validated paradigms to test emotion-related behaviour 
in mice. These are based on the conflict-avoidance approach and exploit the natural 
tendency of mice to avoid aversive conditions such as brightly lit and open spaces. In 
this study mice were tested for anxiety- and depressive-like behaviour using the 
marble-burying test, open field test, climbing test and light/dark box test. These 
techniques and scoring system were initially mastered under the kind supervision of 
Dr. Robert Deacon, Department of Experimental Psychology, University of Oxford. 
 
Mice were group-housed in quiet environmental conditions with food and water 
provided ad libitum. Temperature, room lightening and noise level were kept 
consistent for all the subjects throughout the tests.  
 
2.17.1 Marble-burying test 
Marble-burying tests were performed as described in Deacon RM, Nature Protocol 
2006 (246). In details, 15 marbles were organized in 3 columns of 5 marbles each on 
5-6 cm of lightly pressed sawdust in cages with tall walls (Figure 2.17, left picture). 
Mice were acclimated for 15-30 min in the room before performing the test. Single 
mice were observed for a period of 15 min during which several parameters were 
scored. These are: digging latency (the time elapsed before digging begins), number 
of bouts, total digging time and number of buried marbles- 2/3 of their depth  (Figure 
2.17). 
 
 
  Materials & Methods 
 
 109 
 
Figure 2.17. Marble-burying test. Mice were tested for anxiety-like behaviour using 
marble-burying test. It is 15-min test for single mouse in which a) total digging time, 
b) digging latency, c) number of bouts and d) number of buried marbles are scored. 
 
 
2.17.2 Open field test 
Motility, fear and explorative behaviour were tested through the open field test as 
described by Deacon (247). Briefly, mice were placed in a white wide arena 
(50x12x30cm) where a grid of 10cmx10cm squares was drawn (Figure 2.18, left 
picture). Explorative and emotional behaviours were scored for a time period of 
3min measuring three different parameters: rearing latency (the time elapsed before 
the first rearing), numbers of rearing, numbers of squares crossed, number of passage 
through central squares and urination/defecation (Figure 2.18). Rearing is considered 
a natural movement of the mouse to stands up on its hind legs stretching its body up 
or towards a wall (Figure 2.18, middle picture). Between mice the walls and floor 
were cleaned with a moist, followed by a dry tissue. 
 
 
 
15 marbles 
T=0 
b) Digging latency 
a) Total digging time 
c) N. of bouts 
T= 15 min 
15-30 min 
Acclimation 
d) N. buried marbles 
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Figure 2.18. Open field test. Mice were tested for fear and explorative behaviour 
using the open field test. It is 3-min test for single mouse during which a) rearing 
latency (the time elapsed before the first rearing), b) total number of rearing and c) the 
number of crossed squares are scored. 
 
 
2.17.3 Climbing test 
The climbing test is a paradigm used to study fear and explorative behaviour in mice. 
We followed the procedure described in Deacon (personal communication). Single 
mice were placed inside a cylinder of wire mesh (6mm
2
) 60 cm high, 28 cm 
diameter, closed at the top. The cylinder was placed on flat surface covered with a 
thin layer (about 0.5cm) of sawdust. Climbing is for a mouse to have all 4 feet on the 
wire mesh. Mice were recorded for 5 min during which the recorded parameters were 
latency to the first climbing (the time elapsed before the first climbing), total 
duration of climbing (the total time spent perched on the wire mesh) and number of 
climbing (Figure 2.19).  
 
 
 
 
a) Rearing Latency  
b) N. of Rearing c) N. of squares  
T=0 T= 3 min 
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Figure 2.19. Climbing test. Mice were tested for fear and explorative behaviour using 
the climbing test. It is 5-min test per single mouse in which a) climbing latency, b) 
total number of climbing and c) the total climbing time are scored. (X= mouse at T0; 
red arrows: mouse during the climbing). 
 
 
2.17.4 Light/Dark box test 
The light/dark box test is widely used to study anxiety in rodents and to test classical 
and new anxiolytic drugs such as benzodiazepines (248). The apparatus consists of 
an open white compartment 30x20x20 cm joined by a 3x3 cm opening to a dark box 
(painted black with a lid) 15x20x20 cm. One side of the light box is made transparent 
by making it from clear plastic, permitting viewing of the mouse from the side 
(Figure 2.20).  
 
The test was performed as described in Deacon (249). Mice were placed in the 
middle of the lit side facing away from the opening. The latency to cross (all four 
feet) to the dark side, the time spent in the lit side (all four feet) and the number of 
transitions between the two compartments though the opening were measured for the 
5 min duration of the test (Figure 2.20). The number of faecal boli and the 
T= 5 min 
a) Climbing latency  
b) N. of climbing 
c) Total climbing time 
X
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presence/absence of urination were also recorded. The cleaning regime between mice 
was to remove urine and/or faeces and wipe with moist followed by dry tissues the 
surfaces. 
 
 
 
Figure 2.20. Light/Dark box test. Mice were tested for anxiety-like behaviour using 
the light/dark box test. It is 5-min test per single mouse during which are scored a) 
total time in light, b) crossing latency and c) the total number of crossings. (X= mouse 
at T0, red arrows: crossing direction). 
  
a) Time in Light 
T= 5 min 
c) N. of Crossings 
T=0 
  
X
 
b) Crossing Latency 
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2.18 Statistical analysis 
According to the nature of the data, t-test, one-way or two-away ANOVA analyses 
were used. Behavioural data were analysed with non-parametric tests such as Mann 
Whitney U test and Kruskal-Wallis method. Time-course observations were analysed 
with the repeated measures analysis and Boneferroni’s post-doc test. All statistical 
analyses were performed through GraphPad PRISM software (version 4.0c) with the 
exception of microarray analysis which was performed as described in section 
2.15.2. Data were considered significant when p-value was < 0.05. 
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3.1 AnxA1tg mice 
The T cell-specific AnxA1
tg
 mice were generated by a previous PhD student in our 
lab. A detailed analysis of the immune cell repertoire and of thymocytes positive and 
negative selection was already been performed when I joined the lab. The following 
sections show part of the analyses that I have performed just at the beginning of my 
PhD.  
 
3.1.1 Characterization of the T cell repertoire in AnxA1
tg
 mice 
During their development in the thymus, thymocytes pass through stages of 
development defined by expression of cell surface markers. CD4- CD8- double 
negative (DN) cells differentiate into CD4+ CD8+ double positive (DP) cells that 
then mature into single positive CD4+ and CD8+ T cells. The DN population can be 
further subdivided by cell surface expression of CD44 and CD25: the most immature 
CD44+ CD25- DN cells (DN1) acquire CD25 expression to become CD44+ CD25+  
(DN2). CD44 is then downregulated as cells become CD44- CD25+  (DN3), and 
CD25 is also downregulated as cells become CD44- CD25-  (DN4). The DN4 
population differentiates to DP cells. 
 
In the thymus, the frequencies of pro-T cells (CD3- CD4-
 
CD8-) divided in the four 
DN stages showed no significant changes in wild type and AnxA1
tg
 mice (Figure 
3.1a). Similarly, there were no significant difference in the percentage of DP (CD4+ 
CD8+) as well as single positive CD4+ or CD8+ populations between wild type and 
AnxA1
tg
 mice (Figure 3.1b).   
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Figure 3.1 Thymocyte profile during T cell development. a) Development from 
DN1 to DN4 of thymocytes in wild type and AnxA1
tg
 mice using the expression of 
CD44 and CD25 surface cell markers: CD44+ CD25- (DN1), CD44+CD25+ (DN2), 
CD44- CD25+ (DN3) and CD44- CD25- (DN4). b) Maturation from DN to DP and 
then single positive CD4 and CD8 T cells in the thymus of wild type and AnxA1
tg
 
mice. 
 
  
10
0
10
1
10
2
10
3
10
4
FL2-H: FL2-Height
10
0
10
1
10
2
10
3
10
4
F
L
1
-H
: 
F
L
1
-H
e
ig
h
t
4.3 1.53
5.6888.5
10
0
10
1
10
2
10
3
10
4
FL2-H: FL2-Height
10
0
10
1
10
2
10
3
10
4
F
L
1
-H
: 
F
L
1
-H
e
ig
h
t
6.31 1.26
5.4287
CD25 
C
D
4
4
 
 
DN1 DN2 
DN3 DN4 
 
1.5 
5.7 
4.3 
88.5 
1.3 
5.4 
6.3 
87 
Wild 
type
AnxA1
tg
 
a) 
CD4 
C
D
8
 
10
0
10
1
10
2
10
3
10
4
FL1-H: FL1-Height
10
0
10
1
10
2
10
3
10
4
F
L
2
-H
: 
F
L
2
-H
e
ig
h
t
4.03 69.7
7.0719.2
10
0
10
1
10
2
10
3
10
4
FL1-H: FL1-Height
10
0
10
1
10
2
10
3
10
4
F
L
2
-H
: 
F
L
2
-H
e
ig
h
t
3.92 70
7.4418.6
 
CD8 DP 
CD4 DN  
 
 
69.7 
7.0 
4.0 
19.2 
70 
7.4 
3.9 
18.6 
b) 
                                                                        Results 
 
 
 
117 
The overexpression of AnxA1 does not influence the T cell development. In line 
with this, total cell counts of thymus are comparable between wild type and AnxA1
tg
 
mice. However, total cell counts of lymph nodes, but not spleen show higher 
cellularity in the AnxA1
tg
 compared to wild type (Figure 3.2).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. AnxA1
tg
 lymphoid organ cellularity. Cell counts of thymus, spleen and 
lymph nodes of wild type and AnxA1
tg
, after organ homogenisation and mononuclear 
cell isolation (**p<0.01, n=4-5 mice per group; representative of N=2 separate 
experiments). 
 
 
Lymphocytes were stained for CD3 as well as for CD4 and CD8. Although the 
percentages of CD3+ T cells do not change in the two groups, the number of CD3+ T 
cells is higher in the AnxA1
tg
 lymph nodes due to the higher cellularity (Figure 3.3). 
Then, analysis of the CD4+ and CD8+ T cells showed an increased percentage and 
number of CD4+CD3+ but not CD8+CD3+ T cells in AnxA1
tg
 compared to wild 
type (Figure 3.4). 
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Figure 3.3. Lymphocytes in AnxA1
tg 
mice. a) Typical SSC/FSC dot plots of 
lymphocytes and b) CD3+ T cells collected from wild type and AnxA1
tg
 lymph nodes. 
Percentage values and total cell counts are reported in the right graphs. (*p<0.05; 
**p<0.01; representative of N=2 experiments of n=4-5 mice per group).  
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Figure 3.4. CD4 and CD8 in AnxA1
tg
 lymph 
nodes. Dot plots of CD4 and CD8 T cells 
isolated from the lymph nodes of wild type and 
AnxA1
tg
 mice. Percentage values and cell 
numbers for CD4+ and CD8+ populations are 
represented in the top right and bottom right 
graphs, respectively. (*p<0.05; representative of 
N=2 experiments of n=4-5 mice per group). 
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3.3.2 T cell proliferation 
 CD4+ T cells were tested for proliferation by CFSE dye dilution. Lymphocytes were 
stimulated using several conditions: a) plate-bound anti-CD3 (1 and 0.3 &g/ml); b) 
plate-bound anti-CD3 (1 and 0.3&g/ml) plus plate-bound anti-CD28 (1&g/ml); 3) 
plate-bound anti-CD3 (0.3&g/ml) plus soluble anti-CD28 (1&g/ml) and 4) soluble 
anti-CD3 (0.3&g/ml) plus soluble anti-CD28 (1&g/ml).  
 
Stimulation with plate-bound anti-CD3 did not elicit the expected proliferative 
response that one should see based on a number of evidence in the literature. Both 
wild type and AnxA1
tg
 CD4+ T cells did not show a concentration-dependent 
response to anti-CD3 stimulation. The proliferation indexes were comparable to the 
non-stimulated condition in both wild type and AnxA1
tg 
T cells. However, these 
results in the Table 3.1 show that AnxA1
tg
 T cells has higher basal proliferation 
index. 86% of AnxA1
tg
 CD4+ T cells went through cell division against 69% of wild 
type and in addition these performed higher number of cell cycles compared to wild 
type as indicated by the replication indexes (Rep Index: 4.5 and 2.9, respectively) 
(Table 3.1; N=1 experiment).   
 
Table 3.1: Proliferation analyses after plate-bound anti-CD3 stimulation 
CD4+ T cells 
Anti-CD3 
(!g/ml) 
% Divided Prolif. Index Rep. Index Time 
Wild type 
- 68.5 1.33 2.9 72h  
0.3 85 1.24 2.7 72h 
1 75 1.3 2.9 72h 
AnxA1
tg
 
- 86 2 4.45 72h 
0.3 84.3 2 4.5 72h 
1 78.4 2 4.7 72h 
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Wild type and AnxA1
tg 
CD4+ T cells also showed similar proliferation rate (Prolif. 
Index) upon plate-bound stimulation with anti-CD3/CD28 (Table 3.2). Interestingly, 
AnxA1
tg 
CD4+ T cells showed greater proliferation responses compared to wild type 
when stimulated with the lower concentration of anti-CD3 either plate-bound or in 
solution in the presence of soluble anti-CD28. This is indicated by the higher 
proliferation index, replication index and percentage of CD4 + cells going in cell 
division of AnxA1
tg
 compared to wild type T cells (Table 3.2; N=1 experiment). The 
Figure 3.5 and 3.6 show the proliferative response of wild type and AnxA1
tg
 
lymphocytes, respectively, in absence of stimulation (left panel) and after plate-
bound or soluble anti-CD3/CD28 stimulation. In particular, Figure 3.35b and 3.36b 
show the percentages of CD4+ T cells that have been through cell division i.e. 
positive for CFSE of wild type and AnxA1
tg
. The CFSE profiles of these cells are 
shown in Figure 3.35c and 3.36c, which indicate the proliferation profile of wild type 
and AnxA1
tg
 CD4+ T cells, respectively.  
 
Table 3.2: Proliferation upon anti-CD3/CD28 stimulation 
 
These are values obtained from one independent experiment   
CD4+ T 
cells 
Anti-CD3 
(0.3&g/ml) 
Anti-CD28 
(1&g/ml) 
% Divided Prolif. Index Rep. Index 
Wild type 
Plate-bound Plate-bound 72.6 1.35 3 
Plate-bound Soluble 68.7 1.6 4 
Soluble Soluble 79.5 2 6.5 
AnxA1
tg
 
Plate-bound Plate-bound 81.9 1.3 2.7 
Plate-bound Soluble 75 1.9 5 
Soluble Soluble 85.5 2.4 8.4 
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Figure 3.5. Wild type CD4+ T cell proliferation upon anti-CD3/CD28 stimulation. 
a) SSC/FSC and b) CD4+/CFSE dot plots of AnxA1
tg
 T cells without stimulation (left 
panel) or stimulated with anti-CD3 (0.3&g/ml) and anti-CD28 (1&g/ml) either plate-
bound or soluble. c) CFSE fluorescence intensity in cell generations after proliferation 
calculated for CD4+ T cells gated in panel b.   
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Figure 3.6. AnxA1
tg
 CD4+ T cell proliferation upon anti-CD3/CD28 stimulation. 
a) SSC/FSC and b) CD4+/CFSE dot plots of AnxA1
tg
 T cells without stimulation (left 
panel) or stimulated with anti-CD3 (0.3&g/ml) and anti-CD28 (1&g/ml) either plate-
bound or soluble. c) CFSE fluorescence dilution in cell generations after proliferation 
calculated for CD4+ T cells gated in panel b.  
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3.2 Development of MOG35-55-induced EAE and pristane-induced 
lupus in AnxA1tg mice  
The sections below describe in details the parameters we have used to compare the 
development of autoimmune diseases in Anxa1
tg
 to wild type mice. The 
experimental models we have used were the MOG35-55-induced EAE as model of 
multiple sclerosis and the pristane-induced lupus as model of systemic lupus 
erythematosus.  
 
3.2.1 Weight loss  
The averaged weight of a healthy 6-7 week old C57BL/6 male mouse is about 19-
22g and it typically increases over time as shown in Figure 3.7a. Body weight of 
wild type mice was tracked daily for a period of 20 days and the percentage of 
gain/loss weight was plotted over time. The mice gradually increased their body 
weight, which rises on average of 10%. On the contrary, MOG35-55-immunised mice 
reduce their body weight over an equal period.  
 
The weight of MOG35-55-immunised mice was tracked for 20 days. In figure 3.7b, the 
percentages of the weight variation are plotted. These mice showed a biphasic 
change of body weight: first they gained gradually 10% weight in less than 10 days, 
and then rapidly lost a double amount of their weight increase in the following 5 
days. Finally, in the last period of 5 days they gained again weight but they never 
recovered the initial body weight.  
 
                                                                        Results 
 
 
 
125 
The dramatic weight drop occurs simultaneously to the onset phase of EAE. The 
weight loss starts even before the clinical signs of EAE were visible as is highlighted 
by the yellow box in Figure 3.7c. Thus, the body weight was used as parameter to 
monitor health and/or illness in mice. 
 
 
Figure 3.7. Weight variation as disease biomarker. a) Typical daily variation of 
weight in 6-7 week old male control mice (n= 3). b) Typical weight loss in MOG35-55-
immunised mice (n=6). The graph in c) shows an overlay of the weight loss and the 
EAE clinical scores. The appearance of disease signs occurs simultaneously to weight 
sinking (yellow square-dot box).  
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3.2.2 MOG35-55 induced EAE in AnxA1
tg
 mice 
Weight loss is one of the parameter that can be used to assess and track the 
development of the EAE, as mentioned above. As shown in Figure 3.8a, AnxA1
tg
 
mice displayed a more pronounced body weight loss compared to wild type as the 
disease developed. The reduction of body weight for AnxA1
tg
 mice started at day 10 
and reached about 15% at day 20. Conversely, for wild type mice the weight loss 
started at day 13 and never reached more than 5% in the following days.  
 
When we considered the percentage of incidence of disease it was interesting to 
notice that AnxA1
tg
 showed a reduced number of diseases animals (about 20%) 
compared to wild type (about 70%) at day 12. However, these differences quickly 
levelled off in the following 2 days and remained comparable from day 14 onwards 
(Figure 3.8b).  
 
Although the incidence of disease progressed and reached the same levels in wild 
type and AnxA1
tg
 mice, the severity of the clinical score were remarkably different 
from day 16
th
 onwards. The EAE in AnxA1
tg
 mice showed a progressive linear 
increase in clinical score that reached a maximum of 4-5 at the later stages (day 17
th
 
onwards). Conversely, wild type mice showed a maximum score of 2-3 at day 16
th
 
and remained at this level till the end of the experiment. The difference between the 
two EAE clinical score curves is statistically significant and independent of the 
experiment size (p<0.0001 calculated by two-way ANOVA test, Figure 3.8c).  
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Figure 3.8. MOG35-55 induced EAE in wild type and AnxA1
tg 
mice. a) Percentage of 
weight gain-loss, b) incidence of disease and c) EAE clinical score of wild type and 
AnxA1
tg
 mice, respectively (Two-way repeated measure ANOVA, Bonferroni post-
test, *p<0.05, **p<0.01, ***p<0.001; n=8; representative experiment of N=3). 
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Consistent with these results, analysis of the H&E staining of the spinal cord sections 
obtained at day 14 showed fewer areas of leukocytes infiltration and tissue damages 
in the wild type compared to AnxA1
tg
 (Figure 3.9). 
 
 
 
 
 
 
 
 
Figure 3.9. Spinal cord sections at 14
th
 day of MOG35-55 induced EAE. H&E 
staining of lumbar sections of spinal cords collected from wild type (left panel) and 
AnxA1
tg
 (right panel) mice at day 14
th
 after immunisation with MOG35-55. Arrowheads 
highlight areas of leukocytes infiltrations. 
 
 
The exacerbated development of disease in AnxA1
tg
 mice was most evident when 
wild type control mice showed middle to mild signs of disease. Indeed, we could not 
observe any significant difference in experiments where control mice reached that 
maximum score of disease. The Table 3.3 shows the analysis of disease incidence 
and area under the curve (AUC) between wild type and AnxA1
tg
 mice in two typical 
experiments with different disease severity. The autoimmune-prone phenotype of 
AnxA1 is better revealed in the experiment #2 where the severity of the disease of 
the control is lower compared to that obtained in the experiment #1. 
  
Wild type 
Day 14 
AnxA1
tg
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Table 3.3: Difference in disease development between wild type and AnxA1tg mice.  
 
Data are from two independent experiments with n=8-10 mice per group. 
 
These results suggest that AnxA1 overexpression in T cells acts as a catalyser and 
amplifier of disease development and are consistent with previous observations 
obtained in vitro that suggested AnxA1 as a homeostatic modulator of strength of 
TCR signalling (145).  
 
  
Exp Mice Incidence AUC 
 
% of AUC 
increase 
#1 
Wild type 90%  (9/10) 20.5 ± 3.4  
AnxA1
tg
 90%  (9/10) 25± 4.8 22% 
#2 
Wild type 87.5% (7/8) 16 ± 3.0  
AnxA1
tg
 100% (8/8) 26.3± 4.0 62% 
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3.2.3 Pristane-induced lupus in AnxA1
tg
 mice 
As for the EAE, monitoring weight gain/loss during the development of pristane-
induced lupus provides a very useful indication of the severity of the disease. Similar 
to what we observed with the EAE model, pristane-challenged AnxA1
tg
 mice 
showed a dramatic weight loss compared to wild type especially during the first two 
weeks of assessment (Figure 3.10a). These early signs of disease were associated to a 
progressive reduction in survival that started as early as 7 days from the challenge 
and reached 70% after 3 weeks (Figure 3.10b).  
 
 
Figure 3.10. Pristane-induced lupus in wild type and AnxA1
tg 
mice. a) Percentage 
of weight gain-loss and b) Kaplan-Meier survival curve of wild type and AnxA1
tg
 
mice. c) Number of mice alive or dead per group at day 35; contingency table used for 
Fisher’s exact test. (Two-way repeated measure ANOVA, Bonferroni post-test, 
***p<0.001; n=8-10 per group). 
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This increased lethality was matched by more severe signs of tissue inflammation as 
evidenced by the histological analysis of the target organs such as the spleen and the 
lungs. Macroscopically, the spleens of AnxA1
tg
 mice were twice the size of those of 
wild type, with clear differences in colour with the AnxA1
tg
 being of a much lighter 
red colour compared to the wild type (Figure 3.11a, left panels). The lungs of 
AnxA1
tg
 mice also showed a very different outlook with peculiar dark-dots spotted 
parenchyma (an indication of haemorrhagic areas) compared to the classical clear 
pink colour of the control parenchyma (Figure 3.11b, left panels).   
 
Figure 3.11. Macroscopical and microscopical difference of the spleens and lungs 
of pristane-challenged AnxA1
tg
 and wild-type mice. a) Spleen of wild type (top left 
panel) and AnxA1
tg
 (bottom left panel) mice one month after the challenge. On the 
right panels, the related sections after H&E staining (10x). RP: red pulp; WP: white 
pulp. b) Right lung of wild type (top left panel) and AnxA1
tg
 (bottom left panel) mice 
one month after the challenge and the related H&E staining of histology sections 
(right panels; 10x). 
 
H&E staining of the same tissues showed a clear accumulation of white material in 
in the spleen and dense area of inflammation and cell infiltration in the lung of 
AnxA1
tg
 mice compared to wild type (Figure 11a and b, bottom right panel).  
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3.3 Investigate the nature of AnxA1tg T cells in EAE 
The results showed so far in two models of autoimmune diseases support the 
hypothesis of AnxA1
tg
 mice being an autoimmune-prone phenotype. To further 
investigate mechanisms responsible for the in vivo effects, we performed quantitative 
and qualitative analyses of the T cell phenotype developed during the progression of 
the EAE in AnxA1
tg
 and wild type mice.  
 
As I have discussed in the Introduction (section 1.2.4 T helper cells and autoimmune 
diseases), current views on the role of effector Th cells in autoimmune diseases have 
recognised the importance of T cell plasticity in determining the pathogenic function 
of these cells in these diseases. To assess the impact of AnxA1 overexpression on T 
cell plasticity I have performed the analyses of the Th phenotype at two time points: 
at day 9 and day 16.  
 
Day 9 is a time preceding the development of signs of disease and has thus been 
chosen to identify differences in events like T cell priming and activation that occur 
in the peripheral lymphoid organs at the early stage of the disease. Day 16 is the time 
the disease is fully developed and thus has been chosen to investigate the phenotype 
of the T cells infiltrated in the target organ i.e. in the spinal cord in this case. These 
tests has allowed us to investigate how the overexpression of AnxA1 in T cells 
would influence the “plastic” adaptation that Th cells experience once they are in the 
target organ i.e. spinal cords and hence indirectly, the effect of AnxA1 on T cell 
plasticity (Figure 3.12). 
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3.3.1 Influence of AnxA1 on T cell priming and differentiation in vivo 
Analysis of the total cell count of lymph node and spleen cells harvest from AnxA1
tg
 
and wild type mice at 9 day after the immunisation showed no significant 
differences. To investigate possible differences in T cell phenotypes, cells were 
stimulated with MOG35-55 (100&g/ml) or anti-CD3 and anti-CD28 (5&g/ml) for 72h 
and then analysed by intracellular staining. 
 
Gated CD4+ T cells from wild type (top panels) and AnxA1
tg
 (bottom panels) from 
control un-stimulated conditions showed no difference in the profile of IFN" and IL-
17 or GM-CSF and IL-17 production (Figure 3.13 and 3.14, respectively). 
Stimulation with either MOG35-55 or anti-CD3/anti-CD28 showed higher percentages 
of IFN"+ or GM-CSF+ CD4+ T cells in AnxA1
tg
 cultures compared to wild type. 
However, analysis of the cumulative data performed on a number of experiments 
showed no significant difference in the percentages of CD4+ T cells producing IFN", 
GM-CSF or IL-17 between the two groups (Figure 3.15). 
 
Analysis of the cell supernatants at the end of their differentiation by CBA confirmed 
these findings and showed no significant difference in the levels of IFN" and IL-17 
whereas GM-CSF was found to be significantly higher in the AnxA1
tg 
than the wild 
type (p=0.029) (Figure 3.16).  
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Figure 3.13. IFN" and IL-17 expression in CD4+ T cells from wild type and 
AnxA1
tg
 mice at day 9 of EAE. Lymphocytes from peripheral lymphoid organs were 
cultured in only medium (Control, left panels), in presence of MOG35-55/anti-CD28 
(middle panels) or anti-CD3/antiCD28 (right panels) for 72h.  
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Figure 3.14. GM-CSF and IL-17 expression in CD4+ T cells from wild type and 
AnxA1
tg
 mice at day 9 of EAE. Lymphocytes from peripheral lymphoid organs were 
cultured in only medium (Control, left panels), in presence of MOG35-55/anti-CD28 
(middle panels) or anti-CD3/anti-CD28 (right panels) for 72h.  
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Figure 3.15. Cytokines expression of CD4+ T cells from peripheral lymphoid 
organs after restimulation with MOG35-55/anti-CD28. Percentagees of a) IFN"+, b) 
GM-CSF+ and c) IL-17+ CD4+ T cells in wild type and AnxA1
tg
 lymphocytes 
collected at day 9 of EAE and restimulated in vitro with MOG35-55/anti-CD28 
(unpaired t-test; cumulative data of N=4 experiments with n=4-5 mice). 
 
 
 
 
 
Figure 3.16. Cytokine production by lymphocytes from peripheral lymphoid 
organs after restimulation with MOG35-55/anti-CD28. CBA quantification of a) 
IFN", b) GM-CSF and c) IL-17 released by wild type and AnxA1
tg
 lymph node cells 
and splenotytes after restimulation for 72h (p=0.029, unpaired t-test; cumulative data 
of N=4 experiments with n=4-5 mice). 
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3.3.2 Influence of AnxA1 on T cell plasticity in vivo 
Total cell counts as well as pecentages of CD4+ and CD8+ T cells did not change in 
the spinal cord at day 9 of EAE (Figure 3.17a, top panels, and 3.17b), and hence it 
was not technically possible for us appreciate potential differences in phenotype 
between wild type and AnxA1
tg
 mice.  
 
 
Figure 3.17. T cells infiltrated in the spinal cord of wild type and AnxA1
tg
 mice at 
day 9 and 16 of EAE. a) CD4+ and CD8+ T cells infiltrated in the spinal cord of wild 
type and AnxA1
tg
 mice at day 9 (top panels) and day 16 (bottom panels). Total cell 
counts of leukocytes purified b) at day 9 and c) at day 16 from the spinal cord of wild 
type and AnxA1
tg
 mice (unpaired t-test, n=4-5 per group of N=2 experiments).  
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Conversely, analysis of the total cell count of T cells infiltrated into the spinal cord 
of immunised mice at day 16 showed a larger population of infiltrated CD4+ and 
CD8+ T cells in AnxA1
tg
 mice compared to wild type (Figure 3.17a, bottom panels 
and 3.17c). Both cell number and percentages of CD4+ T cells were almost doubled 
in AnxA1
tg
 compared to wild type (Figure 3.18).  
 
 
Figure 3.18. CD4 T cells in the spinal cord on day 16 of EAE. a) Percentage and b) 
number of CD4+ T cells purified from the spinal cord of wild type and AnxA1
tg
 mice 
at day 16 (*p<0.05, unpaired t-test; n=4-5 mice per group of N=2 experiments). 
 
 
When we next investigated IFN", GM-CSF and IL-17 production by ICS, we 
observed an increased percentage of IL-17 producing T cells in the infiltrates of 
AnxA1
tg
 mice; both as single defined IL-17+ populations and as double positive 
populations for IL-17 and IFN" or GM-CSF (Figure 3.19a and 3.19b, top- and 
bottom- right gates in each dot plot). The pronounced Th17 phenotype of AnxA1
tg
 
mice was also associated with a reduction of a single IFN" producing CD4+ T cell 
population when compared to wild type mice (top left gates in Figure 3.19a).  
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The graphs in Figure 3.20 represent the cumulative data of two independent 
experiments and confirmed the increased percentage of IL-17+/IFN" and IL-
17+/GM-CS CD4+ T cells in the spinal cord infiltrates of AnxA1
tg
 mice compared to 
wild type. 
 
 
Figure 3.19. CD4+ T cell subsets in spinal cord infiltrate on day 16. a) IFN" (top-
left gate), IL-17 (bottom-right gate) and IFN"/IL-17 (top-right gate) expressing CD4+ 
T cells in wild type and AnxA1
tg
 mice. b) GM-CSF (top-left gate), IL-17 (bottom-
right gate) and GM-CSF/IL-17 (top-right gate) expressing CD4+ T cells in wild type 
and AnxA1
tg
 mice.  
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Figure 3.20. Pathogenic phenotype of CD4+ T cells purified from spinal cord at 
day 16. Percentages of a) IFN"+/IL-17+ and b) GM-CSF+/IL-17+ CD4+ T cells 
purified from the spinal cord of wild type and AnxA1
tg
 at day 16 of the EAE (*p=0.02, 
unpaired t-test; cumulative data of N=2 independent experiments with n=3-5 mice).  
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3.4 AnxA1tg T cells in pristane-induced lupus 
To investigate the phenotype of CD4+ T cells in pristane-induced lupus, we used the 
day 14 peritoneal lavage fluids of pristane-challenged mice. AnxA1
tg
 mice show 
lower percentages and number of CD4+ T cells compared to wild type most likely 
because of the exacerbated severity of the disease of the former compared to the 
latter (Figure 3.21). The paucity of recovered cells has made the analysis of the 
CD4+ T cell phenotype by ICS very difficult. Figure 3.22 shows the percentages of 
of CD4+ and IFN", IL-17 or IL-4 positive T cells found. 
 
 
 
Figure 3.21. T cells in peritoneal fluid of pristane injected mice. a) Total cell 
number in peritoneal fluid of wild type and AnxA1
tg
 mice. b) Percentages and c) 
number of CD4+ T cells recovered in the peritoneal lavage of wild type and AnxA1
tg
 
14 days after the challenge with pristane (N=1 experiment with 4-5 mice per group). 
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Figure 3.22. ICS of exudates from peritoneal fluid of pristane injected mice. 
Percentages of CD4+ T cells and a) IFN"+, b) IL-17+ and c) IL-4+ cells isolated from 
the peritoneal lavage of wild type and AnxA1
tg
 mice 14 days after the pristane 
injection. 
 
 
Analysis of cytokine levels in the peritoneal lavages of these mice showed no 
significant difference between wild type and AnxA1
tg
 most likely because of the 
advanced status of disease of the AnxA1
tg
 and the consequent high variability of the 
samples (Figure 3.23). 
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Figure 3.23. Cytokines in the peritoneal fluid of pristane injected mice. 
Concentrations of IFN", IL-17 and IL-4 (top panels) as well as of IL-6, Il-23 and 
TNFa (bottom panels) measured in the peritoneal lavages of wild type and AnxA1
tg
 
mice 14 days after the pristane injection (N=1 experiment with n=4-5 per each group). 
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3.5 Altered emotional behaviour in AnxA1
tg
  
Surprisingly, AnxA1
tg
 mice showed signs of mood disorders. Both the two strain 
founders developed either maternal cannibalism or anxiety-like behaviour with the 
establishment of the homozygous genotype.  
 
3.5.1 AnxA1
tg
: maternal cannibalism  
The AnxA1 transgenic colony coming from the female founder showed cannibal 
behaviour towards the offspring (Figure 3.24). This phenomenon was not observed 
with heterozygous mice obtained during the background crosses. Few sporadic 
events of missed pups were noticed for one breeding pair (G-12; data not shown). G-
12 offspring were used for future breeding (Trio H-13 and -14). From this point 
onwards, pups were found dead, missing or eaten soon after their delivery. Both H-
13 and H-14 showed a “fully developed” cannibalism phenotype (Fig 3.25).  
 
Removing male breeders from the cage before the delivery of the newborn did not 
interfere with this phenomenon thus suggesting maternal driven cannibalism. 
Interestingly, the cannibal behaviour of the mothers was very specific towards their 
own progenies since it did not manifest with litter of different breeding pairs of the 
same backgrounds (C57BL/6). 
 
To overcome the risk of loosing the colony, offspring were fostered with wild type 
mothers. Of all the pups that were obtained we managed to save one fostered female 
from H-13 whose first litters were all female that also showed cannibalism (Figure 
3.25). In addition to this, other impaired and aggressive behaviour started to 
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manifest. As an example, a group of female littermates showed clear signs of 
excessive barberism as evidenced by the absence of whiskers and missing fur on the 
back of some subjects (Figure 3.26). 
  
The cannibal behaviour was conserved notwithstanding the fostering of the pups. 
However, and more intriguingly, the continuous fostering over generations seemed to 
“mellow” the cannibal attitude of these mice since we have been able to save and 
retrieve more male and female pups (data not shown). These are currently exploited 
to maintain the colony.  
 
Besides fostering, we tried to rescue the pups administering perphenazine (0.5 or 
0.025 mg/ml in drinking water) to pregnant cannibal mothers (Trio L- 15 and 16). 
This pharmacological treatment was unsuccessful.  
 
 
 
Figure 3.24. Offspring found dead. Three pups found dead post-partum in AnxA1
tg
 
mice. Clear signs of cannibalism can be observed in the pup in the middle, while the 
other two showed missed limp.  
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Figure 3.25. Maternal cannibalism flow chart. AnxA1
tg
 progeny coming from the 
Bella founder. In the chart breeding Pair I-13, Trio L-15 and 16 were the first breeding 
to fully show the cannibal phenotype. Pair K-16 and Quartet L-17 were the next 
generation breeding obtained thanks to mother fostering. Each breeding and related 
progeny are highlighted with a specific colour. Male breeders were interchanged at 
least between two different breeding as shown by the dashed arrows. A group of 6 
female mice at the second filial generation showed barberism. f.d.: pups found dead; 
EE: enriched environment.  
 
  
 
Figure 3.26. Barberism in AnxA1
tg
. The barber (top panels) is the mouse that 
overgrooms other littermates causing patches on their coat and missing whiskers 
(bottom panels).   
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3.5.2 The anxious phenotype of AnxA1
tg
 
AnxA1
tg
 mice coming from the male founder did not showed cannibal phenotype, 
however they showed a different behaviour compared to wild type; they frenetically 
digged and moved in their home cage once the lid had been open. We decide to 
investigate the behavioural phenotype of these mice compared to wild type, and so 
we collaborated with Dr Robert Deacon, who is an expert murine behaviourist. With 
the help of Dr Deacon, we performed a battery of behavioural tests to define 
explorative behaviour and motility in mice. We then exploited the approach-
avoidance conflict of these tests to describe and interpret the anxiety-like or fear-
related behaviour in mice. 
 
3.5.2.1 Marble-burying test 
The marble-burying test gives a measurement of anxiety provoking obsessions in 
mice. It is a good test to measure and thus compare the obsessive digging activity 
that was readily observable by the naked eye. This test showed that AnxA1
tg
 mice 
start to dig earlier than wild type mice (Figure 2.27a). Although the absolute number 
of bouts was similar between the two groups, AnxA1
tg
 mice spent more time digging 
and buried more marbles compared to wild type (Figure 2.27b-d).  
 
3.5.2.2 Open field test 
The open field test assesses simultaneously environmental exploration, locomotor 
activity and anxiety-related behaviour in mice. AnxA1
tg
 mice show equal explorative 
and locomotor activity compared to wild type as indicated by the number of rearing 
                                                                        Results 
 
 
 
150 
and total square crossed (Figure 3.28b and 3.28c). In addition to this, AnxA1
tg
 mice 
showed a reduced lag time to rear compared to wild type (Figure 3.28a). 
 
3.5.2.3 Climbing test 
The climbing test assesses vertical environmental exploration that has been 
correlated to dopaminergic activity in mice (250). AnxA1
tg
 mice show an overall 
decrease in climbing activity compared to wild type. This effect was accompanied by 
increased latency and decreased number and duration of climbing (Figure 3.29a-c).  
 
3.5.2.4 Light/Dark box test 
The light/dark box test assesses the anxiety-like behaviour prompted by a novel and 
bright environment. Mice were placed in the lit area of the box at the start of the test. 
AnxA1
tg
 mice showed a very peculiar behaviour in the lit area characterised by 
freezing and a general appearance of “feeling lost” that was difficult to measure or 
describe. Similar to the other tests, we could observe an increased lag time in finding 
the opening and hence to the first crossing (Figure 3.30a). Once the first crossing 
occurred, the AnxA1
tg
 mice spent about 11% of the time in the light area (35s out of 
300s) while the wild type mice about 30% (90s out of 300s) (Figure 3.30b). This 
difference was also accompanied by reduced number of transitions for AnxA1
tg
 mice 
compared to wild type (Figure 3.30c). 
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Figure 3.27. Marble-burying test. AnxA1
tg
 and wild type mice were tested for 
anxiety-like behaviour with the marble-burying test. a) Digging latency, b) total 
digging time, c) number of bouts and d) number of buried marbles are representative 
of four independent experiments. (*p<0.05, **p<0.01, Mann-Witney test; n=5-9 per 
each group). 
 
 
 
 
Figure 3.28. Open field test. AnxA1
tg
 and wild type mice were tested for explorative 
activity and anxiety-like behaviour with the open field test. a) Rearing latency, b) 
number of rearing and c) number of total squares crossed are representative of three 
independent experiments. (*p<0.05, Mann-Witney test; n=4-6 per each group). 
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Figure 3.29. Climbing test. AnxA1
tg
 and wild type mice were tested for vertical 
explorative activity with the climbing test. a) Latency to climb, b) total climbing time 
and c) number of climbing are representative of two independent experiments. 
(*p<0.05, Mann-Witney test; n=6-8 per each group). 
 
 
 
 
 
Figure 3.30. Light/dark box test. AnxA1
tg
 and wild type mice were tested for 
anxiety-like behaviour with the light/dark box test. a) Latency to the first crossing, b) 
time in light after the first crossing and c) number of crossing are representative of 
three independent experiments. (**p<0.01, Mann-Witney test; n=6-8 per each group). 
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3.6 T cells and mood change in early EAE  
AnxA1
tg
 mice show a hyper-reactive T cell phenotype, higher susceptibility to 
develop autoimmune diseases and an interesting “emotional dysfunction”. Several 
evidences in the clinic show that patients suffering from autoimmunity have higher 
prevalence of anxiety or depression compared to patients suffering from other 
unrelated diseases or healthy controls. Most interestingly browsing through their 
clinical history it is often possible to find emotional issues at time earlier than the 
first manifestation of autoimmune disease. To address whether the emotional 
changes of AnxA1
tg
 mice were conducive to the exacerbated signs of EAE, we took 
a step back and investigated if the same emotional changes observed in the clinic 
could be measured in our experimental system. To this aim, we performed a 
systematic assessment of the emotional changes at early stage of EAE i.e. soon after 
the immunisation with MOG35-55. We used the open filed and marble-burying test 
and assessed changes in behaviour over 10 days, every other day from the day of 
immunisation.  
 
Immunised mice took more time to start to rear compared to control non-immunised 
mice (Figure 3.31a) while the number of rearing was similar (Figure 3.31b). Same 
effect was observed on the marble-burying test: immunised mice showed higher 
latency to dig while the number of buried marbles was comparable between the two 
groups (Figure 3.31c and 3.31d). 
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Figure 3.31. Emotional changes in MOG35-55-induced EAE. Time course for a) 
rearing latency and b) number of rearing during the open field of wild type mice 
immunised with MOG35-55 (EAE) and littermates not immunised (control). In c) and d) 
are represented the time course for digging latency and the number of buried marbles, 
respectively. Values are plotted as percentage from the baseline for each single mouse. 
(**p<0.01, repeated measure two-way ANOVA; cumulative plots of N=5 separate 
experiments with n=4-6 -per group). 
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To correlate these behavioural changes to T cell function at these time points, we 
next tracked the movement of these cells in and out of circulation. As shown in 
Figure 3.32a and 3.32b, we observed that CD3+ T cells varied in number both in 
spleen and blood of the immunised mice. More specifically, the number of CD3+ T 
cells increases up to day 4 after immunisation mirroring the trend of the behaviour 
changes we observed.  
 
 
Figure 3.32. CD3+ T cells of mice subjected to MOG35-55-induced EAE. Number of 
CD3+ T cells a) in the spleen and b) in blood of control or immunised mice at 
different time points, in particular at day 2, 4 and 8 after immunisation with MOG35-
55. (*p<0.05, un-paired t-test; n=3 per time point). 
 
 
No difference in blood cytokines was detected in those mice. The association 
between behavioural changes and the increase of CD3+ T cells number in the blood 
was also observed in mice immunised with OVA323-339 plus CFA, but not only CFA 
(data not shown). In addition, the treatment with GA prevented the behavioural 
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changed observed in MOG35-55 immunised mice and interestingly increased the 
number of T cells in peripheral lymphoid organs (Figure 3.33a and 3.33b). 
  
 
Figure 3.33. GA treatment inhibits the emotional changes observed in MOG35-55-
induced EAE. a) Percentages of rearing latency in the open field test of no-
immunised (control) and vehicle (PBS) or GA treated mice after immunisation. b) 
Total T cell number in the draining lymph nodes of vehicle or GA treated mice at the 
4 of EAE. (**p<0.01, repeated measure two-way ANOVA; representative of N=2 
experiments with n=6-8 per group). 
 
 
Thus, we were able to shown that activation and mobilisation of T cells into the 
blood correlated in time with the changes in emotional behaviour. These data have 
been published and a copy of this article has been attached at the appendix of this 
thesis.  
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3.7 AnxA1
tg
 T cells adoptive transfer 
AnxA1
tg
 mice show anxiety-like behaviour and they are prone to develop 
autoimmune diseases. These two distinct but intertwined observations rose the 
question whether the AnxA1
tg
 T cells induce anxiety as well as lead to exacerbated 
outcomes in the autoimmune models. To address this point, we performed T cell 
adoptive transfer experiments of AnxA1
tg
 T cells in wild type mice. These chimeric 
mice were tested for their behaviour using the light/dark box test as read-out and 
thereafter were immunised with MOG35-55 to study the development of the EAE. 
Alongside T cells, sera from the same donor mice were adoptively transferred into 
wild type mice.  
 
3.7.1 CD3+ T cell transfer, anxiety test and EAE induction 
In a first series of experiments we adoptively transferred the whole CD3+ T cell 
population isolated from wild type and AnxA1
tg
. Host mice were tested before the 
injection (Day -1) and at different time points (day 1, 4, 7, 14 and 21) after the 
adoptive transfer.  
 
As shown in Figure 3.34a and 3.34b, the behaviour of mice that received CD3+ T 
cells from wild type or AnxA1
tg
 mice did not significantly changed throughout the 
experiment till day 14. At this time point, the time spent in light and the number of 
crossing drastically halved in both groups. Administration of serum from wild type 
animals increased the time spent in light and the number of transitions at about day 7 
(Figure 3.34c and 3.34d) and this did not occur in mice receiving the AnxA1
tg
 mice 
sera. 
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At day 21, mice were immunised with MOG35-55. Figure 3.35 shows that the transfer 
of CD3+ T cells or serum in wild type mice leads to different outcomes: mice 
receiving wild type CD3+ T cells showed an earlier onset of disease (at day 7) and 
developed severe EAE (Figure 3.33a and 3.35b). Conversely, mice that received 
AnxA1
tg
 CD3+ T cells showed milder EAE whose onset was around day 10. The 
pattern of EAE development of mice receiving AnxA1
tg
 T cells almost overlapped 
that of control PBS-injected immunised mice (Figure 3.35c and 3.35d). 
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Figure 3.34. Light/dark box test after T cell or serum adoptive transfer. Wild type 
mice were tested for their basal activity at the light/dark box test (Day -1). Then, they 
received either CD3+ T cells or sera from wild type (empty square) and AnxA1
tg
 mice 
(full square). Percentage from the baseline of a) time spent in light and b) number of 
crossing after CD3+ T cells or of c) time spent in light and d) number of crossing after 
sera transfer are shown for 5 different time points. (Repeated measure two-way 
ANOVA, n=4 per each group). 
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Figure 3.35. MOG35-55-induced EAE after T cell or serum adoptive transfer. a) 
Weight gain/loss and b) EAE clinical score of wild type mice that received either wild 
type or AnxA1
tg
 CD3+ T cells (empty and full black squares, respectively) or PBS 
(full grey square). c) Weight gain/loss and d) EAE clinical score of wild type mice 
that received either wild type or AnxA1
tg
 sera or PBS. Mice were adoptively 
transferred 21 days before the MOG35-55 immunisation (n=4 per each group). 
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3.7.2 CD4+ T cells transfer, anxiety test and EAE induction 
In a second set of experiments we adoptively transferred CD4+ T cells. Chimeric 
mice were tested as described above. 
 
Mice that received wild type CD4+ T cells spent more time in the light compared to 
their basal and the same increase was observed in those injected with PBS vehicle. 
Conversely, those that received AnxA1
tg
 CD4+ T cells spent more time in the dark 
compared to the other two groups (Figure 3.36a). In line with this, AnxA1
tg
 CD4+ T 
cell recipient mice performed a lower number of crossing compared to both PBS and 
wild type CD4+ T cell recipient mice (Figure 3.36b). 
 
CD4+ T cell recipient mice were tested for the EAE. The overall severity of the 
disease was mild compared to the ones we routinely run with the onset falling four 
days later than the expected one i.e. at day 16 rather than day 10-12 and the clinical 
score reaching a maximum of 1.5 (Figure 3.37). Intriguingly, AnxA1
tg
 CD4+ T cell 
recipients developed signs of disease earlier (Figure 3.37). 
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Figure 3.36. Light/dark box test after CD4+ T cell adoptive transfer. a) Time in 
light and b) number of crossing of wild type mice that received either wild type or 
AnxA1
tg 
CD4+ T cells or PBS. (*p<0.05, Kruskal-Wallis test; representative of N=2 
experiments with n=4 per each group). 
 
 
 
 
 
 
Figure 3.37. MOG35-55-induced EAE after CD4+ T cell adoptive transfer. a) 
Weight gain/loss and b) EAE clinical score of wild type mice that received either wild 
type or AnxA1
tg
 CD4+ T cells (empty and full black squares, respectively) or PBS 
(full grey square). (n=4 per each group). 
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3.8 Microarray analysis of AnxA1
tg
 brain and CD4+ T cells 
AnxA1
tg
 mice show signs of anxiety-like behaviour and develop severe signs of 
disease in autoimmune models. To study the mechanism(s) behind these 
observations in vivo, we decided to perform microarray analyses on brain or CD4+ T 
cells of AnxA1
tg
 and wild type mice.  
 
3.8.1 AnxA1
tg
 brain gene fingerprint  
Whole brains were used to study gene expression profile in wild type and AnxA1
tg
 
CNS. The gene expression analysis showed a short list of genes (36 out of 23,307 
interrogated genes) that have significant different expression in AnxA1
tg
 compared 
to wild type brain (Figure 3.38).  
 
The most pronounced differences of fold changes were observed for genes found 
downregulated in AnxA1
tg
 brain. Among these genes, Snca was almost 16 times, 
while Mageb16 was almost 8 times less expressed in AnxA1
tg
 brain (Table 3.4). 
 
To fully appreciate the meaning of these data, the Signaling Pathway Impact 
Analysis (SPIA) was performed to identify the most relevant signalling pathways 
modulated in the AnxA1
tg
 mice. This functional analysis identified several GO hits 
(pathways) for the downregulated genes, but not for the upregulated genes. All the 
identified signalling pathways resulted inhibited in the AnxA1
tg
 mice compared to 
wild type mice. However, the adjusted p-values for each pathway were higher than 
0.05 (Table 3.5). 
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Figure 3.38. Heat-map for the microarray of wild type and AnxA1
tg
 brains. Gene 
expression of three different brains of both wild type and AnxA1
tg
 represented in 
colour scale going from the most downregulated (bright green) to the most 
upregulated (bright red). 
  
F
D
A
2
_
W
T
2
_
0
4
0
9
2
0
1
2
.C
E
L
F
D
A
1
_
W
T
1
_
0
4
0
9
2
0
1
2
.C
E
L
F
D
A
3
_
W
T
3
_
0
4
0
9
2
0
1
2
.C
E
L
F
D
A
1
2
_
2
3
5
_
3
_
1
4
0
9
1
2
_
.M
o
G
e
n
e
.1
_
0
.s
t.
v
1
..
C
E
L
F
D
A
1
1
_
2
3
5
_
2
_
1
4
0
9
1
2
_
.M
o
G
e
n
e
.1
_
0
.s
t.
v
1
..
C
E
L
F
D
A
1
0
_
2
3
5
_
1
_
1
4
0
9
1
2
_
.M
o
G
e
n
e
.1
_
0
.s
t.
v
1
..
C
E
L
Pisd!ps1
Erdr1
Snca
Mageb16
Gm20867
Plac9a
Tmem254a
Trdn
Gm5148
Duxbl1
Rps25
Cetn4
G530011O06Rik
Mid1
Entpd4
Ankrd32
Mir15a
Mir384
Pla2g4e
Scg5
Gabra2
4932438A13Rik
Ott
Katnbl1
Wdfy1
Cox5b
AF357355
9330155M09Rik
Gm10033
Vmn2r86
!1.5 !0.5 0.5 1.5
Value
0
1
0
2
5
Color Key
and Histogram
C
o
u
n
t
W
ild
 ty
pe
  
A
nx
A
1
tg  
W
ild
 ty
pe
  
W
ild
 ty
pe
  
A
nx
A
1
tg  
A
nx
A
1
tg  
                                                                        Results 
 
 
 
165 
Table 3.4: Differential expressed genes in AnxA1
tg
 brain 
 
 
 
  
I.D. Fold change Adj p-value 
Snca -3.995 0 
Mageb16 -2.81 0.000194 
Gm5148 -1.512 0.000152 
G530011O06Rik -1.351 0.002523 
Tmem254a -1.317 0.001787 
Mid1 -0.986 0.003069 
Gm20867 -0.975 0.020271 
Rps25 -0.937 0.01628 
Cetn4 -0.926 0.043414 
Erdr1 -0.881 0.003186 
Duxbl1 -0.878 0.001844 
Trdn -0.855 0.002523 
Plac9a -0.821 0.022588 
Pisd-ps1 -0.695 0.033088 
Entpd4 -0.689 0.003159 
Trdn -0.643 0.006034 
Cetn4 -0.64 0.006392 
Mageb16 -0.612 0.008714 
Adal 0.507 0.020271 
Mir421 0.509 0.020271 
4932438A13Rik 0.537 0.029653 
Fut9 0.537 0.041221 
Cox5b 0.615 0.005176 
Mir15a 0.618 0.016149 
Katnbl1 0.619 0.004552 
9330155M09Rik 0.623 0.029653 
Gm10033 0.628 0.041221 
Ankrd32 0.659 0.005176 
Scg5 0.69 0.003186 
AF357355 0.698 0.035643 
Vmn2r86 0.704 0.041221 
Wdfy1 0.813 0.004544 
Mir384 0.854 0.011995 
Pla2g4e 0.946 0.001862 
Gabra2 0.955 0.001088 
Ott 0.997 0.000739 
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Table 3.5: SPIA on differential expressed genes in AnxA1
tg
 brain 
 
 
 
* KEGG (Kyoto Encyclopedia of Genes and Genomes); pNDE, pPERT and pGFWER: 
probability values.  
 
  
KEGG pathway pNDE pPERT pGFWER STATUS 
1 Parkinson's disease 2 0 0.569100693 Inhibited 
2 Alzheimer's disease 2 0 0.569100693 Inhibited 
3 Long-term depression 1 0 0.569100693 Inhibited 
4 VEGF signaling pathway 1 0 0.569100693 Inhibited 
5 Fc epsilon RI signaling pathway 1 0 0.569100693 Inhibited 
6 GABAergic synapse 1 0 0.569100693 Inhibited 
7 Morphine addiction 1 0 0.569100693 Inhibited 
8 Fc gamma R-mediated phagocytosis 1 0 0.569100693 Inhibited 
9 GnRH signaling pathway 1 0 0.569100693 Inhibited 
10 Retrograde endocannabinoid signaling 1 0 0.569100693 Inhibited 
11 Pancreatic secretion 1 0 0.569100693 Inhibited 
12 Lysosome 1 0 0.569100693 Inhibited 
13 Vascular smooth muscle contraction 1 0 0.569100693 Inhibited 
14 Glutamatergic synapse 1 0 0.569100693 Inhibited 
15 Toxoplasmosis 1 0 0.569100693 Inhibited 
16 Serotonergic synapse 1 0 0.569100693 Inhibited 
17 Huntington's disease 1 0 0.613054537 Inhibited 
18 MAPK signaling pathway 1 0 0.690539103 Inhibited 
19 Neuroactive ligand-receptor interaction 1 0 0.690539103 Inhibited 
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3.8.2 AnxA1
tg
 CD4+ T cells gene fingerprint  
The microarray analyses performed on wild type and AnxA1
tg
 CD4+ T cells showed 
a long list of genes differentially expressed. Among 35,556 genes that have been 
interrogated, a total of 2,487 genes were differentially expressed of which 1,746 
were upregulated and 741 were downregulated in AnxA1
tg
 CD4+ T cells compared 
to wild type CD4+ T cells. Table 3.6 shows a list of 77 upregulated genes (red 
numbers; fold change >0.5) and 60 downregulated genes (green numbers; fold 
change <-0.5). Genes with a p value <0.05 AND fold change >1.5 were clustered and 
represented in heat-map (Figure 3.39). 
 
The most upregulated gene in AnxA1
tg 
CD4+ T cells was AnxA1, which was 8 times 
higher than wild type. Many known genes were found differently regulated such as 
IL12rb1 (Interleukin 12 receptor, beta 1), Nmnat1 (Nicotinamide mononucleotide 
adenylyltransferase 1), Hmgb1 (High mobility group protein 1), Ccr8 (Chemokine C-
C motif receptor 8) or Ccl22 (Chemokine C-C motif ligand 22). However, we 
selectively focused our attention on unknown modulated genes such as 
2610019F03Rik. 
 
The Signaling Pathway Impact Analysis (SPIA) identified several signalling 
pathways that are altered in the CD4+ T cells of AnxA1
tg
. The most significantly 
modified pathways are listed in Table 3.7.  
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Figure 3.39. Heat-map for the microarray of wild type and AnxA1
tg
 CD4+ T cells. 
Gene expression of CD4+ T cells from wild type and AnxA1
tg
 represented in colour 
scale going from the most downregulated (bright green) to the most upregulated 
(bright red). Genes with p<0.05 AND fold change >1.5 are represented. 
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Table 3.6: Differential expressed genes in AnxA1
tg
 CD4+ T cells  
ID Fold change Adj p-value 
1 Anxa1 2.978 0 
2 Speer4d 1.108 4.00E-06 
3 Il12rb2 0.997 0.012621 
4 Nmnat1 0.99 0.000434 
5 Ifit3 0.982 0.000678 
6 Gas5 0.928 0.002568 
7 Il7r 0.866 0.001596 
8 Speer4d 0.818 0.000157 
9 Pydc4 0.804 0.000456 
10 Atg4a 0.765 0.012388 
11 Pydc3 0.744 0.022645 
12 Oasl2 0.741 5.20E-05 
13 Gm12250 0.71 0.004814 
14 Rpa3 0.706 0.001792 
15 Gbp8 0.697 0.002842 
16 Pde2a 0.695 0.006101 
17 Slfn8 0.691 0.005709 
18 Gbp9 0.685 0.004982 
19 Gbp4 0.683 0.002126 
20 5031410I06Rik 0.667 0.001792 
21 Irgm1 0.662 0.001885 
22 Zfand1 0.662 0.024261 
23 Ly6c1 0.651 0.014999 
24 Usp28 0.648 0.002507 
25 BC094916 0.639 0.001792 
26 Speer8-ps1 0.636 0.000437 
27 Srsf5 0.635 0.018716 
28 Snord14a 0.63 0.007099 
29 Nlrc5 0.627 0.011906 
30 Usp18 0.624 0.003771 
31 Samd9l 0.621 0.000939 
32 Phf11c 0.621 0.007725 
33 Mrpl23 0.605 0.004471 
34 Gbp5 0.605 0.012632 
35 Ly6c2 0.6 0.006604 
36 Gbp6 0.595 0.006362 
37 Nnt 0.591 0.000939 
38 Ifit1 0.591 0.001655 
39 Prrg4 0.588 0.002663 
40 Cox5b 0.585 0.002877 
41 Irgm2 0.58 0.004982 
42 Psenen 0.573 0.013998 
43 Atp8b4 0.571 0.004982 
44 Dennd2d 0.571 0.035523 
45 Lgr4 0.569 0.007959 
46 Timm21 0.566 0.001331 
47 Parp14 0.566 0.004982 
48 Ccl1 0.564 0.007422 
49 Ifit2 0.562 0.002507 
50 Snhg1 0.561 0.002663 
51 2210404J11Rik 0.56 0.000827 
52 Irf1 0.555 0.006959 
53 Snord16a 0.553 0.009438 
54 Rpl12 0.55 0.007026 
55 Snora69 0.546 0.018716 
56 Gbp7 0.541 0.002732 
57 Iigp1 0.539 0.010244 
58 Irf7 0.534 0.001001 
59 Rtp4 0.528 0.010244 
60 Nlrc5 0.518 0.016305 
61 Atm 0.517 0.009637 
62 Srp54b 0.516 0.004814 
63 Atpbd4 0.514 0.003672 
64 Nlrc5 0.512 0.014385 
65 Snora28 0.511 0.004788 
66 Snord42b 0.511 0.014652 
67 Snord37 0.509 0.018516 
68 Nlrc5 0.507 0.021578 
69 Ppp2r3c 0.506 0.001945 
70 Snhg1 0.502 0.011906 
71 Rnf213 0.501 0.006326 
72 Dapl1 0.498 0.0194 
73 Tk2 0.497 0.004814 
74 Fnip1 0.496 0.005709 
75 Nlrc5 0.493 0.014559 
76 2610019F03Rik 0.492 0.002842 
77 9330175E14Rik 0.49 0.004982 
ID Fold change Adj p-value 
1 Mageb16 -2.774 0 
2 Cphx1 -1.528 0.000305 
3 Rbmy -1.321 7.00E-06 
4 Rbmy -1.234 5.00E-06 
5 G530011O06Rik -1.205 1.00E-06 
6 Hmgb1 -1.163 0.028011 
7 Fscn1 -1.065 0.000434 
8 Mid1 -0.969 5.00E-06 
9 Ccr8 -0.958 7.00E-06 
10 Duxbl1 -0.925 0.001596 
11 Erdr1 -0.913 9.00E-06 
12 Gm10375 -0.902 0.024667 
13 Tmem254a -0.891 1.20E-05 
14 Tcp10a -0.868 0.000678 
15 Sly -0.867 0.000827 
16 Gm20736 -0.844 0.041444 
17 Zfp600 -0.84 0.002332 
18 Duxbl1 -0.829 0.000717 
19 Gm5114 -0.8 0.000142 
20 Ccl22 -0.771 0.001655 
21 Hist1h2br -0.768 0.011906 
22 Rpl38 -0.763 0.016424 
23 Synb -0.737 0.000823 
24 Sly -0.735 0.000305 
25 Vmn1r114 -0.683 0.025858 
26 Mki67 -0.679 0.000117 
27 Gm20736 -0.673 0.017194 
28 Gm10375 -0.651 0.020606 
29 Rln3 -0.649 0.000366 
30 Gm21943 -0.641 0.00214 
31 Cphx1 -0.633 0.000802 
32 Gm20736 -0.633 0.002605 
33 Hist1h2bb -0.593 0.013642 
34 Srsy -0.59 0.001223 
35 2810417H13Rik -0.584 0.000802 
36 Gm13271 -0.569 0.004739 
37 Gm7609 -0.56 0.00871 
38 Gm20815 -0.554 0.013851 
39 D830030K20Rik -0.55 0.049643 
40 Pros1 -0.547 0.013262 
41 Ccna2 -0.545 0.001585 
42 Defa20 -0.543 0.011564 
43 Defa5 -0.542 0.010244 
44 Mir713 -0.537 0.011763 
45 Sprr2a1 -0.529 0.002663 
46 Gm3696 -0.527 0.006326 
47 Olfr538 -0.526 0.005027 
48 Ccnb2 -0.522 0.006659 
49 Hist1h2br -0.522 0.007099 
50 Gm10058 -0.521 0.001945 
51 Il23r -0.521 0.003995 
52 Mup2 -0.521 0.011416 
53 Arhgap20 -0.518 0.001655 
54 Cd80 -0.517 0.001494 
55 Mageb16 -0.516 0.002507 
56 Hist1h3f -0.515 0.015734 
57 Hist1h2an -0.514 0.03121 
58 Plk1 -0.498 0.001792 
59 Ssty2 -0.498 0.002605 
60 Ccl17 -0.498 0.004471 
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Table 3.7: SPIA of differential expressed genes in AnxA1
tg
 CD4+ T cells 
 
  KEGG pathway pNDE pPERT pGFWER STATUS 
1 Herpes simplex infection 1.06E-09 0.619 1.89E-06 Activated 
2 RIG-I-like receptor signaling pathway 4.56E-07 0.36 0.000354732 Activated 
3 Influenza A 9.33E-07 0.574 0.001075025 Activated 
4 Epstein-Barr virus infection 3.44E-05 0.071 0.004420838 Activated 
5 Hepatitis C 3.62E-06 0.863 0.005552269 Activated 
6 Cytosolic DNA-sensing pathway 1.29E-05 0.66 0.014060477 Activated 
7 Systemic lupus erythematosus 1.30E-05 0.752 0.015888115 Inhibited 
8 Toll-like receptor signaling pathway 4.07E-05 0.78 0.046831327 Activated 
9 Autoimmune thyroid disease 0.000184486 0.261 0.068487394 Inhibited 
10 Allograft rejection 0.000328624 0.296 0.129463911 Inhibited 
11 Jak-STAT signaling pathway 0.000396472 0.444 0.220716176 Inhibited 
12 Cytokine-cytokine receptor interaction 0.001468527 0.149 0.268163061 Inhibited 
13 Cell cycle 0.000955963 0.241 0.280806633 Activated 
14 RNA transport 0.000541036 0.468 0.30550975 Activated 
15 NF-kappa B signaling pathway 0.000446669 0.85 0.438102725 Inhibited 
16 Adipocytokine signaling pathway 0.003217325 0.13 0.477361906 Inhibited 
17 Type I diabetes mellitus 0.003340756 0.205 0.737739117 Inhibited 
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3.9 A candidate gene: 2610019F03Rik 
2610019F03Rik is a gene coding for a relatively short protein of 31KDa and has 
more than 75% of homology with the human gene C8orf42 (or Trdp- testis 
development related protein). The mRNA expression analysis by Real Time PCR 
confirmed the increased levels of 2610019F03Rik gene in CD4+ T cells of AnxA1
tg
 
compared to wild type (Figure 3.40).  
 
To confirm the expression of 2610019F03Rik at the protein level, we used 
lymphocytes freshly isolated or stimulated with plate-bound anti-CD3/CD28 
(1&g/ml) overnight. We observed that higher number of AnxA1
tg
 CD4+ T cells 
produced more 2610019F03Rik protein at basal condition compared to wild type 
(Figure 3.41a, left panel). This difference was maintained after stimulation, although 
the production of 2610019F03Rik protein increased in both AnxA1
tg
 and wild type 
CD4+ T cells (Figure 3.41a, right panel).  
 
In addition, we measured the released of 2610019F03Rik protein in the conditioned 
media of AnxA1
tg
 and wild type lymphocytes by western blot analysis. We found 
higher amount of 2610019F03Rik protein in the media of no-stimulated AnxA1
tg
 
cells compared to wild type. The 2610019F03Rik protein level decreased in both 
conditioned media after stimulation (Figure 3.41b).  
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Figure 3.40. 2610019F03Rik expression in CD4+ T cells. 2610019F03Rik mRNA in 
CD4+ T cells of wild type and AnxA1
tg
 were detected by Sybr green based Q-PCR. a) 
Number of cycles normalised to GAPDH and b) fold increase of 2610019F03Rik 
expression in AnxA1
tg
 compared to wild type. (*p<0.05, unpaired t-test; n=3 mice per 
group). 
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Figure 3.41. 2610019F03Rik protein in CD4+ T cells. a) 2610019F03Rik 
expression in CD4+ T cells freshly isolated (left panel) or simulated with anti-
CD3/CD28 (1&g/ml) overnight (right panel) of wild type (dark grey) or AnxA1
tg
 
(blue) mice. Isotype control is in light grey. b) Immunoprecipitates of 2610019F03Rik 
from conditioned media of wild type and AnxA1
tg
 lymphocytes. CP= positive control 
(human recombinant homologue of 2610019F03Rik).  
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3.9.1 The 2610019F03Rik as modulator of anxiety  
We next tested whether 2610019F03Rik would mediate the anxiety-like behavior of 
the AnxA1
tg
 CD4+ T cells. To this aim, we used two different approaches: 1) 
administration of a polyclonal anti-2610019F03Rik antibodies to AnxA1
tg
 mice; 20 
administration of human recombinant 2610019F03Rik to wild type mice. 
 
AnxA1
tg
 mice were tested with the light/dark box test before the administration of 
the antibodies to record their basal levels (Day 0) and then at day 2, 4 and 7. Mice 
injected with the IgG isotype were used as control. Care was taken in using AnxA1
tg 
mice with similar levels of anxiety in the light and dark test  (Figure 3.42). Mice 
treated with anti-Rik showed a significant increase in the time spent in light 
compared to IgG control. This effect was particularly evident and statistically 
significant at day 7 (Figure 3.42a). No changes in the number of crossing were 
observed (Figure 3.42b).  
 
Administration of recombinant 2610019F03Rik (rRik) to wild type mice 
significantly decreased the time spent in the light compared to mice treated with 
vehicle (PBS). These effects became evident at day 4 and were absent at day 2. 
These effects were not observed in mice receiving heat-denatured rRik (d-rRik) 
(Figure 3.43).  
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Figure 3.42. Light/dark box test after treatment with anti-2610019F03Rik 
antibody. AnxA1
tg
 mice were tested at day 0 and then treated with polyclonal anti-
2610019F03Rik antibody (500ng/mouse; black bars) or IgG isotype (500ng/mouse; 
white bars). The treatment was a single i.p. injection at day 0. a) Time spent in light 
after the first crossing and b) number of crossing performed by the two groups after 2, 
4 and 7 days from the treatment. (*p<0.05, **p<0.01, Kruskal-Wallis test followed by 
Dunn’s multiple comparison test; cumulative data of N=2 separated experiments with 
n=3-6 mice per group).  
 
 
Figure 3.43. Light/dark box test after injection of 2610019F03Rik recombinant 
protein. Wild type mice were tested at day 0 and then treated with 2610019F03Rik 
recombinant protein (rRik; 500ng/mouse; black bars), its denatured form (d-rRik; 
500ng/mouse; grey bars) or PBS (white bars). a) Time spent in light after the first 
crossing and b) number of crossing performed by the three groups after 2 and 4 days 
from the injection. (**p<0.01, Kruskal-Wallis test followed by Dunn’s multiple 
comparison test; cumulative data of N=2 with n=5 per group).   
0
2
4
6
8
10
12 IgG
anti-Rik
Day 0 Day 7Day 2 Day 4
0
30
60
90
120
150
180
210 IgG
anti-Rik
Day 0 Day 7Day 2 Day 4
* 
** 
* 
a
)
b
)
0
4
8
12
16
Day 0 Day 2 Day 4
PBS
rRik
d-rRik
0
30
60
90
120
150
Day 0 Day 2 Day 4
PBS
rRik
d-rRik
a
)
b
)** 
                                                                        Results 
 
 
 
176 
3.10 VJ-4B6 as treatment in autoimmune diseases 
Given the therapeutic potentials of targeting AnxA1, we tested the AnxA1 
neutralizing antibody VJ-4B6. Firstly, we tested the toxicity or side effects of VJ-
4B6 in wild type mice. Secondly, we tested the effect of VJ-4B6 in a model of acute 
inflammation such as zymosan-induced peritonitis. Finally, VJ-4B6 was tested in 
MOG35-55 induced EAE. 
 
3.10.1 VJ-4B6 effects in vivo  
We first tested potential toxic or side effect of VJ-4B6 in vivo. To this aim, we 
collected thymus, spleen and lymph nodes of C57BL/6 3 days after the treatment 
with VJ-4B6 (50ng/mouse i.p.).  
 
No gross differences were found in thymi (data no shown) or secondary lymphoid 
organs. The percentages of CD4+ and CD8+ T cells in both lymph nodes and spleen 
of VJ-4B6 treated mice were comparable to those of the vehicle treated ones (Figure 
3.44a and 3.44c). Interestingly, total cell number was found triplicated in the spleen 
of VJ-4B6 treated mice compared to wild type (Figure 3.44d).  
 
The treatment with VJ-4B6 did not affect either the percentages of B cells or 
granulocytes in the same tissues. Indeed, the percentages of CD11b- CD19+ as well 
as Ly6G+CD115low cells were comparable between lymph nodes and spleens of 
vehicle and VJ-4B6 treated mice (Table 3.8). 
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Figure 3.44. Effects of VJ-4B6 on CD4 and CD8 T cells in lymph nodes and 
spleens. CD4 and CD8 dotplots of a) lymph node cells and c) splenocytes of vehicle 
and VJ-4B6 treated mice. Total cell counts of b) lymph nodes and d) spleens from the 
two studied groups. (**p<0.01, unpaired t-test; n=4 mice per group). 
 
 Table 3.8: FACS staining of leucocytes in peripheral lymphoid organs 
  
 
 
 
 
 
Data show the mean values ± SEM of percentage of B cells or granulocytes.   
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3.10.2 VJ-4B6 effects in zymosan-induced peritonitis  
To study the possible influence of VJ-4B6 on leukocyte recruitment, C57BL/6 mice 
were injected with 50ng/mouse of VJ-4B6 or IgG2b (isotype antibody) and after 24h 
were challenged with zymosan (1mg/mouse). The peritoneal lavages were collected 
4h after the injection to quantify the number of PMNs and monocytes in the 
peritoneal cavity. 
 
As shown in Figure 3.45, there was no difference in the total cell count as well as in 
the number of PMN or monocyte between VJ-4B6 and isotype control-treated mice. 
A blind experiment, done by a colleague in the department, confirmed this result 
(data not shown).  
 
 
Figure 3.45. Effects of VJ-4B6 in zymosan –induced peritonitis. a) Total cell count, 
b) PMN and c) monocyte number of peritoneal lavages of IgG2b or VJ-4B6 treated 
mice at 4h of zymosan challenge (unpaired t-test; n=5 mice per group). 
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3.10.3 MOG35-55 induced EAE in VJ-4B6 treated mice 
C57BL/6 mice were treated with different doses of VJ-4B6 antibody (5, 50 and 
100ng/mouse). IgG2b (100ng/mouse) was administered as negative control. Mice 
treated with VJ-4B6 showed lower percentages of weight loss compared to control 
mice from day 10 onwards (Figure 3.46). The 50ng/mouse VJ-4B6 treatment 
resulted to be the best dose compared to 5 and 100ng (Figure.3.46c).  
 
Figure 3.46. Change of weight of VJ-4B6 treated mice on MOG35-55 induced EAE. 
Percentages of weight gain or loss of MOG35-55 immunised mice treated with a) 100ng 
IgG2b or b) 5ng, c) 50ng and d) 100ng of VJ-4B6. All the treatments were given i.p. 
(*p<0.05, repeated measure two-way ANOVA; representative of N=2 with n=6-8 
mice per group). 
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The VJ-4B6 reduced the incidence of EAE compared to control and IgG treated 
groups. Indeed, about 50-60% of VJ-4B6 treated mice manifested signs of EAE 
compared to 100% in the other two groups  (Figure 3.47).  
 
 
!2=4.56, p<0.05 
 
Figure 3.47. Incidence of MOG35-55 induced EAE in VJ-4B6 treated mice. a) 
Percentages of mice that show signs of EAE per day of control and treated group with 
IgG2b (100ng) or VJ-4B6 (5, 10 and 100ng). All the treatments were given i.p. b) 
Distribution of number of mice per each group showing or not signs of disease at day 
18. (*p<0.05, Chi-square ('2) trend test; representative of N=2 experiments with 
n=6-8 mice per group). 
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Within the VJ-4B6 treated group, those that developed EAE only showed mild signs 
of disease. In Figure 3.48, the development of EAE is compared for control and 
treated mice. The averaged score in control mice was of 3.5-4 (Figure 3.48a). This is 
reduced by VJ-4B6 in dose dependent manner. Indeed, the averaged EAE score was 
of 2 in mice treated with 5ng VJ-4B6 while it reached score of 1-1.5 in the 50 and 
100ng VJ-4B6-treated mice (Figure 3.48b-d).  
 
The AUC values are significantly reduced with 50ng and 100ng VJ-4B6 treatment 
(p<0.05, Figure 3.48c and 3.48d), and no much difference is observed between these 
two doses. At the contrary, the IgG2b treatment does not exert effect in the EAE 
development (Figure 3.48a). Thus, the therapeutic effect of VJ-4B6 is specific and it 
is mediated by the neutralization action on AnxA1 during the EAE. These results 
were confirmed by independent experiments with 6-8 mice per group each.     
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Figure 3.48. Effect of VJ-4B6 on MOG35-55 induced EAE. EAE development in 
mice treated with a) 100ng IgG2b or b) 5ng, c) 50ng and d) 100ng of VJ-4B6. All the 
treatments were given i.p (*p<0.05, repeated measure two-way ANOVA; 
representative of N=2 experiments with n=6-8 mice per group). 
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We also tested the therapeutic effect of VJ-4B6 administering the drug post onset of 
disease. Thus, mice showing first signs of disease (about score of 1 or 2) were 
clustered for VJ-4B6 (50ng/mouse) or vehicle treatment.  
 
Similar to the previous results, the treatment with VJ-4B6 improved the EAE 
outcome as shown by the reduced weight loss and lower clinical scores compared to 
not treated mice (Figure 3.49). 
 
Figure 3.49. VJ-4B6 as post-onset treatment of MOG35-55 induced EAE. a) 
Percentages of gain/loss of body weight and b) EAE clinical score of wild type mice 
immunised and treated with vehicle or 50ng VJ-4B6 after EAE onset (treatment 
window and black arrow). All the treatments were given i.p. (**p<0.05, repeated 
measure two-way ANOVA; N=1 experiment with n=8 mice per group). 
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onset of diseases and slowed down the development of EAE compared to control 
(p<0.05; Figure 3.50b). 
 
 
 
Figure 3.50. Effect of glatiramer acetate on MOG35-55 induced EAE. a) 
Percentages of gain/loss of body weight and b) EAE clinical score of untreated (PBS) 
and GA treated mice. (p<0.05, repeated measure two-way ANOVA; 8 mice per 
group).  
  
a) b) 
6 8 10 12 14 16 18 20
0
1
2
3
4
5
6
PBS
GA
days after immunisation
0 2 4 6 8 10 12 14 16 18 20
-10
0
10
20 PBS
GA
days after immunisation
* 
                                                                        Results 
 
 
 
185 
3.10.4 T cell phenotype in VJ-4B6 treated mice 
We next investigated the effects of VJ-4B6 treatment on T cell phenotypes at day 9 
from EAE. The treatment with VJ-4B6 did not affect the frequencies of either CD4+ 
or CD8+ T cells (Figure 3.51a and 3.51c). However, total cell counts in the lymph 
nodes and spleens increased by 50% after the treatment. The number of CD4+ and 
CD8+ T cells in turns doubled compared to control (Figure 3.51b and 3.51d).  
 
 
Figure 3.51. Characterisation of T cells of VJ-4B6 treated mice at day 9 of EAE. 
CD4+ a) percentages and b) T cell number, and CD8+ c) percentages and d) T cell 
number in peripheral lymphoid organs of wild type or VJ-4B6 treated mice after 9 
days from EAE immunisation. (*p<0.05, unpaired t-test; cumulative data of N=5 
experiments with n=4-5 mice per group).  
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Analysis of CD4+ T cell phenotypes by ICS showed an increase in IFN"+ and GM-
CSF+ cells in VJ-4B6 treated mice compared to wild type (Figure 3.52a and Figure 
3.52b). Instead, IL-17 producing CD4+ T cells were comparable between the two 
groups (Figure 3.52c). 
 
 
Figure 3.52. ICS of CD4+ T cells of VJ-4B6 treated mice. Percentages of a) IFN", 
b) GM-CSF and c) IL-17 CD4+ T cells of wild type or VJ-4B6 treated mice. ICS was 
performed after stimulation with MOG35-55 and anti-CD28 in vitro for 48h. (*p<0.05, 
**p<0.01, unpaired t-test; cumulative data of N=3 experiments with n=4-5 mice per 
group).  
 
 
Thereafter, we sought to investigate the T cells in the spinal cord at day 16. 
Infiltrated T cells were counted and stained for CD4 and CD8 (Figure 3.53a and 
3.53b). VJ-4B6 treatment clearly influenced the percentage and cell number of CD4+ 
T cells – halved number of CD4+T cells infiltrated the spinal cord – compared to 
wild type (Figure 3.53c and 3.53d). In addition, CD8+ T cells also showed decrease 
in both percentage and cell number after VJ-4B6 treatment (Figure 3.53e and 3.53f).   
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Figure 3.53. Characterisation of T cells in the spinal cord of VJ-4B6 treated mice 
at day 16. a) Total cell count and b) dot plots of CD4+ and CD8+ T cells infiltrated in 
the spinal cords of wild type and VJ-4B6 treated mice after 16 days from the 
immunisation. CD4+ c) percentages and d) T cell number, and CD8+ e) percentages 
and f) T cell number of wild type and VJ-4B6 treated mice. (*p<0.05, unpaired t-test; 
cumulative data of N=2 experiments with n=4 mice per group). 
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4.1 Discussion 
One of the most interesting aspects of AnxA1 biology is the powerful and broad 
range of effects in inflammation (251). On one hand, it is able to contribute to the 
resolution of inflammation modulating the migration and activation of innate 
immune cells such as neutrophils and macrophages into the inflamed tissue (132, 
141, 147, 151). On the other hand, in the context of adaptive immunity it contributes 
to T cell proliferation and activation hence fostering chronic and autoimmune 
inflammatory reactions (140, 145, 152, 164, 167). 
 
The main aim of this PhD was to investigate the pro-inflammatory role of AnxA1 in 
T cells and the potential therapeutic effect of AnxA1 neutralisation in the context of 
autoimmune diseases. Unexpectedly, we observed that the AnxA1 overexpression in 
T cells influenced mouse behaviour. This brought us to a novel area of research and 
propelled the exploration of the fascinating link between “pro-inflamed T cell 
phenotype” and emotional dysfunctions. T cells have been the subject (and target) of 
many studies focused on the pathogenesis and treatments of autoimmune diseases. 
Recent investigations have, however, revealed a key role of these cells in CNS 
development and function (170, 180, 182, 189, 252). The rather surprising picture 
emerging from the literature and from the results of this PhD thesis suggests that 
mental disorders and autoimmune diseases are indeed tightly connected and have 
common cellular and molecular pathways. This might help to define causes and new 
therapeutic actions for these pathologies. 
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4.1.1 AnxA1
tg
 mice and autoimmunity 
To investigate the contribution of T cell-AnxA1 in the pathogenesis of autoimmune 
diseases, we studied the development of MOG35-55 induced EAE and the progression 
of pristane-induced lupus in AnxA1
tg
 mice compared to wild type. MOG35-55 induced 
EAE is a model of demyelination mainly driven by T cells and macrophages (58, 
237), although the involvement of B cells in this disease has been recently discussed 
(253). Pristane-induced lupus is a chemical-induced model of SLE, which develops 
after the administration in the peritoneum of a hydrocarbon causing typical 
pathological organ failures – such as lungs, spleen and kidney – that are observed in 
SLE (241).  
 
Striking differences were observed in the development of EAE between AnxA1
tg
 and 
wild type mice. The results showed that AnxA1
tg
 mice are prone to develop more 
severe EAE compared to wild type mice. Indeed, AnxA1
tg
 mice had greater body 
weight loss compared to wild type mice, conceivably reflecting a major status of 
general malaise. This was accompanied by higher susceptibility to EAE development 
and higher scoring of disease. These results were reproducible in independent 
experiments and consistent with previous studies showing reduced development of 
MOG35-55 induced EAE in AnxA1-/- mice (167).  
 
Similarly, AnxA1
tg
 mice showed exacerbated signs of sickness, such as weight loss 
and lethality, compared to wild type mice following pristane challenge. The prompt 
manifestation of these signs and hence the relative short time used for the 
observation of this model has not given us the possibility to score proteinuria or 
autoantibodies, which are robust markers at longer time points (254). However, we 
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were able to associate the increased sickness of the AnxA1
tg
 mice with severe 
splenomegaly and heavy inflammatory infiltration in their lungs, which are typical of 
this model (240).  
 
4.1.2 AnxA1
tg
 T cells and immune disorders 
At basal conditions, the T cell repertoire of AnxA1
tg
 mice did not show gross 
differences in T cell development in the thymus compared to wild type mice. This is 
in agreement with the idea that AnxA1 exerts an action on T cells mostly during 
activation processes, as previously shown by in vitro studies with recombinant 
AnxA1 (145) or by studies with AnxA1-/- mice (155). In the lymph nodes, 
conversely, we found an increase in the total cell number of CD4+ T cells. This 
difference was not observed in the spleen.  
 
To understand how AnxA1 overexpression in T cells influences autoimmune disease 
progression in vivo, we analysed the Th phenotypes of AnxA1
tg
 and wild type mice. 
For pristane-induced lupus, peritoneal fluid has been reported as suitable sources of 
lymphocytes to study the T cell phenotypes at early stage of this model (242). 
Analysis of CD4+ T cells in the peritoneal cavity revealed a reduced number of these 
cells in AnxA1
tg
 compared to wild type mice with no qualitative changes in their 
effector phenotype. We can speculate that T cells from AnxA1
tg
 might have a faster 
priming/activation and thus already be in the target organs, as suggested by the 
accelerate disease course of AnxA1
tg
 compared to wild type mice. Interestingly, the 
cytokines measured in the peritoneal lavages have similar concentration in AnxA1
tg
 
and wild type mice. 
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The MOG35-55 induced EAE provided us with more insightful results and this might 
be because this model is more suited to study T cell effector functions and plasticity 
or, in more general terms, to evaluate the contribution of T cells to the pathogenesis 
of autoimmune conditions like MS. Through these studies, we were able to study the 
biologic influence that AnxA1 has in T cell priming and activation in pathological 
setting. 
 
For decades, IFN" producing Th1 cells have been considered the only effector T 
cells able to induce EAE. This conclusion was supported by several evidences 
including presence of high levels of IFN" in the inflammatory lesion in the CNS 
and/or the induction of EAE by adoptive transfer of T clone with a Th1 phenotype 
(112, 113). In addition, knocking out key molecules involved in the production of 
IFN", in particular T-bet and STAT-4, has been shown an increased resistance to the 
development of EAE (114, 115). Paradoxically, mice knocked out for either IFN" or 
IFN"-receptor could still develop EAE (118).  
 
IL-12 knockout mice showed the opposite outcomes depending on which of the two 
subunits of IL-12 was genetically ablated. In particular, the resistance to EAE was 
associated with deletion of the IL-12p40 subunit, which later was discovered to be 
the common subunit of IL12 and IL-23. The fact that even the absence of IL-23p19, 
the second subunit of IL-23, abrogated the EAE let to the conclusion that IL-23 is 
indispensable for development of this disease (121).  
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The discovery of IL-23 paved the way to the identification of Th17 cells. Indeed, IL-
23-induced Th17 cells were shown to be stronger inducer of EAE upon adoptive 
transfer compared to Th1 cells (255). On the other hand, Th1 cells were shown to be 
more potent or even facilitate the entry of Th17 in the CNS (256). Interestingly, the 
absence of IL-17 in mice merely reduced, but not abrogate the signs of EAE (122). 
Thus, the role of Th17 cells in EAE and autoimmunity is still controversial and 
currently a very hot topic in the field.  
 
Studies on adoptive transfer of Th1- and Th17-polarized myelin-specific T cells 
showed that both Th phenotypes were able to induce EAE; their pathogenic effects 
was potentiated when transferred in combination (257). However, IL-12-polarized 
IFN"-deficient T cells transferred in IL-17-receptor knockout mice were still 
encephalitogenic (124). This study led to the conclusion that there is a new type of 
IFN"- and IL-17-independent T cells that are crucial for the development of EAE: 
these are the recently identified GM-CSF producing T cells (ThGM-CSF cells). 
Consistent with this, treatment of mice with GM-CSF neutralising antibodies as well 
as GM-CSF knocked out mice showed a complete protection against EAE (97, 124). 
 
In light of all these findings, we have given particular attention to Th1, Th17 and 
ThGM-CSF phenotypes to investigate the potential differences between AnxA1
tg
 and 
wild type mice during EAE. In particular, we carefully analysed the effects of 
AnxA1 on T cell plasticity investigating the phenotype of Th cells both before (day 
9) and after (day 16) the onset of EAE. 
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At day 9, we observed that neither the total cell number nor the percentage of CD4+ 
T cells in the periphery was different between AnxA1
tg
 and wild type mice. 
However, the percentages of CD4+ T cells were significantly higher in AnxA1
tg
 
compared to wild type upon antigen re-challenge in vitro suggesting an increased 
capability for clonal expansion and survival of AnxA1
tg
 T cells. The percentages of 
IFN", GM-CSF and IL-17 producing CD4+ T cells consistently increased in concert 
with the type of stimulation in both AnxA1
tg
 and wild type. We also observed a 
hierarchy in the cytokine production with higher percentage of IFN"+ CD4+ T cells 
followed by GM-CSF+ and IL-17+ CD4+ T cells. This holds true in both wild type 
and AnxA1
tg
 mice and did not change over a number of experiments.  
 
Higher concentrations of GM-CSF were detectable in the culture medium of 
AnxA1
tg
 lymphocytes after antigen specific stimulation. This increased production 
was not matched by the results obtained with the intracellular staining and are likely 
due to either reduced sensitiveness of ICS technique (it measures cytokines produced 
intracellularly at a single time point rather than their accumulation in the medium) in 
revealing differences in GM-CSF producing Th cells or due to the detection of GM-
CSF produced by other T cells rather than only CD4+ T cells. This could be indeed 
the case for IL-17 which has been shown to be also highly expressed in "' T cell 
population (105). 
 
We observed some degree of variability within each single experiment. This is a 
common effect and it might be explained by the lack of “synchronization” in T cell 
activation in vivo (not all animals develop disease at the same time and to an 
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equivalent extent) and/or by the somehow not fully defined effector phenotypes 
during the pre-onset phase of EAE. In line with this, Korn et al. showed that effector 
Th cells in the peripheral lymphoid organs as well as in the circulation do not show 
great variation in their phenotype during the development of EAE, while those 
infiltrated in the CNS do (238). Hence, we investigated T cells migrated from the 
periphery to the CNS.  
 
The development of EAE in AnxA1
tg
 and wild type mice appears to run in a similar 
way from the onset of disease till the clinical score reaches a value between 2 and 3. 
However, at later stage (roughly from day 16), these mice progressed differently 
showing exacerbated signs of disease in AnxA1
tg
 mice only. Previous studies on the 
same EAE model showed that the frequency of Th secreting IL-17 or IFN" changes 
over time in both periphery and CNS, with particular pattern moving from IL-17 
single positive to double positive IL-17/ IFN" and IFN" single positive T cells. Then, 
Hirota et al. were able to show that the committed Th17 phenotype progressively 
changes their phenotype in Th1-like at the site of chronic inflammation. Indeed, 
Th17 cells reduce the expression of IL-17 while increasing IFN" once they move 
from the lymph nodes to the spinal cord (105, 109).  
 
Lately, the existence of two main Th17 populations has been proposed: non-
pathogenic and pathogenic Th17 cells. The latter differentiate under either IL-1#- or 
TGF#- plus IL-6-skewing conditions and subsequently expand under IL-23-mediated 
signalling. These cells express high levels of T-bet, STAT4 and GM-CSF as well as 
reduced IL-10 and IL-10- related genes. Thus, pathogenic Th17 cells are considered 
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to be those cells that acquire a Th1-like phenotype in the CNS during the EAE 
pathogenesis (127). 
 
In our studies we observed an increase in the total cell number and CD4+ T cells 
infiltrating the CNS in AnxA1
tg
 mice compared to wild type. Infiltrated AnxA1
tg
 T 
cells expressed less or equivalent amount of IFN" and GM-CSF, whereas higher IL-
17 levels compared to wild type cells. More intriguingly, higher presence of GM-
CSF or IFN" and IL-17 double positive T cells was quantifiable in AnxA1
tg
 
comparing to wild type mice.  
 
Th17 is considered an unstable Th subtype that, as mentioned earlier, during the 
course of chronic inflammatory conditions, such as EAE, loses IL-17 expression to 
switch on producing IFN". Our data suggest that AnxA1
tg
 Th17 cells maintain the 
pathogenic phenotype of co-producing IL-17 and IFN" or GM-CSF for longer time 
compared to wild type. The increased percentage of Th17/ThGM-CSF as well as of 
Th17/Th1 populations in AnxA1
tg
 mice might explain the higher severity of EAE 
signs in these mice compared to wild type mice.  
 
Thus, the influence of AnxA1 in the Th17 plasticity ultimately reduces the number of 
IFN" producing T cells. It might seem a contradiction, but the Th1 phenotype has 
been shown to be more susceptible than Th17 to the suppressive actions of Treg cells 
(238). Thus, the conversion from Th17 to Th1 might be an important mechanism for 
the resolution of the disease. In this way, we can speculate that AnxA1 interfere with 
a biological protective phenomenon by impairing Th17 plasticity.  
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4.1.3 AnxA1
tg
 T cells and mental disorders 
Rodents have “emotions and personalities” and their behaviour can be studied and 
used for investigating pathways and thus screening a variety of experimental 
conditions mimicking CNS pathologies. Serendipitously, we observed a difference in 
behaviour between AnxA1
tg
 and wild type mice. Under the supervision of Dr Robert 
Deacon, an expert behaviourist from the University of Oxford, we explored potential 
changes in emotional behaviour using several paradigms. Many of these create an 
adverse situation for the animal, which tent to avoid it for natural fear; as cats do not 
like water, mice are wary of bright and lit open areas (258). The systems we used 
were the marble-burying, the open field, the climbing, and the light/dark box tests.  
 
All these tests allow evaluation of several parameters that are used to score and 
interpret fear-related or anxiety-like state in mice (246, 248, 259, 260). The reactions 
that mice have in the new adverse condition share analogous, if not homologous, 
mechanisms of defence with anxiety disorders in human (259, 261). Hence, 
behavioural studies in rodents have been long used for either improve our knowledge 
on the etiopathogenesis of these diseases or for drug testing.  
 
From these behavioural studies, we observed that AnxA1
tg
 mice have an overall 
increased marble-burying activity – they start to dig earlier and their total digging 
time is longer than wild type mice showing also by a higher number of buried 
marbles. In addition, we observed reduced time spent in light and number of crossing 
in the light/dark box test of AnxA1
tg
 compared to wild type mice. These behaviours 
have been duly associated to anxious-like behaviour as well as the hesitation – 
expressed by the latency to rear – for the exploration of the open field. In the 
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climbing test, AnxA1
tg
 mice spent less time climbing compared to wild type. 
However, AnxA1
tg
 mice showed equivalent number of bouts in the marble-burying 
test as equivalent number of rearing and total squares crossed in the open field. All 
together this behaviour profile highlights a divergence in “emotionality” of AnxA1
tg
 
compared to wild type rather than an explorative or motile impairment of these mice 
(262, 263). 
 
The most interesting part of these behavioural studies is the consideration that 
AnxA1
tg
 mice derived from a genetic modification in lymphoid cells. These findings 
have prompted us to focus and investigate how T cells influence the emotional 
response (a topic that we are currently studying in our group). With great surprise we 
found support in literature suggesting the importance of T lymphocytes in the 
regulation of a number of functions including cognition, memory and even trauma 
(170, 179-185, 264). Among this, Prof Schwartz (Weizmann Institute of Science, 
Rehovot, Israel) and Prof Kipnis (Center for Brain Immunology and Glia, University 
of Virginia, Charlottesville, Virginia, USA) also proposes a beneficial action and 
purpose for CNS-auto-reactive T cells for neurofunctions since they are necessary 
for cognitive functions – such as memory and spatial learning (170, 181-183). Other 
findings suggest that active, mostly Th2-skewed CD4+ T cells are critically involved 
in cognitive functions (183) and elegantly show that they bear a CNS antigen 
specific TCR (264). Hence the hypothesis of a positive autoimmunity, currently 
questioned concept in the field since it undermines the historical dogma of CNS as 
immunoprivileged organ. This novel view considers the CNS as any other tissue and 
organ in the body so it is as well patrolled by the immune system. The immune 
response brought about by auto-reactive T cells bearing CNS antigen-specific TCR is 
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fundamental to restore the homeostasis in the tissue after an insult or stimulus, such 
as tissue damage or cognitive input. 
 
Our studies suggest that overexpression of AnxA1 in T cells increases the anxiety-
like behaviour of C57BL/6 mice providing a novel mechanism by which T cells 
control emotions. Intriguingly, we observed that T cell priming against either a CNS-
specific or an irrelevant antigen (MOG35-55 and OVA323-339, respectively) followed by 
T cell mobilisation into the blood stream are sufficient to cause an emotional 
disorder in mice (73). This might suggest that AnxA1
tg
 T cells might be correlated to 
emotional disorders because of their hyper-reactive phenotype. Another hypothesis 
could be that the presence of AnxA1
tg
 T cells in circulation might influence 
neurogenesis as mice develop. Indeed, we now know that emotional abnormalities 
observed in immunodeficient mice are restored to the level of wild type in those born 
with CD4+, but not CD8+, T cell population. Most strikingly, we found that the 
presence or absence of T cells in circulation could influence the pattern of gene 
expression in the brain (252). This suggested to us that T cells per se exert a 
homeostatic control on brain function and consequent emotional response. 
 
We thus sought to better understand how AnxA1 overexpression in T cells influence 
the emotional response and to do so we explored three main approaches:  
a) Adoptively transfer of AnxA1
tg
 T cells into wild type C57BL/6 mice;  
b) Investigate the gene expression profiles of AnxA1
tg
 CD4+ T cells; 
 c) Investigate the gene expression profiles of AnxA1
tg
 whole brain. 
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Transfer of control or AnxA1
tg
 CD3+ T cell population (CD4 plus CD8) into 
C57BL/6 mice affected similarly the anxiety-like behaviour of the recipients. In both 
cases, we observed a reduced time spent in light and reduced number of crossing in 
the light/dark box test three weeks after the T cell transfer, thus suggesting a 
relationship between T cells and emotional behaviour.  
 
We observed remarkable differences when we transfer CD4+ T cells. Indeed, the 
transfer of CD4+ T cells from AnxA1
tg
 T cells into C57BL/6 mice induced an 
increased anxiety-like behaviour compared to wild type donors and PBS control 
group. This suggests that AnxA1
tg
 CD4+ T cells were able to induce and transfer 
anxiety-like behaviour. Interestingly, no significant changes in anxiety-like 
behaviour were observed in mice receiving sera isolated from the same groups of 
donors ruling out the possible contribution of inflammatory cytokines or antibody in 
the behavioural response we observed.  
 
AnxA1 is well known as one of the second messengers of GCs action (133). It has 
been well described its function of paracrine/juxtacrine mediator in the 
neuroendocrine system and in particular to be responsible of the negative feedback 
action exerted by GCs on the HPA axis (211-215). This might raise the query 
whether the changes in emotional behaviour are due to an alteration of HPA axis in 
AnxA1
tg 
mice. However, this is a very unlikely mechanism for a number of reasons. 
First, the transgenic mouse is tissue specific (T cells only) and not a general 
transgenic. Second, we measured the levels of corticosterone in the plasma of wild 
type and AnxA1
tg
 mice, and the concentrations were similar (31.6 ± 5, and 34 ± 7.8 
ng/ml, n=5 male mice per group). Last but not least, the “extra” amount of AnxA1 
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produced by T cells in the AnxA1
tg
 mice would not influence the amount of AnxA1 
that is present in circulation in view of the relatively low content compared to 
myeloid cells. 
 
Microarray analysis of CD4+ T cells revealed that AnxA1 has 3-fold increase in 
expression in transgenic compared wild type. However, this increase of AnxA1 is 
paltry to justify any direct effect of AnxA1 on the behaviour. Indeed, the amount of 
AnxA1 in CD4+ T cells remains much lower – even after such boost – than the 
quantity expressed in the innate immune cells, which physiologically express 25-fold 
more AnxA1 than CD3+ T cells (138).  
 
In AnxA1
tg
 T cells many interesting cell pathways are altered compared to wild type. 
Just to mention some, cell cycle, Jak-STAT, and NF-(B signalling pathways which 
are known to be relevant for T cell proliferation (88, 89, 101, 265) and lineage 
commitment (78, 92, 101). This might further explain the effects of AnxA1
 
on the Th 
phenotype in the transgenic mice. Indeed, we found higher number of T cells 
populating the lymph nodes of AnxA1
tg
 mice, and AnxA1
tg
 CD4+ T cells have a 
higher proliferating rate as well as lower threshold of TCR signaling (data not 
shown) compared to wild type mice. Other interesting altered pathways are related to 
autoimmune diseases and viral infectious, such as Herpes simplex, Influenza A, and 
Epstein-Barr virus. This is intriguing since many studies claim a strong association 
among infectious diseases, autoimmune diseases and mood disorders (169). It has 
been reported that the risk to develop mood disordered increase by 62% and 45% 
after infection and autoimmune disease diagnosis, respectively, and this percentage 
further increase if they co-occur in patients, suggesting a negative synergistic effect 
                                                                        Discussion 
 
 
 
202 
(169). All together this might explain the autoimmune-prone phenotype of AnxA1
tg 
mice, however does not fully explain how the overexpression of AnxA1 in T cells 
leads to anxiety-like behaviour.  
 
In humans, several clinical studies have described the role of T cells in mood 
disorders in conflicting ways. On one hand, the decreased number of T cells 
contributes to establish depression (226) while increased T cell number is associated 
to optimism (225). In line with these findings, stress conditions and anxiety increase 
levels of GCs which suppress activation, proliferation and trafficking of immune 
cells, including T cells (266). On the other hand, psychotic disorders, patients with 
treatment-resistant depression and anxiety disorders showed elevated number of total 
white blood cell and helper T cell count (230, 232). Hence, neuroendocrine 
variations cause changes in leukocytes including lymphocytes. Thus, microarray 
analysis of T lymphocytes has been proposed as a powerful technique to study CNS 
abnormalities such as psychiatric disorders (235). Indeed, T cells might promptly 
reflect changes in CNS homeostasis through their complex communication network 
made of neurotransmitters, neurotrophic factors and cytokines.  
 
In line with this, to explore how CD4+ T cells could elicit the observed anxiety-like 
behaviour in AnxA1
tg
 mice we used the microarray analysis. Out of 2,487 genes that 
were modulated we focused our attention to the new ones and in particular on 
2610019F03Rik [http://www.ebi.ac.uk; query: 2610019F03Rik]. This is a yet to be 
identified protein that is highly inducible upon T cell activation and is expressed at 
higher levels in AnxA1
tg
 T cells, at both mRNA and protein level. The 
2610019F03Rik is evolutionary conserved gene in vertebrates expressing a short 
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amino acid sequence (190aa) with unknown in vivo function and 75% homology 
with the human protein [http://blast.ncbi.nlm.nih.gov/Blast.cgi]. In our studies, the 
blocking of 2610019F03Rik by polyclonal antibody or the injection of 
2610019F03Rik recombinant protein caused an anxiolytic and anxiogenic effect, 
respectively. Several other genes, including the vasopressin or cathepsine B gene, 
have been described to exert a role in anxiety-like phenotype in rodents. Those, 
however, have been identified in the microarray analysis of brain regions within the 
limbic area (267). To the best of my knowledge, no gene expressed in lymphocytes 
has been so far linked to mood disorders. Hence, the 2610019F03Rik might be one 
of the first factors that is expressed in T cells and might be able to influence anxiety 
disorders.  
 
All of these results become even more interesting after we compared the gene 
expression profile of the whole brain of AnxA1
tg
 and wild type mice. The results of 
this analysis revealed less than 40 genes differentially expressed. The restricted 
numbers of genes we found provided us with restricted and focused field to research. 
SPIA analysis of these genes suggested many as being related to neurodegenerative 
diseases (they include Parkinson’s, Alzheimer’s or Huntington’s diseases, which 
share highly inflammatory features) or to signalling pathways described in mental 
disorders i.e. glutamatergic or serotonergic synapses.  
  
                                                                        Discussion 
 
 
 
204 
4.2 Clinical relevance and AnxA1 therapeutic potential 
Several lines of evidence suggest that changes in AnxA1 expression are associated 
with the development of autoimmune diseases. Biochemical analysis of post-mortem 
CNS tissues of MS patients revealed co-localization of high level of AnxA1 and 
expression of CD3 in the white matter plaques (161). Similarly, CD4+ T cells 
isolated from RA patients show higher expression of AnxA1 at both mRNA and 
protein levels comparing to CD4+ T cells isolated from healthy volunteers (145, 
164). Finally, CD4+ T cells isolated from patients suffering from SLE or MS show 
higher expression of AnxA1 compared to healthy controls (166, 268). 
 
To explore the therapeutic potential of the findings obtained with AnxA1
tg
 mice, we 
tested the effects of an AnxA1 neutralizing antibody, VJ-4B6, on the development of 
MOG35-55 induced EAE. Mice treated with VJ-4B6 were significantly protected from 
EAE since 50% manifested signs of disease and these were in addition mild and 
stable over time. Similarly, the administration of VJ-4B6 after EAE onset slowed 
down the EAE development. Overall the therapeutic effects were specific i.e. IgG-
isotype antibody was ineffective, and promising when compared to the efficacy of 
the GA treatment used as positive therapeutic control.  
 
Preliminary experiments investigating the effect of VJ-4B6 in vivo showed no toxic 
effects. The treatment did not cause any changes in the total cell count in thymus or 
in lymph node. The CD4+/CD8+ T cell ratio was comparable to control mice in the 
peripheral lymphoid organs, as well as no difference was found in B cell or 
monocyte number. Interestingly, we observed a surprisingly increased cell number in 
the spleen. 
                                                                        Discussion 
 
 
 
205 
 
Likewise, we found increased total cell number and CD4+ or CD8+ T cells, although 
they show similar frequencies, in peripheral lymphoid organs of VJ-4B6 treated mice 
at 9 day from EAE immunisation. Interestingly, the phenotype of the CD4+ T cells 
was highly positive for IFN" and GM-CSF in VJ-4B6 treated compared to wild type. 
This suggests that VJ-4B6 might protect from autoimmune diseases by trapping T 
cells, including the most pathogenic ones, in peripheral lymphoid organs – similarly 
to the mechanism of action described for the Fingolimod. This hypothesis is indeed 
supported by our microarray analysis that has shown an increased expression of 
sphingosine 1- phosphate (S1P) receptor in CD4+ T cells stimulated overnight in 
presence of VJ-4B6 (data not shown).  Consistently, the spinal cord infiltrates at day 
16 showed a decreased number of CD4+ as well as CD8+ T cells in VJ-4B6 treated 
mice. Further studies are needed to investigate if these effects are due a dual action 
of VJ-4B6 on T cells as well as on APCs including DCs. This might be relevant 
considering the previously observed tolerogenic properties of AnxA1-/- bone 
marrow-derived dendritic cells (269).  
 
Our experimental observations are consistent with clinical data reporting higher 
prevalence of anxiety and depression in patients suffering from autoimmune diseases 
(28, 52, 53, 55). It was interesting to observe that the adoptive transfer of CD3+ T 
cells anticipated the onset of EAE (of about three days) and exacerbated clinical 
signs, and similar outcomes occurred after CD4+ T cell adoptive transfer. More 
impressive in my view was the association between the anxious profile displayed by 
the mice and the severe outcome of diseases after the transfer of T cells. This might 
suggest a cause-effect relationship between number and/or activation state of T cells, 
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and anxiety-like behaviour. A recent article by Harpaz et al., showed that stress 
negatively affected Treg but not effector T cells, which increase in number and 
polarise towards Th1-Th17 phenotype. Mice under stress showed, indeed, 
exacerbations in EAE, which were prevented by a glucocorticoid antagonist (234). 
Thus, the chronic activation of the HPA axis causes desensitization towards the 
immunosuppressive effects of glucocorticoid (270) and consequently increases 
susceptibility to autoimmune diseases. Clinically, periods of high stress have been 
correlated with relapses of multiple sclerosis or psoriasis (271, 272). Looking at a 
bigger picture, we could describe this as a physiologic circuit where mood, emotion 
and mental health induce changing in the peripheral physiology including the state of 
T cells, and these in turn influence brain functions shaping emotion and cognition 
according to their state or phenotype. 
 
4.4 Conclusion and future experimental approaches 
The AnxA1
tg
 mice revealed to be anxious-like per se and when appropriately 
challenged it was severely susceptible to autoimmune diseases. AnxA1 
overexpression in T cells is the only connector between these two phenotypes. The 
variegated experimental approaches and studies showed in this thesis reveal the 
complexity of neuro-immune interactions and in particular the connection between 
autoimmune diseases and mood disorders – such as such anxiety, depression and 
psychosis. Most importantly, we underline the importance and ability of hyper-
reactive CD4+ T cells to affect emotional behaviour. Indeed, the overexpression of 
AnxA1 in T cells makes T cells highly responsive to proliferative and activation 
stimuli, and imprints an anxiogenic phenotype (Figure 4.1). In addition to this, 
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AnxA1 seems to have a strong influence on the plasticity of Th cells and their 
pathogenic effects. 
 
 
Figure 4.1. Effects of AnxA1
tg
 T cells in mental and body homeostasis.  Depicted 
are the major discoveries made out of the studentship. 1) CD4+ T cells overexpressing 
AnxA1 induce alterations in the mental health homeostasis causing an anxiety-like 
behaviour. 2) This effect is mediated by a poorly characterised gene product termed 
protein 2610019F03Rik: this protein is overexpressed in AnxA1
tg
 CD4+ T cells. 3) In 
the context of autoimmunity, AnxA1
tg
 CD4+ T cells promote severe development of 
experimental autoimmune encephalomyelitis. Altogether these novel findings indicate 
that the AnxA1
tg
 mouse is a viable model for studying the reciprocal influence and 
shared pathways between mood disorders and autoimmune diseases. 
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All together these results bring to the conclusion that AnxA1 is an optimal biomarker 
as well as candidate to therapeutically intervene in both autoimmune diseases and 
emotional disorders. We also identified 2610019F03Rik protein as mediator that is 
released by AnxA1
tg
 CD4+ T cells and might be targeted for the treatment of anxiety 
disorders (Figure 4.1). The results of this thesis provide first evidence for a 
protective and therapeutic effect of neutralizing antibodies against AnxA1 in a model 
of MS. Preliminary studies have been done to test the potential therapeutic action of 
VJ-4B6 in depression and anxiety. Recently, humanised forms of VJ-4B6 antibody 
have been generated and are currently being tested to confirm the therapeutic 
potential of targeting AnxA1 in models of autoimmune diseases. Ideally, one of these 
will be soon selected for future tests assessing efficacy and safety in clinical trials.   
 
Many questions still remain unaddressed. How does anxiety-like behaviour 
transferred by AnxA1
tg
 CD4+ T cells ensue? We know that the 2610019F03Rik 
protein might be responsible for the anxiogenic effect of AnxA1
tg
 CD4+ T cells. In 
addition, the systemic administration of 2610019F03Rik as recombinant protein as 
well as the administration of a polyclonal antibody against it caused significant 
modulation of anxiety-like behaviour. However, it remains to establish whether the 
release of this mediator in the periphery is sufficient to alter the behaviour or whether 
it is necessary that AnxA1
tg
 CD4+ T cells enter and release their factor into CNS. 
Consistent with the latter hypothesis, we observed a consistent time lapse between 
the T cell adoptive transfer and the onset of anxiety – about a delay of at least 14 
days – making the tracking of the transferred T cells in vivo over time a very 
interesting next step to explore. In addition, it remains to be explained if the action of 
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2610019F03Rik is broad and this is affecting other physiological processes or 
whether it is delineated and specific for brain and/or T cells. 
 
I think it is also worth getting up deep analyses for the understanding of the tight link 
between anxiety-like status and the susceptibility to the development of autoimmune 
diseases. Is this something that we are able to manipulate? Removing the cause of 
the anxiety-like status, are we able to reduce the susceptibility to autoimmune 
diseases? For instance, if we block AnxA1 and/or 2610019F03Rik in the transgenic 
CD4+ T cells, are we able to rescue both detrimental phenotypes (autoimmunity and 
mood disorders)? It would be revolutionary to simultaneously treat patients suffering 
from mood disorders and autoimmune diseases through the manipulation of T cell 
phenotype. 
 
These results open new research questions as well. If emotions as well as cognition 
are dramatically influenced by the presence, amount and type of T cells, is the 
inverse equation valid too? We already are familiar with the outbreak of 
opportunistic infections, cold and/or cold sores coinciding with stress periods. 
However, how do positive feelings and/or general psychological wellbeing influence 
the immune defences? Are psychotherapy, aromatherapy, meditation, or any positive 
mood boosting activity able to educate the immune system? AnxA1
tg
 mice represent 
a unique valuable mouse model to explore all these research questions.  
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Autoimmune diseases like multiple sclerosis (MS) are known to be associated with debil-
itating emotional disorders that manifest long before the flaring of motor dysfunctions.
Given the emerging role of T cells in controlling both emotions and autoimmunity, in this
study we explored possible correlation betweenT cell activation and changes in emotional
behavior in a mouse model of MS. Our results showed a significant increase in blood
circulating T cells as soon as at day 4 post immunization. This lymphocytosis remained
stable with time and preceded the infiltration ofT cell in the CNS.The kinetic ofT cell entry
in the blood matched the kinetic of changes in behavior measured using the open field
test. Treatment with glatiramer acetate, a well-known immunomodulatory drug for MS,
suppressed behavioral changes while retaining the T cells in the draining lymph nodes.
Together these results provide evidence of a positive correlation between the emigration
of T cells in circulation and changes in emotions during chronic inflammatory diseases.
The validation of these findings in the clinic might help to better understand the cause
of the emotional and psychological burden of patients suffering MS or other autoimmune
diseases. Most importantly our study suggests novel therapeutic venues for the treatment
of the emotional changes associated with autoimmunity.
Keywords:T cells, multiple sclerosis, immunomodulation, mood disorders, behavior
INTRODUCTION
A wealth of studies in the literature has indicated a significant
increase in emotional changes in patients suffering from multiple
sclerosis (MS) (1–3) as well as from other autoimmune diseases
(4). Major depression (5–7), bipolar depression (2, 8), anxiety (9–
11), alcohol abuse (12, 13), and other substance abuses (14) are all
at an increased prevalence inMSpopulation. These emotional dys-
functions are not simply a reactive psychological response to the
impact of this pathology on the patient’s life style and have been
correlated with the development of MS and other autoimmune
diseases. Indeed, the depression and anxiety rates are higher inMS
than in those patients experiencing other chronic diseases (15). It
is in fact estimated that between 40 and 50% of patients with MS
will experience a type of depression within their lifetime. As con-
sequence of this, MS patients show a higher rate of suicides when
compared to a normal population with most occurring within
5 years of diagnosis (16, 17).
One of the most unexpected aspects of the correlation between
emotional disorders and MS is their association in time. Recent
evidence suggests that depression usually presents before the onset
of MS symptoms or even before diagnosis (9, 18) and with over
a third of MS patients having a family history of depression (19,
20). Indeed, looking at MS patient blogs1,2 as well as at system-
atic epidemiological studies, it is clear that patients often lament
of having suffered panic attack or anxiety over limited period of
1http://www.mssociety.org.uk/forum/everyday-living
2http://www.thisisms.com/forum/
time. In other words, patients suffered from unexpected attacks of
anxiety that did not necessarily correlated with any manifestation
of the disease. In other cases, it seems that these “bouts” of anx-
iety and panic attack precede or follow the same pattern of MS.
Most intriguingly, MS and mental disorders like depression show
a large degree of similarities. Indeed, both can provoke cognitive
impairment, muscle weakness, or tiredness (21–23).
Previous studies, summarized in Table 1, addressed the behav-
ioral modifications occurring in mouse models of MS, the exper-
imental autoimmune encephalomyelitis (EAE). These studies
reported either no changes (24) or an inverse correlation between
social exploration and the rise of inflammatory mediators includ-
ing IL-1, TNF-α, and PGE2 (25). Conversely, Peruga et al. demon-
strated thatmice immunizedwith a suboptimal dose of MOG35–55
(50µg) showed the manifestation of motor impairment at day 60
after immunization and had an increase anxiety-like behavior that
correlated with an increase in the level of TNF-α and with neu-
ronal loss in the hippocampus (26). This was also associated with
a doubled depressive-like behavior in the learned helplessness par-
adigm. In a more recent study, Haji et al. assessed the behavior of
mice subjected to EAE before locomotor defects started to show
(27). Their results suggested firstly that high anxiety indexes in
EAE mice precede the appearance of motor defects and secondly
that TNF-α has a pivotal role in the high anxiety response because
of the ability of this cytokine to cause striatum inflammation and
microglia activation. In addition, intracerebroventricular admin-
istration of etanercept, an inhibitor of TNF-α signaling, resulted
in anxiolytic-like effects in EAE mice.
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Table 1 | Previous studies characterizing behavioral changes in mouse models of EAE.
Pollak et al. (25) Peruga et al. (26) Rodrigues et al. (24) Haji et al. (27) Acharjee et al. (28)
Animals Female SJL/J mice Female C57BL/6 mice Female C57BL/6
mice
Female C57BL/6
mice
Female C57BL/6 mice
EAE protocol 150µg of PLP139–151
15–20×106 activated
lymph node cells i.p.
50µg of MOG35–55
100 ng of PTX i.p.
100µg of MOG35–55
300 ng of PTX i.p.
200µg of MOG35–55
500 ng of PTX i.p.
100µg of MOG35–55
800 ng of PTX i.p.
Onset of
motor deficits
(days)
Not specified Signs of tail weakness
at 60 dpi
Clinical signs of
disease at 11 dpi
Expected at
10–11 dpi [according
to Ref. (29)]
Limp tails at 9–13 dpi
Behavioral
parameters/
paradigms
Food and sucrose intake;
social exploration
Open field; rotarod;
light/dark box; startle
response and pre-pulse
inhibition; learned
helplessness paradigm
Elevated plus maze;
inhibitory avoidance
task; object
recognition task
Open field; elevated
plus maze
Open field; elevated plus
maze; forced swim test;
tail suspension; sociability
test; fear conditioning
Cytokine
levels
IL-1β expression/level
(RT-PCR/ELISA) andTNF-α
expression (RT-PCR); PGE2
production (RIA assay);
brain (cerebellum,
hypothalamus,
hippocampus, brain stem)
IL-6 andTNF-α
expression (RT-PCR);
brain (hippocampus);
15, 29, 41, 59 dpi
– TNF-α levels (ELISA);
Brain (striatum);
10 dpi
IL-1β andTNF-α expression
(RT-PCR); brain
(hippocampus,
hypothalamus, amygdala)
7 dpi
Main results Transient sickness behavior
episodes associated with
EAE attacks; Increased
pro-inflammatory cytokine
levels before the onset of
motor impairment;
decrease in
pro-inflammatory
cytokines at the peak of
the neurological symptoms
Anxiety- and
depression-like
behavior before the
occurrence of motor
deficits; Increased
TNF-α and neuronal loss
in the hippocampus
No differences in
anxiety-like behavior
and memory in
animals induced with
EAE
Anxiety-like behavior
before the
occurrence of motor
deficits; Increased
TNF-α levels and
activated microglia in
the striatum
Anxiety- and
depression-like behavior,
memory loss and
conditioned learning
deficits in early stage of
EAE; elevated levels of
IL-1β andTNF-α in the
hypothalamus and
increased basal plasma
corticosterone levels
All these studies focused on the biochemical and cellular
changes occurring in the CNS while very little has been explored
in terms of possible changes occurring in the periphery such
as in the blood. Indeed, a great deal of studies, including our
own in RAG-1−/− (30), have shown that T cells plays a piv-
otal role in regulating emotion in mice (31–34) as well as in
humans (35, 36) besides being the main drive of autoimmune
diseases.
In this study we set to investigate the correlation between emo-
tional changes and T cell activation during the very early stages
of the EAE. Consistent with the already published experimental
and clinical studies mentioned before, our results confirmed that
emotional changes occur long before the manifestation of motor
dysfunction and within the first days after the immunization.
In addition, we provide evidence of a direct correlation between
changes inbehavior and the time-dependent activation and expan-
sion of T cells, thus confirming a very tight crosstalk between
immunity and mental health during the development of chronic
inflammatory diseases.
MATERIALS AND METHODS
MICE
We used 6-week-old male mice for all the experiments. Mice were
housed in groups of six per cage under specific-pathogen-free con-
ditions and with free access to food and water. Mice were housed
for at least 7 days prior to testing. Wild type C57BL/6 mice pur-
chased fromCharlesRiver.All experimentswere performedduring
the light phase of the light-dark cycle and no more than two tests
per day were performed. All tests were conducted under license
from theHomeOffice and according to theUKAnimals (Scientific
Procedures) Act, 1986.
MOG35–55-INDUCED EXPERIMENTAL AUTOIMMUNE
ENCEPHALOMYELITIS
This model of autoimmunity is mainly driven by T cells and
has been extensively used to investigate the early events that
characterized the development of MS including the activation
of the immune response that precedes the neuronal damage
caused by inflammatory cells (37). Male C57BL/6 mice received
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an intradermal injection of MOG35–55 (300µg) emulsified in
Complete Freund’s adjuvant (CFA) and two doses of pertus-
sis toxin (PTX) at day zero and day 2 as previously reported
(38). The MOG35–55/CFA emulsion was prepared by dissolving
300µg of MOG35–55 peptide (MEVGWYRSPFSRVVHLYRNGK,
synthesized by Cambridge Research Biochemicals, Cleveland,UK)
in 150µl of PBS and then mixed with 150µl of CFA (Com-
plete Freud’s Adjuvant, Sigma-Aldrich). The resulting suspen-
sion was emulsified using a high-pressure polytron homoge-
nizer. The severity of the disease was scored on a scale of
0–6 with 0= no neurological signs, 1= tail weakness, 2= tail
paralysis, 3= loss of righting reflex (the mouse can no longer
right themselves after being laid on their back), 4= hind leg
paralysis, 5= quadriplegia, and 6= death. In some experiments,
mice were immunized with CFA only or with the antigenic
ovalbumin peptide OVA323–339 (100µg) and received the two
doses of PTX at day 0 and 2. For the treatment with glati-
ramer acetate (GA; Poly Ala, Glu, Lys, Tyr [6:2:5:1], Sigma),
mice were subcutaneously immunized with GA (150µg/100µl
of PBS) every day for 7 days before the immunization with
MOG35–55/CFA.Controlmicewere administered the samevolume
of PBS vehicle.
LEUKOCYTES ISOLATION FROM CENTRAL NERVOUS SYSTEM
Vertebral columns were dissected from the lumbar to the cer-
vical region and washed several times in PBS to remove blood
trace. Spinal cords were extracted by hydro pressure in the
spinal canal by using a 2-ml syringe and 19-gage needle. Sub-
sequently, tissues were torn apart in sterile PBS by mechanical
pressure through a 70-µm mesh cell strainer (Falcon). Mononu-
clear cells and lymphocytes were isolated by density gradient
centrifugation in Percoll (GE Healthcare). In detail, cells were
pelleted at 400 g for 5min and suspended in a 30% Percoll
solution. The 30% Percoll solution was carefully layered onto a
70% Percoll solution in a ratio 2:1 and centrifuged at 500 g for
30min. In this density gradient mononuclear cells sediment at
the interface between 30 and 70% Percoll layers. About 2–3ml
of interface solution was collected only after the fatty layer at
the top of the centrifuge tube was carefully removed. The puri-
fied mononuclear cells were washed twice in RPMI supplemented
with 100U/ml of penicillin and streptomycin and 10% of FCS
(Invitrogen).
FLOW CYTOMETRIC ANALYSIS
Lymphocytes were stained in 100µl of FACS buffer (PBS con-
taining 5% FCS and 0.02% of NaN3) containing the following
antibodies: anti-CD3 PE-Cy5 (clone 145-2C11, eBioscience), anti-
CD4 FITC (cloneGK1.5, eBioscience), anti-CD8PE (clone 53-6.7,
eBioscience) as previously reported (39). Cells were labeled with
the appropriate concentration of conjugated antibodies for 1 h at
4°C as previously described. Samples were acquired with FAC-
SCalibur and analyzed using FlowJo™ software (Tree Star, Inc.,
Oregon Corporation). Peripheral blood leukocytes were collected
at different time points after immunization. Briefly, blood samples
were collected by intracardiac puncture performed under anesthe-
sia in syringes containing sodium citrate 3.2% (w/v). Cells were
pellet at 300 g and resuspended in FACS buffer containing 1:500
Fc blocking antibody (anti-mouse CD16/32) and then stained
with anti-CD3 (clone 145-2C11). Red blood cells were lysed with
RBC Lysis Buffer according to the manufacturer’s instruction
(eBioscience).
PLASMA CYTOKINE MEASUREMENT
Blood was collected by intracardiac puncture performed under
anesthesia. Plasma was obtained from the clotted blood by cen-
trifugation (8000 rpm, 5min) and stored at −80°C before the
assay. Cytokine levels in the same samples were measured (dil.
1:500) usingMouse Th1/Th2/Th17/Th22 16plex Kit FlowCytomix
and according to the manufacturer’s instructions (eBioscience).
OPEN FIELD ACTIVITY TEST
The open field is a test commonly used to assess locomotor,
exploratory, and anxiety-like behavior in laboratory animals. It
is based on the conflict between the spontaneous aversion that
rodents have of the central area of a novel or brightly lit open field
versus their desire to explore new environments (40). The test was
performed as previously described with some modifications (41).
The open field consisted of awhite PVC arena (i.e., a plastic rectan-
gular container size 50 cm× 30 cm) divided into 10 cm× 10 cm
squares (n= 15). Mice were brought into the experimental room
15min before testing. Each mouse was placed in one of the corner
squares facing the wall. A mouse was observed and recorded for
5min. The total number of squares crossed, latency to the first
rear and the total number of rears were assessed. After each test
the arena was cleaned with water to attenuate and homogenize
olfactory traces.
DATA ANALYSIS
Pairwise comparisons were made by t -test and comparisons of
more than two groups were analyzed using one-way ANOVA.
The differences in behavior between control and immunized mice
were determined using two-way repeated measure ANOVA and
day-by-day Bonferroni post-test. The results were expressed as
mean± SEM. Fit linear regressions and 95% confidence bands
to the means of parameters over time were calculated by Prism
(GraphPad software).
RESULTS
PHASES OF DISEASE IN MOG35–55-INDUCED EAE
Immunization of C57BL/6 mice with MOG35–55/CFA causes a
neurodegenerative inflammatory disease that resembles the pri-
mary progressive form of MS (42, 43). Although the manifesta-
tions of the disease are not always synchronous in all the mice, it is
possible to distinguish three main phases: the pre-onset, the onset,
and the disease phase (Figure 1A). During the pre-onset (day 0–
10), mice do not show any visible motor defects while behavioral
changes are readily visible since day 2 post immunization. At the
onset of the disease (day 10–12),mice develop aweak or flaccid tail
and start to show signs of motor dysfunction. During the disease
phase (day 12–22) mice progressively loose the ability to move the
hind legs and a significant weight loss (up to 10%) occurs. Mice
were tested starting from day 2 (before PTX injection) and every
other day till day 10, i.e., before the occurrence of anymotor defect
(Figure 1B).
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FIGURE 1 | Phases of the disease in MOG35–55-induced EAE and
behavioral assessment protocol. The graph in (A) shows a typical pattern
of development of the EAE clinical score with the three main phases of the
disease while the scheme in (B) shows a schematic of the behavioral test
protocol used in the study. The results in (A) are from a single experiment
with n=10 mice and are representative of N =5–6 separate experiments.
CHANGES IN BEHAVIOR IN THE OPEN FIELD TEST
The open field test has been previously used in the majority of
studies assessing anxiety behavior during EAE (see Table 1). We
used this test as read-out system for the behavioral changes at
the early stages of the EAE. The convenience of this test is that it
provides easy and simultaneous measure of multiple parameters
including locomotion, exploration, and anxiety.
As shown in Figure 2, both MOG35–55/CFA immunized mice
and PBS-treated control group showed a gradual and time-
dependent decrease in locomotor activity (between 50 and 35%,
respectively) that became almost stable from day 4 onward
(p< 0.05;Figure 2A). The number of passages through the central
square is considered a measure of anxiety and exploratory activ-
ity in this test. Control mice showed a variable but overall stable
number of central square visits throughout the 8-days of testing.
In contrast, immunized mice showed a significant reduction by
day 2 and a further decrease at day 4. This value also remained
constant for the next 4 days (p< 0.01; Figure 2B).
Rearing in mice and other rodent is an emotional and protec-
tive response to the stress of a new environment; this is a typical
vertical activity that consists in the standing completely erect on
the hind legs. This “risk-assessment” behavior indicates that the
animal is hesitant to move from its present location to a new posi-
tion. In the open field test, the latency to the first rear is considered
a measure of depression and associated anxiety (40, 44). Control
mice did not show any significant changes in the number of rear-
ing (data not shown) or in the latency to the first rear throughout
the time of the experiment. Conversely, immunizedmice showed a
steep increase in latency to rearing until day 4 and then a decline to
almost basal level from day 8 (Figure 2C).When we compared the
fold changes versus baseline values of all the parameters we have
measured (Figure A1 in Appendix), the latency to rearing showed
the highest fold change (about fivefold). Most interestingly, this
followed a linear correlation from day 0 to 4 with a slope that
was significantly different from zero [b= 20.51, F(1,15)= 16.26,
p< 0.01; Figure 2D].
BEHAVIORAL CHANGES AT THE EARLY STAGE OF EAE MIRROR THE
EXPANSION AND MOBILIZATION OF T CELLS
To test if the changes in behavior observed in immunized mice
were correlated to early cellular and molecular events that are
important for the development of EAE, we sacrificed mice at day
0, 2 and 4, and 8 and collected peripheral blood and spleens. As
shown in Figure 3, the total number of CD3+ cells in the spleen
peaked at day 4 and then returned to basal level at day 8. No
changes in the percentages of CD4 or CD8 T cell subsets profile
were observed (Figure A2 in Appendix). Similarly, the percentages
and total number of CD3+ cells in peripheral blood increased until
day 4 while starting to decline at day 8. This decline of peripheral
T cell number was even more evident if the mice started to show
signs of disease at day 8.
The reduction of circulating T cells at day 10 coincided with
the expected infiltration in the CNS. Indeed, consistent with other
previously published studies, very few T cells were detected in the
spinal cord of control mice while a significant increase (fourfold)
were found in the same tissues of the EAEmice at day 8 (Figure A3
in Appendix). The percentage of T cells further increased as the
EAE progressed and was directly correlated to the severity of the
disease (data not shown).
T CELL MOBILIZATION AT THE EARLY STAGE OF EAE IS INDEPENDENT
OF PERIPHERAL INFLAMMATORY CYTOKINES AND NOT RELATED TO
IMMUNIZATION WITH CFA
We next investigated whether the time dependent emigration of
T cells in circulation and the changes in behavior we observed
were due to changes in circulating inflammatory cytokines. When
we scanned serum samples for inflammatory or classical T cell
cytokines, only IL-1, IL-18, and GM-CSF could be detected. How-
ever, none of these mediators was differentially modulated over
time (Figure 4) ruling out the possibility that none of cytokines
we have measured (IL-2, IFN-γ, IL-4, IL-5, IL-6, TNF-α, and IL-
17) are released in circulation upon immunization and could be
associated with the changes of rearing latency.
To further demonstrate that the changes in behavior we
observed over time were associated with T cell activation and
not just the effects of CFA, we tested mice immunized with CFA
only or with the immunogenic peptide OVA323–339. We used the
change in latency as this was the parameter that gave us the
highest fold changes and hence most suitable to appreciate any
modulatory effect. This parameter shows the lapse in time to the
first “reactive and solution-seeking” event and suggests a delay
to react to unexpected and novel conditions (the open field) – a
response that is typical of anxious state. As shown in Figure 5,
CFA only immunized mice showed no difference compared to
vehicle-injected mice while OVA323–339 immunized mice showed
a significant (p< 0.05) increase in latency (Figure 5A).
Immunization with CFA only caused a significant increase
in the percentage of CD3+ T cells that was associated with the
expected leukocytosis induced by this treatment. However, mice
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FIGURE 2 | Behavior of MOG35–55-immunized mice in the open field
test. The graphs show the total number of squares crossed (A), number
of central squares entries (B), latency to rearing, and the relative linear
regression (C,D) of control or MOG35–55-immunized mice assessed
during a 5-min test. Values are expressed as mean±SEM for six to
eight mice and are representative of N = 5–6 separate experiments.
*p<0.05, **p<0.01 indicate significant values compared to control
mice.
FIGURE 3 | Expansion and mobilization ofT cells during the early stages
of MOG35–55-induced EAE. The dot plots show the percentages of CD3+ T
cells while the bar graphs show the comparison of the total number of CD3+
T cells in spleen (top panels) or peripheral blood (bottom panels) of control or
MOG35–55-immunized mice. Values are expressed as mean±SEM for three to
four mice. *p<0.05 indicates significant values compared to control mice.
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FIGURE 4 | Levels of inflammatory cytokine in the plasma of MOG35–55-immunized mice. The graphs show the level of the indicated cytokines in the
plasma of control or MOG35–55-immunized mice sacrificed at the indicated time points. The results are representative of n=4 mice.
treated in the same condition but immunized with OVA323–339
showed a further and significant increment in the percentages
and number of circulating T cells (Figures 5B,C, respectively).
Together these results provide a further link between antigenic
stimulation of T cells and emotional response in mice.
GLATIRAMER ACETATE ATTENUATES THE INCREASED DIGGING
LATENCY OF MOG35–55-IMMUNIZED MICE
To further confirm the link between T cell emigration and
increased latency to rearing, we pre-treated mice with a known
immunomodulatory drug that is effective in the treatment of MS.
As shown in Figure 6A, administration of dose of GA that inhibits
the development of EAE (45) (data not shown) caused a significant
reduction in the latency to rearing (p< 0.01). Most importantly,
when we counted the number of T cells in the draining lymph
nodes, we could observed a significant increase in cell number in
mice treated with GA compared to those receiving PBS control
(Figure 6B). This result further suggested that the retaining of T
cells from the circulation significantly influence and mirror the
changes in behavior.
DISCUSSION
Emerging evidences have shown that T cells contribute to func-
tions other than those related to the immune response (30, 33,
46–50). The aim of this study was to explore a possible correla-
tion between T cell activation and behavioral changes that occur
at the early stage of the MOG35–55-induced EAE. Consistent with
previous observations (24, 25, 27, 28, 40) and the results obtained
by Haji et al. (27), immunized mice showed a reduced number of
crossed central squares in the open field and an overall decrease in
exploratory activity as indicatedby the reducednumber of squares.
The EAE is a classical model of autoimmune diseases where
mice are immunized with an antigen that resembles a tissue com-
ponent of the target organ. Activated antigen presenting cells
present the antigenic MOG35–55 to T cells in the local drain-
ing lymph nodes (37, 42). Clonally activated T cells expand and
then move first into the blood stream and thereafter into “homing
licensing organs” like the lung (51). Here, their membrane make-
up and gene profile change to acquire a “pathogenic” phenotype.
These “licensed” cells are in fact capable of infiltrating the target
organs (spinal cord and brain in this case) and initiate a cascade
of events that ultimately lead to chronic inflammation and tissue
damage (52).
Consistent with this model, our results show that the number
of T cells increases in the spleen of immunized mice and this is
followed by their migration into the bloodstream (time when the
changes in emotional behavior occur) and ultimately into the CNS
(time when the emotional behaviors come back to basal level). In
light of these findings, it is possible to hypothesize that the two
stages of T cell movement, i.e., first in the bloodstream and then
into the CNS, mirror the two stages of MS development: mood
changes first and motor dysfunction later. These events are not
antigen specific (in this case neuronal antigen specific) or a spe-
cific feature of MS. Indeed, the results obtained using another
non-endogenous antigen such as OVA323–339 provided us with
the same findings obtained with the MOG35–55. This highlights
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FIGURE 5 |The increase in latency to rearing relies onT cell antigenic
stimulation. The graph in (A) shows the percentage of latency to rearing of
control, CFA only or OVA323–339-immunized mice. Values are expressed as
mean percentage±SEM of the basal activity for eight to nine mice. The dot
plots (B) show the percentages of CD3+ T cells while the bar graph (C) shows
the comparison of the total number of CD3+ T cells in peripheral blood of
control, CFA only or OVA323–339-immunized mice at day 4. The results are
representative of n=6–8 mice.
FIGURE 6 | Glatiramer acetate inhibits the emotional changes of
MOG35–55-immunized mice. The graph in (A) shows the percentage of
latency to rearing of vehicle-treated non-immunized mice, glatiramer
acetate-(GA), or control PBS-treated mice subjected to MOG35–55-induced EAE
and assessed during the 5-min test. The values are expressed as mean
percentage±SEM of the basal activity for six to eight. **p<0.01 indicates
significant values compared to control mice. The bar graph in (B) shows the
total number of T cells in the draining lymph nodes of glatiramer acetate-(GA)
or control PBS-treated mice subjected to MOG35–55-induced EAE at day 4. The
results are representative of n=6–8 mice.
the importance of T cell priming and expansion rather than
a general inflammation for the emotional changes. Indeed, the
lack of any significant changes in circulating cytokines suggests
that these events are not part of the classical sickness behavior
observed during acute inflammation (53). Further studies, now in
progress in the lab, will verify this hypothesis in other models of
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autoimmunedisease such as the collagen-induced arthritis or dou-
ble strand DNA/peptide-induced lupus. The validation of these
findings might indeed explain or provide a “consensus hypothe-
sis” for the high incidence of mood disorders as a common feature
of autoimmune pathologies.
Although we have not explored the passage of T cells through
the lungs in our system, there are some indications that this might
be a likely event. Several studies have already shown that traffick-
ing of T lymphocytes to specific organs, such as the skin and lungs,
is part of the body’s defense mechanism following acute psycho-
logical stress (35, 36, 54). It is interesting to note at this regard that
patients suffering panic and anxiety attack often declare to be “out
of breath” and that problems get “under our skin” when there is
something that we cannot be rid of.
On a more scientific ground, seminal investigations from
Schwartz’s group have recently shown that T lymphocytes migrate
to the brain in response to psychological stress and that their func-
tion there is to alleviate its negative behavioral consequences. In
addition to this, the authors also showed that immunization of T
cells with a CNS-related peptide reduced the stress-induced anxi-
ety and restored levels of BDNF, shown to be important for stress
resilience (55, 56). In light of these findings, it is feasible to hypoth-
esize that the drop in latency we have observed in our study might
be due to the infiltration of T cells in the CNS and concomitant
induction of a protective “resilient response.”
Further studies by Kipnis’s team have provided further insights
on the multiple roles of T cells as homeostatic keepers of CNS
functions. The authors were the first to describe a critical role for
T cell derived IL-4 as key cytokine involved in learning and mem-
ory through regulation of myeloid cells present in the meningeal
space (32, 57). This intriguing new concept has been recently
confirmed by showing improved learning and memory in T cell
deficient SCID mice adoptively transferred with M2 macrophages
(58). Considering thewell-known crosstalk between cognition and
emotion regulation (31), it would be interesting to explore the pos-
sible changes in myeloid cell phenotype during the early stages of
the EAE.
Glatiramer acetate, known in the clinic as copaxone, is one of
the most common disease-modifying drugs together with inter-
feron beta. Although its mechanisms of action have not been fully
defined, a great deal of evidence suggests that it acts directly or
indirectly on T cell activation (59–62). When we tested it in our
system, we could clearly see a significant reduction of latency
to rearing (Figure 6). Most interestingly, we also observed that
GA pre-treatment caused a significant retention of T cells in the
periphery compared to control mice. In light of these findings, it is
tempting to speculate that the reduced activation of T cells, while
reducing the signs of motor dysfunctions and the progression of
the disease, it also reduces emotional changes.
In conclusion, the results of this study suggest a further mech-
anism (besides CNS inflammation) for the link between the neu-
ronal and immune systems – more specifically the emotional state
and immune response – during the course of autoimmune dis-
eases like MS. The validation of these results in the clinic, together
with further exploration of the mechanism by which T cells cause
debilitating mood changes during the early stage of MS, might
help to identify alternative immunomodulatory treatments with
reduced impact on the mental well being of these patients.
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APPENDIX
FIGUREA1 | Behavior of MOG35–55-immunized mice in the open field
test. The graphs show the percentage of total number of squares crossed
(A), number of central squares entries (B), and latency to rearing (C) of
control or MOG35–55-immunized mice compared to their baseline levels
assessed during a 5-min test. Values are expressed as mean
percentage±SEM for six to eight mice and are representative of N =5–6
separate experiments. *p< 0.05, **p<0.01, ***p<0.001 indicate
significant values compared to control mice.
FIGUREA2 | CD4/CD8T cell profile of MOG35–55-immunized mice. The dot plots show the percentages of CD4+ and CD8+ T cells in the spleen of control or
MOG35–55-immunized mice sacrificed at the indicated time points. The results are representative of n=6–8 mice.
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FIGUREA3 | Infiltration ofT cells in the CNS of MOG35–55-immunized
mice. The dot plots and bar graph show the comparison of the percentages
and total number of CD3+ T cells infiltrated in the spinal cord of control or
MOG33–55-immunized mice. Values are expressed as mean±SEM for three
mice and are representative of N =3 separate experiments. **p<0.01
indicates significant values compared to control mice.
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